

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

An integrated communication support program for oncologists, caregivers, and patients with rapidly progressing advanced cancer to promote patient-centered communication: J-SUPPORT 1904 study protocol for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-036745
Article Type:	Protocol
Date Submitted by the Author:	04-Jan-2020
Complete List of Authors:	<p>Fujimori, Maiko; National Cancer Center Japan, Division of Health Care Research, Behavioral Science and Survivorship Research Group, Center for Public Health Sciences, National Cancer Center Japan</p> <p>Sato, Ayako; National Cancer Center Japan, Division of Health Care Research, Behavioral Science and Survivorship Research Group, Center for Public Health Sciences</p> <p>Jinno, Sayaka; National Cancer Center Japan, Division of Health Care Research, Behavioral Science and Survivorship Research Group, Center for Public Health Sciences</p> <p>Okusaka, Takuji; National Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology Division</p> <p>Yamaguchi, Takuhiro; Tohoku University Graduate School of Medicine Department of Medical Biochemistry, Division of Biostatistics</p> <p>Ikeda, Masafumi; National Cancer Center-Hospital East, Department of Hepato-biliary Pancreatic Oncology</p> <p>Ueno, Makoto; Kanagawa Cancer Center, Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division</p> <p>Ozaka, Masato; Public Interest Incorporated Foundation Cancer Institute Hospital of JFCR, Department of Hepatobiliary and Pancreatic Medical Oncology</p> <p>Takayama, Yukiko; Tokyo Women's Medical University Hospital, Department of Medicine, Institute of Gastroenterology</p> <p>Miyaji, Tempei; Tokyo Medical University School of Medicine Graduate School of Medicine, Department of Clinical Trial Data Management</p> <p>Majima, Yoshiyuki; Pancreatic Cancer Action Network</p> <p>Uchitomi, Yosuke; Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital, & Behavioral and Survivorship Research Group, Center for Public Health Sciences</p>
Keywords:	Adult oncology < ONCOLOGY, Adult palliative care < PALLIATIVE CARE, MENTAL HEALTH, SOCIAL MEDICINE

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5
6

7 **TITLE:** An integrated communication support program for oncologists, caregivers, and
8
9 patients with rapidly progressing advanced cancer to promote patient-centered
10
11 communication: J-SUPPORT 1904 study protocol for a randomized controlled trial
12
13
14

15 **RUNNING TITLE:** Integrated communication program for advanced cancer patients
16
17 and oncologists
18
19

20
21 **AUTHORS:**
22

23
24 **Maiko Fujimori**
25

26
27 Division of Health Care Research, Behavioral Science and Survivorship Research Group,
28
29 Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
30
31

32
33 **Ayako Sato**
34

35
36 Division of Health Care Research, Behavioral Science and Survivorship Research Group,
37
38 Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
39
40

41
42 **Sayaka Jinno**
43

44
45 Division of Health Care Research, Behavioral Science and Survivorship Research Group,
46
47 Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
48
49

50
51 **Takuji Okusaka**
52

53
54 Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital,
55
56 Tokyo, Japan
57
58
59

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 **Takuhiko Yamaguchi**
8

9
10 Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai,
11
12
13 Miyagi, Japan
14

15
16 **Masafumi Ikeda**
17

18
19 Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital,
20
21
22 East, Kashiwa, Chiba, Japan
23

24
25 **Makoto Ueno**
26

27
28 Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology
29
30
31 Division, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
32

33
34 **Masato Ozaka**
35

36
37 Department of Hepatobiliary and Pancreatic Medical Oncology, The Cancer Institute
38
39
40 Hospital of JFCR, Ariake, Tokyo, Japan
41

42
43 **Yukiko Takayama**
44

45
46 Department of Medicine, Institute of Gastroenterology, Tokyo Women's Medical
47
48
49 University, Tokyo, Japan
50

51
52 **Tempei Miyaji**
53

54
55 Department of Clinical Trial Data Management, Tokyo University Graduate School of
56
57
58 Medicine, Tokyo, Japan
59

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 Division of Health Care Research, Behavioral Science and Survivorship Research Group,
8

9
10 Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
11

12
13 **Yoshiyuki Majima**
14

15
16 NPO Pancreatic Cancer Action Network Japan, Tokyo, Japan
17

18
19 **Yosuke Uchitomi**
20

21
22 Division of Health Care Research, Behavioral Science and Survivorship Research Group,
23

24
25 Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
26

27
28 **CORRESPONDING AUTHOR:** Maiko Fujimori, Center for Public Health Sciences,
29

30
31 National Cancer Center, Japan
32

33
34 Postal address: Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045 JAPAN
35

36
37 E-mail address: mfujimor@ncc.go.jp
38

39
40 Telephone number: +81-3-3547-5201 EXT. 3320
41

42
43
44
45
46 Word count: 3716 words, excluding title page, abstract, references, figures, and tables
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

ABSTRACT

Introduction

Communication is an essential aspect of care for patients with progressive serious illnesses. This study aims to evaluate the efficacy of an integrated patient-centered communication support program involving caregivers, oncologists, and patients with rapidly progressing advanced cancer.

Methods and Analysis

The proposed integrated communication support program is in the randomized control trial stage. It comprises a cluster of oncologists from comprehensive cancer center hospitals in a metropolitan area in Japan. A total of 20 oncologists, 200 patients with advanced pancreatic cancer, and the patients' caregivers are enrolled in this study as of the writing of this protocol report. Oncologists are randomly assigned to the intervention group (IG) or control group (CG). Patients and caregivers are allocated to the same group as their oncologists. The IG oncologists receive a 2.5-hour individual communication skills training, and patients and caregivers receive a half-hour coaching intervention to facilitate prioritizing and discussing questions and concerns; the CG participants do not receive any training. Follow-up data will be collected quarterly for 6 months and annually

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 for up to three years. The primary endpoint is the intergroup difference between before-
8
9
10 and after-intervention patient-centered communication behaviors during oncology visits.
11
12
13
14
15

16 **Ethics and dissemination**
17
18

19 This study is conducted in accordance with the ethical guidelines for clinical
20
21
22 studies published by Japan's Ministry of Education, Cultural, Sports, Science, and
23
24
25 Technology, the Ministry of Health, Labour, and Welfare (MHLW), and the ethical
26
27
28 principles established for research on humans stipulated in the Declaration of Helsinki
29
30
31 and further amendments thereto. The protocol was approved by the Institutional Review
32
33
34 Board of National Cancer Center, Japan on July 4, 2018 (ID: 2017-474).
35
36
37
38
39

40 **Trial status**
41
42

43 This study is currently enrolling participants; enrollment period ends July 31,
44
45
46 2020; estimated follow-up date is March 31, 2023.
47
48
49
50
51

52 **Trial registration number**
53
54

55 UMIN Clinical Trial Registry: UMIN000033612; Pre-results.
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5

6
7 (290 words)
8
9

10
11
12
13 **Keywords:** Advance Care Planning, Caregivers, Communication, Decision making,
14
15
16 Empathy, End-of-life care, Patient-centered care, Patient-physician relationship, Quality
17
18
19 of life
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 **ARTICLE SUMMARY**
8
9

10 **Trial registration:** The protocol registered on 2nd August, 2018 at UMIN Clinical Trial
11 Registry. The registration number is UMIN000033612.
12
13
14
15
16
17
18

19 **Data statement:** Study protocol, data definition tables, and dataset will be uploaded to
20 the UMIN- Individual Case Data Repository, <https://www.umin.ac.jp/icdr/index-j.html>.
21
22
23
24
25
26
27

28 **Protocol version:** The protocol version is 1.4 on 20th December, 2019.
29
30
31
32
33

34 **Strengths and limitations of this study:**
35
36

- 37 • A strength of this study is the use of a large group of patients, caregivers, and
38 oncologists in the real-world scenario for which the intervention is being tested.
39
- 40 • The use of multicenter participant samples, controls, and patient follow-up allows
41 for reliable study results.
42
- 43 • This study includes oncologists, patients, and caregivers for intervention.
44
- 45 • The intervention program is complex, consisting of multiple factorial components
46 making it difficult to determine which interventions and components are most
47 efficacious or beneficial; however, participants provide assessments of the
48
49
50
51
52
53
54
55
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5
6

7 intervention components.
8

- 9
- 10 • The study only involves pancreatic cancer so the generalization potential for other
11
12 cancers is unknown. However, as pancreatic cancer is one of the most rapidly
13
14 progressing, the intervention may be effective for patients with other these cancers.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

INTRODUCTION

Pancreatic cancer is the fourth leading cause of death in Japan with approximately 35,000 new cases diagnosed per year, matching the approximate annual number of deaths from the disease nationally.[1] Over 40% of patients with pancreatic cancer are stage IV at diagnosis and the 5-year survival rate is 7%.[2] Although the initial treatment goal for pancreatic cancer is to cure, even prolonged survival and maintenance of QOL are difficult to achieve.

Most patients with advanced cancer prefer to discuss their prognosis and treatments with their physicians.[3] However, physicians may feel burdened by open discussions for fear of patients losing hope or they may face resistance from caregivers; [4] therefore, these discussions rarely occur.[5] Consequently, patients often overestimate prognoses, underestimate disease severity, and have unrealistic expectations for a cure.[6] Patients who have not discussed prognosis and treatment choices with their oncologists are 3 to 8 times more likely to receive aggressive treatments in their last week of life.[5, 7] Although oncologists and patients find prognostic discussions can be stressful for doctors and patients alike, unnecessary expenses and actual harm to the patient may result from uninformed decisions.[8] Additionally, it has been shown that open discussions do not cause hopelessness or increased fear in patients, and well-informed patients make

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 more appropriate treatment choices.[9,10] Hence, oncologists need to provide adequate
8
9 information regarding cancer treatment decisions for patients approaching the end of life
10
11 and their caregivers, confirm their understanding, and achieve shared decision making
12
13 about treatment and care based on patients' personal values, life goals, and treatment
14
15 preferences.
16
17
18
19
20
21

22 Patients go from diagnosis to discontinuation of anti-cancer drug treatment
23
24 (mainly pancreatic cancer patients) desire more “empathic paternalistic communication”
25
26 from oncologists.[11] Oncologists' empathic communication reduces patients'
27
28 psychological distress,[12] increases trust in the oncologist,[12] and enhances
29
30 information recall.[13] Empathic communication is essential, especially for patients with
31
32 rapidly progressing serious illnesses. Therefore, communication skills training (CST)
33
34 programs have been developed for physicians to facilitate communication behaviors that
35
36 strengthen relationships with patients.[14] CST is a learner-centered workshop held in
37
38 small groups, including role-play with simulated patients (SPs).[15] It is strongly
39
40 recommended that medical professionals train communication skills in American Society
41
42 of Clinical Oncology Consensus Guideline in patient-clinician communication. [16]
43
44
45
46
47
48
49
50
51
52
53

54 We conducted a prior survey clarifying the four factors of oncologists'
55
56 communication skills preferred by patients, referred to as SHARE: “Setting”, “How to
57
58
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

deliver the bad news”, “Additional information”, and “Reassurance and Emotional support.”[17,18] A two-day SHARE-CST program for oncologists was developed based on these preferences.[19] Our previous randomized controlled trial (RCT) showed that oncologists who participated in SHARE-CST improved their confidence and behavior in patient-centered communication and their patients experienced a low level of psychological distress and a high level of trust in the oncologist.[12]

In Japan, SHARE-CST was implemented as a 10-year project commissioned by the MHLW for physicians nationwide after the enactment of the National Cancer Control Act. Participants reported that empathic communication attitudes and abilities improved;[20] however, it was difficult for most oncologists to participate in two-day CST group workshops because of busy clinical oncology settings.

Patient-centered approaches using question prompt lists (QPLs) have also been proposed for improving patient-physician communication. A QPL is an inexpensive communication tool employing a structured question list to encourage patient question-asking and participation during consultations.[21] The provision of a QPL and communication interventions with QPL before a consultation is effective in promoting patient question-asking behavior and participation in the consultation, and decreasing patients’ anxiety.[22] Our previous RCT trial showed that QPS might be useful for

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

advanced cancer patients, however, it failed to promote patient question-asking behavior,[23] in part because Japanese patients tend to wait for physicians to encourage them to ask questions.[24] Therefore, in Japan, integrated interventions combining CST for oncologists and QPL-coaching for patients might increase patient questioning behavior and improve patient-centered communication in consultations.[25,26]

Based on the previous trials' results, this study aims to evaluate the efficacy of a new integrated communication support program promoting patient-centered communication regarding treatment and care after standard chemotherapy during first-line chemotherapy among oncologists, caregivers, and patients with rapidly progressing advanced cancer. We hypothesize that, compared to treatment as usual (TAU), the intervention will increase patients' question-asking behaviors, improve patient well-being and patient-centered communication behaviors, and improve health services utilization by reducing aggressive interventions and increasing use of palliative care.

METHODS and ANALYSIS

This protocol was written in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) and SPIRIT PRO Extension Guidelines.[27, 28]

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

Study design

This study is a single-blind cluster RCT conducted in four metropolitan cancer-treatment hospitals: the National Cancer Center Hospital, the National Cancer Center Hospital East, the Cancer Institute Hospital, and the Kanagawa Cancer Center Hospital. This study protocol has been reviewed and approved by the protocol review committee of Japan Supportive, Palliative, and Psychosocial Oncology Group as J-SUPPORT 1704 study, and the Institutional Review Boards at each participating institution.

An independent data center provides computer-generated random allocation sequences. The assignment sequence is centrally managed; assignment results are automatically sent to a clinical research coordinator (CRC) electronically. The oncologist participants are randomly assigned to an intervention group (IG) or control group (CG), after baseline phase and patient/caregiver participants are randomized by proxy to intervention with TAU or control (TAU alone). A stratified block-randomization scheme is used to assure balanced assignment by site. Within each site, oncologists are randomly assigned approximately evenly across the treatment and control conditions. Because participants in intervention group provided intervention in addition to TAU, and are unblinded.

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

Intervention

Oncologist

We modified the original SHARE-CST design,[12] adopting a 2.5-hour individual program consisting of lecture with a textbook and role-play/discussion with a facilitator and SP (See Table 1). The lecture cites evidence of the most important and common patient preferences regarding communication—empathic responses and encouragement to ask questions—variability of patients’ preferences in discussing prognoses and being/not being dispassionate, and demonstrates how to check and elicit patient preferences. Additionally, the lecture explains the QPL and discusses frequently asked questions from patients about information related to treatment and care after standard treatment that relates to patients’ personal values, life goals, and preferences of patients and caregivers. During the role-playing and discussion, participants are required to consider a patient’s emotions and concerns caused by bad news, recognition of his/ her disease, social situations, and information that he/ she would want to know, by empathizing with him/ her. Roleplay also includes dealing with patients who bring QPLs.

Facilitators provide a lecture, lead the role-playing, and discuss patients’ potential emotions and communication-related preferences. Facilitators include

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
 2
 3 AND ONCOLOGISTS
 4
 5
 6

7 Table 1. Components of CST Program Based on SHARE Model

8 Component	Description
9 Conceptual communication skills model: SHARE	
10 S	11 Setting up supportive environment for interview (eg, greeting patient cordially, looking at patient's eyes and face)
12 H	13 Considering how to deliver bad news (eg, not beginning bad news without preamble, checking to see whether talk is fast paced)
14 A	15 Discussing additional information that patient would like to know (eg, answering patient's questions fully, explaining second opinion)
16 RE	17 Providing reassurance and addressing patient's emotions with empathic responses (eg, remaining silent out of concern for patient's feelings, accepting patient's expression of emotions)
18 Module	
19 Lecture	20 Introduction, communication skills model, evidence of preferences of patients with cancer regarding communication
21 Role playing	22 Simulated consultation with simulated patient using communication skills with scenarios, discussing with facilitator, summary
23 Scenarios	24 Discontinuing chemotherapy
	25 Dealing with patient asking questions
26 Setting	27 1 participant
	28 1 facilitator
	29 1 simulated patient
30 Schedule	31 Orientation (10 minutes)
	32 Lecture (20 minutes)
	33 Role playing with peer discussion (45 minutes X 2)
34	
35	
36	
37	Abbreviation: CST, communication skills training.
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

psychiatrists, psychologists, and oncologists, all of whom have had 3 years or more of clinical experience in oncology and participated in specialized 30-hour training workshops for facilitating communication skills in oncology. The SPs have also participated in train-the-trainer workshops and a 15-hour SP training.

Patient and Caregiver

Communication coaching for patients was developed to facilitate communication with physicians using a 63-question QPL based on in-depth focus-group interviews with 18 participants (5 pancreatic cancer patients, 3 caregivers patients with pancreatic cancer, 4 bereaved people who had known a patient with pancreatic cancer, and 6 pancreatic oncologists), and previous QPS studies.[23,24,29] The QPL is a 10-page A4 sheet containing 63 questions grouped into 8 topics (diagnosis and stage of the disease, current and future treatments, management of current/possible future symptoms, daily life activities, care and prognosis post standard treatment, caregivers' needs, psychological distress and management, and values) and a space for free questions. Patient communication coaching using the QPL is a half-hour individual program consisting of reading the list to select personally relevant questions, prioritizing selected questions, discussing encouraging their oncologist to ask some high priority questions at their next

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

oncology visit, discussing difficulties in asking, and practicing asking their oncologist these questions. The intervention is to be provided by clinical psychologists and nurses who have participated in a 10-hour intensive training workshop using an intervention manual. All intervention sessions are noted, summarized, and reported to each oncologist before patients' visits. Intervention providers hold weekly conferences to review their coaching sessions.

Control condition

CG oncologists are provided neither training nor educational materials.

Patients/caregivers in the CG are provided TAU.

Participants

Oncologists

Enrolled oncologists must (1) be mainly engaged in anticancer drug treatment of the pancreatic cancer patients; (2) have provided written informed consent for trial participation.

Patients

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

Enrolled patients must (1) have a diagnosis of pancreatic cancer (adenocarcinoma); (2) have unresectable pancreatic cancer (UICC stage III or IV) or postoperative recurrence; (3) receive a first-line chemotherapy and be scheduled for a second course; (4) be aged 20 years or older; (5) have a ECOG performance status score of 0 or 1; (6) regularly visit an enrolled oncologist; (7) provide written informed consent for trial participation; (8) be able to read, write, understand, and speak Japanese.

Patients are excluded if they are (1) judged by their oncologist to have cognitive impairment; (2) unable to complete an electronic Patient Reported Outcome (e-PRO) Questionnaire; (3) judged unsuitable for participation by their oncologist.

Caregivers

Enrolled caregivers must (1) be aged 20 years or older; (2) regularly accompany an enrolled patient as primary caregiver; (3) provide written informed consent to trial participation; (4) be able to read, write, understand, and speak Japanese.

Caregivers are excluded if they are unable to complete an electronic Patient Reported Outcome (e-PRO) Questionnaire.

Procedures

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

This study consists of 3 phases, a baseline phase, an intervention phase, and a follow-up phase (Figure 1). The schedule for outcome measurement is shown in Table 2. After completing the intervention phase, data analysis will ensue. After this study has closed, oncologists in the control group will be provided with the intervention on demand.

Baseline phase

This phase involves oncologist and patients/ caregiver recruitment, and pre-randomization data collection of oncologists' communication behaviors as baseline data for using as a covariate in the RCT analysis. In this phase, 3 to 5 patients and their caregivers (if available) will be recruited for each oncologist. Participants will be asked to be audio recorded at one oncology visit and provide some feedback as to study measures for potential use as covariates in the RCT analyses.

Intervention phase

This phase involves oncologists' randomization, intervention for participants in IG, and follow-up assessment. After oncologists are randomly assigned to the IG or CG, those in the IG will receive an individual intervention.

Next, 10 patients and their caregivers (if available) who regularly visit the

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

oncologist are recruited and assigned to the IG or CG. After the IG patients and their caregivers receive an intervention or 2 weeks to 1month after baseline in the CG, the conversation of the patient/caregiver and the oncologist audio record at their next consultation. After the visit, patients/caregivers and the oncologists rate the consultation using a follow-up assessment.

Long-term follow-up phase

Patients and their caregivers will be encouraged to provide long-term follow-up assessments at 3, 6, 12, 24, and 36 months after the first follow-up assessment. Caregivers regarding are also asked to provide another assessment at 2 to 6 months post patient death.

Data management, central monitoring, data monitoring, and auditing

We will collect all data, except for audio recorded data, through electronic data capture (EDC) and electronic-patient reported outcomes (ePRO) system or paper-based PRO questionnaires (pPRO) in case of patients' physical limitation. If participants fail to respond to ePRO or pPRO, a CRC blinded to the assignment will elicit subjects' answers to avoid the missing data. Data management and central monitoring will be performed using EDC VIEDOC 4 (PCG Solutions, Sweden) by J-SUPPORT Data Science Team.

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

Auditing is not also planned for this study.

Concomitant treatments

There is no restriction on concomitant treatments.

Stopping rules for participants

If a participant meets any of the following conditions, the research team can discontinue the intervention. However, the participant will not be considered to have dropped out of the trial at that stage and will receive the assessments: (1) the participant wishes to stop the intervention; (2) the research team judges that the risk of the intervention is greater than the benefit for any reason; (3) the research team judges that it is difficult to continue the intervention because of clinical deterioration; and (4) the research team judges that it is inappropriate to continue the intervention for any reason.

Stopping assessment

If a participant withdraws consent for assessment, he or she will not be followed up. Subjects will be excluded from the intention-to-treat (ITT) cohort of the trial only if they are found to meet any exclusion criteria at baseline (e.g., age under 20 years) after

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5

6 participation.
7
8
9

10
11
12
13 **Assessment measures**
14

15
16 Table 2 shows the schedule for outcome measurement.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

Table 2. Schedule for outcome measurement

		Baseline Phase	Intervention Phase		Follow-up Phase	
		Day 28 of 1st line chemotherapy	Day 28 of 1st line chemothera	Day 42 of 1st line chemothera	3, 6, 12, 24, 36 months after	After post-mortem of the patient
Patient	SHARE ¹ RIAS	<input type="checkbox"/>				
	Characteristics	<input type="checkbox"/>				
	Evaluation on consultation	<input type="checkbox"/>				
	SHARE ¹ RIAS			<input type="checkbox"/>		
	HADS		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	FACT		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Short version of CoQOLo		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	TiOS		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	CSQ		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	PEACE		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Evaluation on consultation, QPL, intervention, oncologist			<input type="checkbox"/>		
	PTPQ		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Characteristics		<input type="checkbox"/>			
End-of-life Medical care			<input type="checkbox"/>	<input type="checkbox"/>		
Caregiver	SHARE ¹ RIAS	<input type="checkbox"/>				
	Characteristics	<input type="checkbox"/>				
	SHARE ¹ RIAS			<input type="checkbox"/>		
	EQ- ¹ D- ¹ L		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	K6		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	CSQ		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Characteristics					
	End-of-life Medical care		<input type="checkbox"/>			
	PTPQ		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Evaluation on consultation, QPL, intervention, oncologist			<input type="checkbox"/>		
Short version of Good Death Inventory					<input type="checkbox"/>	
Oncologist	SHARE, RIAS	<input type="checkbox"/>		<input type="checkbox"/>		
	Oncologist's characteristics		<input type="checkbox"/>			
	Evaluation on intervention, QPL			<input type="checkbox"/>		
	Evaluation on consultation	<input type="checkbox"/>		<input type="checkbox"/>		

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 Primary outcome measure
8

9 *Patient-centered communication behaviors*
10
11
12

13 The audio-recorded oncology visits for all participants will be coded for each of
14
15 the four factors of communication behaviors based on patient preference, referred to as
16
17 SHARE: setting, delivery of information, additional information, and reassurance and
18
19 emotional support (see Table 1). [19] The SHARE-RE factor is used as a primary outcome
20
21 to measure empathic communication between patient/caregiver and oncologist after
22
23 intervention for both.
24
25
26
27
28
29

30 Based on previous study methods,[19] the impressions of conversations from
31
32 consultations will be assessed using the 8 SHARE-RE categories of the 27 SHARE
33
34 categories for analysis, in a random order, by two blinded coders who have been trained
35
36 for 30 hours or more for some tasks independently on two occasions with a rating manual.
37
38
39
40
41
42
43
44
45

46 Secondary outcome measure
47

48 *Patient-preferred communication behavior*
49
50
51

52 Patient-preferred communication will be analyzed using impression ratings from
53
54 two blinded coders, as described above. The analysis will include the audio-recorded
55
56 oncology visits for all participants using the total score of the 27 SHARE
57
58
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

categories.[18,19] On the basis of previous study methods,[19] the 40 categories of the Rote intention analysis system (RIAS) will also be used in assessing patient-centered communications. [30]

Patient-reported outcome measures

Several scales will be used to produce a comprehensive profile of each patient participant. These include the Hospital Anxiety and Depression Scale (HADS);[31] the Physical well-being and Functional well-being subscale of the Functional Assessment of Cancer Therapy (FACT- Physical & Functional);[32] the Short version of the Comprehensive Quality of Life Outcome inventory (CoQOLo);[33] the Trust in Oncologists Scale (TiOS).[34] Satisfaction with their oncologist and experience with the disease will be measured with the Client Satisfaction Questionnaire (CSQ);[35] the Peace, Equanimity, and Acceptance in the Cancer Experience (PEACE) questionnaire;[36] and the Prognosis and Treatment Perceptions Questionnaire (PTPQ).[37]

Patients' relevant medical and sociological background information includes stage, diagnosis date, treatment status, treatment history, comorbidities, sex, age, job status, household income, household size, social support, marital status, educational experience, treatment, and care preference at the end of life. Medical utilization at the end

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

of life will be determined by the date of death, any chemotherapy agent given within 14 days of death, any new chemotherapeutic regimen started within 30 days of death, and involvement of hospice; and palliative care services; all of this information is obtained from medical fee information.[26]

A patients' assessment survey of the intervention's usefulness includes "Did you understand how to use the QPL and did you actually use it?" "Do you think you will continue the intervention?" "Was the intervention useful to you?" Their assessment of Oncologists includes "Did the oncologist talk about the QPL?" and "How did the oncologist respond to your questions?", their assessment of QPL includes "Did the QPL helped you ask the oncologist questions?" "Is the QPL useful?" "Did you read the QPL before the visit?" and "Do you think you will read the QPL in the future?" as well as whether they asked selected questions to oncologist after the visit, which questions they selected, and "How much you have discussed with your oncologist in the visit?"

Caregiver survey measures

Several scales will also be used for a comprehensive view of caregivers, including the K6 nonspecific psychological distress scale;[38] and the 5 Dimension EuroQol (EQ-5D).[39] Satisfaction with the oncologist is measured with the CSQ. After

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

the patient's death, the caregiver's QOL as the bereaved is measured with the Short version of Good Death Inventory (GDI).[40]

Caregivers' relevant sociological background information includes sex, age, relationship with the patient, job status, household income, household size, social support, marital status, educational experience, and treatment and care preferences at the end of life).

After the first post-intervention visit, caregivers in the IG will evaluate the intervention, the oncologist, and the QPL and report any selected questions used with the oncologist.

Oncologist survey measures

The relevant data concerning the oncologists include their sociological background (sex, age, clinical experience). The oncologists' medical utilization will be determined by their recollection of the dates and circumstances of the post-intervention consultations with patients/caregivers.

The usefulness of the intervention will also be measured using evaluations provided by the oncologists in the IG.

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

Harms

No specific and serious adverse events are presumed for participants of this study.

However, by participating in the interventions, some participants may potentially experience psychological distress from imagining their situation after standard treatment.

The patients/ caregivers and oncologists will also be subjected to time burdens of a half-hour and 2.5 hours for the intervention, and 10–30 minutes for each baseline and follow-up assessment. Therefore, we will give patients/caregivers a reward of 500 Japanese yen for each participant assessment. There are no financial risks associated with study participation.

Compensation

If participants develop unexpected health issues due to study participation during or after completion of this study, treatment will be adequately provided per standard medical care, covered by the National Health Insurance.

Sample size estimation

Our previous study revealed that the effect size of SHARE-RE scores was 1.9 at post-intervention. [12] For a sample size based on 80% power to detect a significant

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

difference at a significance level of 0.05 (two-sided), 10 oncologists and 70–100 participants (7–10 per oncologist) would be required for each arm in the follow-up phase, assuming some participant drop out and data loss. Assuming that 80% of patients will be accompanied by caregivers at doctor visits, a total of 112–160 participants would be required. Based on previous studies, a total of 60–150 patients (3 to 5 per oncologist) are needed in the baseline phase.[26]

Patient and public involvement statement

This study protocol was co-designed by a patient with pancreatic cancer and a family member of a pancreatic cancer patient who participated as researchers. They spoke with other patients to help determine recommendations for when patients' preferences and/or opinions should be considered. They will play a similar role in the implementation of this study. Thus, patients were and will continue to be involved in this study. The results of this study will be available via a study website.

Data analysis

Primary analyses

To examine the intervention effect parameters of all randomly assigned subjects

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

in the primary analysis set according to the ITT principle, we will analyze the primary outcome with SHARE-RE as an indicator of enhanced empathic communication using a generalized linear model. The primary outcome of interest is the difference in SHARE-RE scores between the two groups after intervention. A two-sided p value < 0.05 will be used to indicate statistical significance.

Secondary analyses

We will perform secondary analyses to supplement our primary analysis and obtain a clearer understanding of our clinical questions. The secondary analyses will use models similar to that of the primary analysis and will examine data for the secondary outcome measures. These analyses will be conducted for exploratory purposes.

Interim analyses

No interim analysis is planned.

Publication policy

The protocol and study results will be submitted to peer-reviewed journals. The first author of the main paper will be a member of the steering committee (authors of the

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

protocol paper). Another person could be the first author if approved by the steering committee. The list of coauthors will be determined before submitting each paper.

Study period

This study period of this trial is April 2017 to March 2023; the registration period is August 2018 to July 2020.

Ethics and dissemination

The present study is subject to ethical guidelines for clinical studies published by Japan's Ministry of Education, Science and Technology and Ministry of Health, Labour, and Welfare and the modified Act on the Protection of Personal Information as well as the ethical principles established for research on humans stipulated in the Declaration of Helsinki and further amendments thereto. If important protocol modifications are needed, the investigators will discuss them and report to the review board for approval. Regarding dissemination, the results obtained will be submitted for publication in peer-reviewed journals. The main and relevant findings will be presented at conferences.

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

DISCUSSION

This study is a multi-site randomized controlled trial to evaluate the efficacy of an integrated communication support program for rapidly progressive advanced cancer patients, caregivers, and oncologists to promote patient-centered communication. The intervention program is unique in intervening with both oncologists and patients/caregivers for a brief time at the time of first-line chemotherapy before they are critically ill.

In clinical oncology, the introduction of personalized precision medicine has allowed great therapeutic progress. While patient-oncologist communication is uncertain and complex, and busy oncologists often find it difficult to take extra time with their patients. As a result, personalized and precise communication between a patient and an oncologist may not be achieved. If empathic communication between patients and oncologists can be improved, including shared decision making based on patient values and preferences about the use of evidence-based medicine, the result can be an effective integration of best practices and patient values, allowing for better use of clinical expertise available resources.

In this study, it is essential that intervention facilitators and SPs be well trained to maintain the quality of the intervention. In the future, it may be possible to reduce costs

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

by developing internet-based programs. Regarding QPL, clinical benefits may increase when it is possible to link medical records with data from wearable devices. Above all, the use of electronic media is expected to make implementation of the intervention program easier.

Strengths and limitations of this study

This study has two methodological limitations. First, we involve both oncologists and patients/caregivers. The intervention program for both is complex, consisting of multiple factorial components. Thus, if the interventions prove superior to usual care, we cannot determine which interventions and components are most efficacious or beneficial in promoting their communication. Second, patient intervention will be applied only with patients with pancreatic cancer. The generalization potential for other cancers is unknown. However, because pancreatic cancer is one of most rapidly progressive, the intervention may be effective in other cancers.

Acknowledgements

We thank Ms. T Mashiko and Ms. M Kurosaki for their data management support. We also thank members of PanCan Japan, Ms. S Furutani, Dr M Mori, Dr Y

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 Shirai, Dr S Umezawa, Ms. N Inomata, Mr. M Umehashi, Dr M Okamura, Dr M Odawara,
8
9 Dr A Hanai, Mr. R Soga, Ms. R Sugihara, Ms. T Akiyama and Ms. M Kanamaru for their
10
11
12
13 support for this study.
14
15
16
17
18

19 **Contributors**

20
21
22 MF is a principal investigator. MY participated in this study as a patient and a
23
24 caregiver. MF and YU developed the CST program. MF, AS, SJ, TO, YM and YU
25
26 developed the QPL. MF, TO, TY, MI, MU, MO, KT, TM, YM and YU participated in
27
28 the design of this study. All authors prepared the protocol and agree of final protocol and
29
30 revisions. MF, AS, SJ, MT prepared of investigators brochure (IB) and CRFs. TY played
31
32 a chief role in the statistical parts. TM played roles in the data management. MF drafted
33
34 the manuscript. All authors participated in, read and approved the final manuscript.
35
36
37
38
39
40
41
42
43
44
45

46 **Funding**

47
48
49 This study is supported by a Grant-in-Aid for Japan Agency for Medical
50
51 Research and Development (JP 17ck0106237h0001) and in part by The National Cancer
52
53 Center Research and Development Fund (30-A-11). This funding source had no role in
54
55 the design of this study and will not have any role during its execution, analyses,
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 interpretation of the data, or decision to submit results.
8
9

10 **Sponsor**
11

12 None
13
14
15
16
17

18 **Competing interests**
19

20 All authors declare that they have no competing interests regarding this work.
21
22

23 TO has received research funding from Ono Pharmaceutical, Kowa, Dainippon
24 Sumitomo Pharma, Chugai Pharmaceutical, Novartis, Yakult Honsha, AstraZeneca, Eisai,
25 Lilly, Bristol-Myers Squibb. TY received consulting fees from Ono Pharmaceutical,
26 Kowa, Japan Tobacco, Chugai Pharmaceutical, Tsumura & CO, CAC Croit, Asahi Intecc,
27 Asahi Kasei Pharma and Clinical Trial. MI has received honoraria from Novartis Pharma,
28 Bayer Yakuhin, Bristol-Myers Squibb, Abbott Japan, Eisai, Taiho Pharmaceutical, Eli
29 Lilly Japan, Daiichi-Sankyo, Yakult, Otsuka Pharmaceutical, Nobelpharma, EA Pharma
30 and Teijin Pharma, research funding from Bayer Yakuhin, Kyowa Hakko Kirin, Yakult,
31 Taiho Pharmaceutical, Eli Lilly Japan, Ono Pharmaceutical, Eisai, AstraZeneca, Zeria
32 Pharmaceutical, Chugai, Bristol Myers Squibb, Merck Serono, Kowa, Nano Carrier,
33 ASLAN, Daiichi-Sankyo., Sumitomo Dainippon, Novartis Pharma, Baxalta, Boehringer
34 Ingelheim and Takara Bio. He is a consulting or advisory role for Nano Carrier, Bayer
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 Yakuhin, Eisai, Kyowa Hakko Kirin, Novartis Pharma, Shire, MSD, Bristol Myers Squibb,
8
9 Eli Lilly Japan, Sumitomo Dainippon, Daiichi-Sankyo, Teijin Pharma, Takara Bio and a
10
11 board member of ASLAN, Chugai. MU has received honoraria from Taiho
12
13 Pharmaceutical, Yakult Honsha, AstraZeneca, Novartis, Lilly, Teijin Pharma, Shire, Ono
14
15 Pharmaceutical, and Merck Serono, and research funding from Taiho Pharmaceutical,
16
17 Shire, Daiichi Sankyo, Eisai, AstraZeneca, Ono Pharmaceutical, MSD, Merck Serono,
18
19 NanoCarrier, Dainippon Sumitomo Pharma, Incyte, ASLAN Pharmaceuticals, and
20
21 Yakult Honsha. MO has received lecture fees from Taiho Pharmaceutical and honoraria
22
23 from Taiho Pharmaceutical, Yakult, Bayer, Pfizer and Novartis.
24
25
26
27
28
29
30
31
32
33
34
35
36

37 **Patient consent for publication**
38

39 Not required.
40
41
42
43
44
45

46 **Ethics approval**
47

48 The protocol was reviewed and approved by the Institutional Review Board of
49
50 National Cancer Center on 4 July 2018 (ID: 2014-474) as well as by the J-SUPPORT
51
52 Scientific Advisory Board.
53
54
55
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5
6

7 **Provenance and peer review**
8
9

10 Not commissioned; externally peer reviewed.
11
12
13
14
15

16 **Open access**
17
18

19 This is an open access article distributed in accordance with the Creative
20 Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others
21
22 to distribute, remix, adapt, build upon this work non-commercially, and license their
23
24 derivative works on different terms, provided the original work is properly cited,
25
26 appropriate credit is given, any changes made indicated, and the use is non-commercial.
27
28
29
30
31
32
33

34 See: <http://creativecommons.org/licenses/by-nc/4.0/>.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 **References**
8
9

- 10 1. Ministry of Health, Labour and Welfare, Japan: White Papers & Reports Annual Health,
11 Labour and Welfare Report 2017.
12
13
14
15
16 2. National Cancer Center, Japan: Cancer Statistics in Japan 2018.
17
18
19 3. Parker SM, Clayton JM, Hancock K, et al. A systematic review of prognostic/end-of-
20 life communication with adults in the advanced stages of a life-limiting illness:
21 patient/caregiver preferences for the content, style, and timing of information. *J Pain*
22 *Symptom Manage* 2007;34(1):81-93.
23
24
25
26
27
28
29
30 4. Otani H, Morita T, Esaki T, et al. Burden on oncologists when communicating the
31 discontinuation of anticancer treatment. *Jpn J Clin Oncol* 2011;41(8):999-1006.
32
33
34
35
36
37 5. Wright AA, Zhang B, Ray A, et al. Associations between end-of-life discussions,
38 patient mental health, medical care near death, and caregiver bereavement adjustment.
39
40
41
42
43
44
45
46
47 6. Weeks JC, Catalano PJ, Cronin A, et al. Patients' expectations about effects of
48 chemotherapy for advanced cancer. *N Engl J Med* 2012;367(17):1616-25.
49
50
51
52 7. Weeks JC, Cook EF, O'Day SJ, et al. Relationship between cancer patients' predictions
53 of prognosis and their treatment preferences. *JAMA* 1998;279(21):1709-14.
54
55
56
57
58 8. Fallowfield LJ, Jenkins VA, Beveridge HA. Truth may hurt but deceit hurts more:
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 communication in palliative care. *Palliat Med* 2002;16(4):297-303.
8

9
10 9. Hagerty RG, Butow PN, Ellis PM, et al. Communicating prognosis in cancer care: a
11
12 systematic review of the literature. *Ann Oncol* 2005;16(7):1005-53.
13
14

15
16 10. Epstein RM, Peters E. Beyond information: exploring patients' preferences. *JAMA*
17
18 2009;302(2):195-7.
19
20

21
22 11. Umezawa S, Fujimori M, Matsushima E, et al. Preferences of advanced cancer
23
24 patients for communication on anticancer treatment cessation and the transition to
25
26 palliative care. *Cancer* 2015;121(23):4240-9.
27
28

29
30 12. Fujimori M, Shirai Y, Asai M, et al. Effect of communication skills training program
31
32 for oncologists based on patient preferences for communication when receiving bad
33
34 news: a randomized controlled trial. *J Clin Oncol* 2014;32(20):2166-72.
35
36

37
38 13. Sep MS, van Osch M, van Vliet LM, et al. The power of clinicians' affective
39
40 communication: how reassurance about non-abandonment can reduce patients'
41
42 physiological arousal and increase information recall in bad news consultations. An
43
44 experimental study using analogue patients. *Pat Educ Couns* 2014;95(1):45-52.
45
46
47
48

49
50 14. Moore PM, Rivera S, Bravo-Soto GA, et al. Communication skills training for
51
52 healthcare professionals working with people who have cancer. *Cochrane Database Syst*
53
54
55
56
57
58 Rev 2018;7:Cd003751.
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 15. Stiefel F, Kiss A, Salmon P, et al. Training in communication of oncology clinicians:
8 a position paper based on the third consensus meeting among European experts in 2018.
9
10 Ann Oncol 2018;29(10):2033-36.
11
12

13
14
15
16 16. Gilligan T, Coyle N, Frankel RM, et al. Patient-Clinician Communication: American
17 Society of Clinical Oncology Consensus Guideline. J Clin Oncol 2017;35(31):3618-32.
18
19

20
21
22 17. Fujimori M, Akechi T, Morita T, et al. Preferences of cancer patients regarding the
23 disclosure of bad news. Psychooncology 2007;16(6):573-81.
24
25

26
27
28 18. Fujimori M, Uchitomi Y. Preferences of cancer patients regarding communication of
29 bad news: a systematic literature review. Jpn J Clin Oncol 2009;39(4):201-16.
30
31

32
33
34 19. Fujimori M, Shirai Y, Asai M, et al. Development and preliminary evaluation of
35 communication skills training program for oncologists based on patient preferences for
36 communicating bad news. Palliat Support Care 2014;12(5):379-86.
37
38

39
40
41 20. Yamada Y, Fujimori M, Shirai Y, et al. Changes in Physicians' Intrapersonal Empathy
42 after a Communication Skills Training in Japan. Acad Med 2018;93(12):1821-26.
43
44

45
46
47 21. Butow PN, Dunn SM, Tattersall MH, et al. Patient participation in the cancer
48 consultation: evaluation of a question prompt sheet. Ann Oncol 1994;5(3):199-204.
49
50

51
52
53 22. Brandes K, Linn AJ, Butow PN, et al. The characteristics and effectiveness of
54 Question Prompt List interventions in oncology: a systematic review of the literature.
55
56
57
58
59

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 Psychooncology 2015;24(3):245-52.
8
9

10 23. Shirai Y, Fujimori M, Ogawa A, et al. Patients' perception of the usefulness of a
11 question prompt sheet for advanced cancer patients when deciding the initial treatment: a
12 randomized, controlled trial. Psychooncology 2012;21(7):706-13.
13
14
15

16 24. Fujimori M, Akechi T, Akizuki N, et al. Good communication with patients receiving
17 bad news about cancer in Japan. Psychooncology 2005;14(12):1043-51.
18
19
20
21
22

23 25. van Weert JC, Jansen J, Spreeuwenberg PM, et al. Effects of communication skills
24 training and a Question Prompt Sheet to improve communication with older cancer
25 patients: a randomized controlled trial. Crit Rev Oncol Hematol 2011;80(1):145-59.
26
27
28
29
30
31
32

33 26. Epstein RM, Duberstein PR, Fenton JJ, et al. Effect of a Patient-Centered
34 Communication Intervention on Oncologist-Patient Communication, Quality of Life, and
35 Health Care Utilization in Advanced Cancer: The VOICE Randomized Clinical Trial.
36 JAMA Oncol 2017;3(1):92-100.
37
38
39
40
41
42
43
44
45

46 27. Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration:
47 guidance for protocols of clinical trials. BMJ 2013;346:e7586.
48
49
50
51

52 28. Calvert M, Kyte D, Mercieca-Bebber R, et al. Guidelines for Inclusion of Patient-
53 Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA.
54 2018;319(5):483-494.
55
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 29. Brown RF, Butow PN, Dunn SM, et al. Promoting patient participation and shortening
8 cancer consultations: a randomised trial. *Br J Cancer* 2001;85(9):1273-9.
9

10
11
12 30. Roter, D.L., Hall, J.A., Kern, D.E., et al. Improving physicians' interviewing skills
13 and reducing patients' emotional distress. Randomized clinical trial. *Arch Intern Med*
14
15
16
17
18
19 1995;155, 1877-1884.
20

21
22 31. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr*
23
24
25
26
27 Scand 1983;67(6):361-70.

28 32. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
9.

33. Miyashita M, Wada M, Morita T, et al. Independent Validation of the Japanese
Version of the EORTC QLQ-C15-PAL for Patients With Advanced Cancer. *J Pain*
Symptom Manage 2015;49(5):953-9.

34. Hillen MA, Postma RM, Verdam MG, et al. Development and validation of an
abbreviated version of the Trust in Oncologist Scale-the Trust in Oncologist Scale-short
form (TiOS-SF). *Support Care Cancer* 2017;25(3):855-61.

35. Zandbelt LC, Smets EM, Oort FJ, et al. Satisfaction with the outpatient encounter: a
comparison of patients' and physicians' views. *J Gen Intern Med* 2004;19(11):1088-95.

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 36. Mack JW, Nilsson M, Balboni T, et al. Peace, Equanimity, and Acceptance in the
8
9
10 Cancer Experience (PEACE): validation of a scale to assess acceptance and struggle with
11
12
13 terminal illness. *Cancer* 2008;112(11):2509-17.
14

15
16 37. El-Jawahri A, Traeger L, Park ER, et al. Associations among prognostic
17
18
19 understanding, quality of life, and mood in patients with advanced cancer. *Cancer*
20
21
22 2014;120(2):278-85.
23

24
25 38. Kessler RC, Andrews G, Colpe LJ, et al. Short screening scales to monitor population
26
27
28 prevalences and trends in non-specific psychological distress. *Psychol Med*
29
30
31 2002;32(6):959-76.
32

33
34 39. Brooks R. EuroQol: the current state of play. *Health policy (Amsterdam, Netherlands)*
35
36
37 1996;37(1):53-72.
38

39
40 40. Miyashita M, Morita T, Sato K, et al. Good death inventory: a measure for evaluating
41
42
43 good death from the bereaved family member's perspective. *J Pain Symptom Manage*
44
45
46 2008;35(5):486-98.
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Participant flow diagram

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5
6

7 **Appendices A**
8
9

10 **Informed Consent Form for Oncologists**
11

12 医師用説明文書
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 医師への質問を支援する研究へのご協力をお願い
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

はじめに

国立がん研究センターでは、患者さんのために最新の医療を提供するとともに、よりよい診断方法や治療方法、そしてがんに関するさまざまな症状を和らげる方法を開発するための取り組みをおこなっています。

このたび説明いたしますのは、すい臓がんに対する化学療法を受けている方を対象とし、患者さんやご家族から医療者に対してよくある質問を簡条書きにした具体的質問集を用いることによって、患者さん・ご家族、医師とのコミュニケーションが促進されるか否かを確認するための研究です。

本研究の内容について説明文書を読まれ、今回私たちが計画している研究の主旨をご理解いただき、その上でこの研究にご参加いただけましたら幸いに存じます。

1. 本研究の目的と意義

本研究では患者さん・ご家族と医師のコミュニケーションを促進するために、介入者（心理士、看護師、相談員）による質問支援を治療早期から導入することにより、治療選択がよりご本人の価値観に沿うものとなり、生活の質に良い影響を及ぼすかどうかを明らかにすることを目的としています。

医師は患者さん・ご家族に医療に関する説明を十分に行い、理解を確認し、患者さんご自身の自由意思に基づいた治療選択を求める必要があります。また、患者さん・ご家族は医師からの共感的行動を必要としていることが、これまでの研究において示されています。また、このような望ましいコミュニケーションが患者さんの健康の保持・増進、ストレスや前向きさによい影響を及ぼすということが明らかにされています。このように治療を行っていく過程において、患者さん・ご家族と医師の間のコミュニケーションは重要です。

そこで本研究では、患者さん・ご家族に対する質問支援プログラムを開発し、患者さん・ご家族－医師間の共感的コミュニケーション促進への有効性を検証します。このプログラムが有用であった場合には、治療早期から患者さん一人一人の自由意思に沿った医療の提供を促す支援法が実用化され、がん患者さんの生活の質を向上させるだけでなく、医師の負担を減らすことができます。一方、有用でなかった際にも、効果がなかった原因等を分析することで、今後有用と考えられる仕組みを作りあげることに関与するものと考えます。

2. 本研究の対象となる方について

すい臓がんと診断され、抗がん剤治療を受けている、満 20 歳以上の、日本語が理解できる患者さんの担当医が対象となります。また、患者さんとそのご家族の方自体も本研究の対象となっています。

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

3. 本研究の内容と方法

本研究では、コミュニケーション・コーチングを受けるグループ（介入群）と受けないグループ（対照群）のどちらかにご参加頂きます。グループは無作為に割り当て、コミュニケーション・コーチングを受けるグループに割り当たった場合には、皆様のご都合のよい時間に、約3時間の講義とロールプレイを受けていただきます。コミュニケーション・コーチングを受けないグループに割り当たった場合には、通常通りの診察をおこなっていただきます。

どちらのグループに参加することになった場合にも、診察の様子を2回録音させていただきます。1回目は同意取得後、2回目は、介入群は適格基準を満たす患者さん・ご家族が質問支援を受けられた次の週の診察後/対照群は通常診療の診察（T1）です。またT0（介入群がコミュニケーション・コーチングを受ける前）とT1両方のタイミングで質問票を用いた調査にご協力頂きます。

本研究に参加して頂ける皆様には、個別の番号をつけさせていただき、研究で集めたデータは個別の番号がわからなければ個人が特定できないようにしたうえで、データセンター（国立がん研究センター社会と健康研究センター健康支援研究部）に集めます。本研究は、平成30年4月より平成35年3月までの間に行われます。最終の質問票を用いた調査を行った時点で、参加終了となります。一回の調査にかかる時間は30分程度です。

スケジュール

同意取得後	T0	介入	T1
両グループ： 診察場面の録音	両グループ： 質問票を用いた調査	介入群のみ： 介入者による質問支援 3時間程度（※支援を受けるグループに割り当たった場合のみ）	両グループ： 診察場面の録音 その後、質問票を用いた調査

4. 研究への参加により予想される利益と不利益、評価調査終了後の対応

本研究に参加されても、通常診療と比べ、皆様が職務上、経済上の特別な利益を得られることはありません。

また、原則として皆様に不利益は生じないと考えておりますが、質問票の記入やコミュニケーション・コーチングが診療業務を行う上でご負担となる可能性があります。この研究への参加を、もしご負担に感じられるようでしたら、いつでもこの研究へのご協力を中止していただいてもかまいません。

5. 健康被害が発生した場合の対応・補償について

本研究のコミュニケーション・コーチングによる介入は投薬や処置といった治療行為

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

を含まないため、本研究によって有害事象が発生することは原則ないと考えられますが、万が一、本研究に関わる何らかの理由により、健康を害する状況が発生した場合には、適切な医療機関で対応させていただきます。これらの場合、用いられる保険は通常のあなたが加入されている医療保険となり、この研究からの補償金は発生いたしませんこと、予めご了承ください。

6. 参加いただかない場合でも不利益を受けないこと

本研究への参加は、皆様の自由意思にもとづくものであり、参加に同意されない場合でも皆様の今後の職務上において不利益を受けることは一切ありません。

7. 同意した後いつでもこれを撤回できること

本研究への同意をいただいた後でも、いつでもこれを撤回することができます。参加への同意を撤回された場合でも、皆様の職務上において不利益を受けることは一切ありません。同意を撤回される場合には、お手数ですが、研究代表者までお知らせください。同意撤回時点までに集めたデータの研究利用も不可とするかどうかのご判断をいただくため、同意撤回文書のご提出をお願いいたします。

8. 研究にご参加いただいた場合の経済的な負担

本研究では、参加いただいた場合に皆様に特別な経済的負担はありません。

9. プライバシーの保護と個人の人権の擁護

本研究で得られた録音した IC レコーダー、解析の過程で生じるテキスト化したデータ及び書類等は、施錠可能なスペースで保管します。皆様のプライバシーに関する情報は、研究期間終了後5年間保存した後に、シュレッダー等を用いて破棄します。

また、当院の別の部署の担当者が、本研究が正しく行われているかを監査するために皆様の記録を見ることがありますが、この場合にも皆様のプライバシーは厳重に守られます。

10. 本研究に関する情報公開

本研究に関する情報については、大学病院医療情報ネットワーク臨床試験登録システム (UMIN-CTR) に登録し、公開いたします。

11. データの二次利用について

本研究で得られたデータを二次利用することがあります。この場合は、個人を識別する情報と結びつかないよう匿名化した上、がん患者さんの生活の質の向上に役立てる目的に

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

限り、データを利用いたします。なお、本研究において提供された個人情報の管理責任者は、研究代表者/研究責任者の藤森麻衣子(項目 16 参照)となります。

1 2. 本研究の倫理審査について

本研究は、国立がん研究センター研究倫理審査委員会の審査を受け、内容や方法が適切であり、皆様の人権が守られていることが確認され、実施について承認を受け、国立がん研究センター理事長の研究許可を得たものです。

1 3. 参加いただく期間と研究全体の実施予定期間、予定参加人数

この研究は平成 30 年 4 月より平成 35 年 3 月まで行い、その後の結果の分析は平成 36 年 3 月までに行う予定です。研究全体の参加予定人数は約 560 名（医師 約 20 名・患者 約 300 名・患者家族 約 240 名）を予定しております。

1 4. 本研究の資金と利益相反について

臨床研究における利益相反とは、研究者が企業等から経済的な利益の提供を受け、その利益の存在により臨床研究の結果に影響を及ぼす可能性がある状況のことをいいます。

本研究は、国立研究開発法人日本医療研究開発機構 平成 29 年度革新的がん医療実用化研究事業 領域 5 の研究（研究代表者：藤森麻衣子、課題管理番号：17ck0106237h0001）であり、その他の特定の団体からの資金提供や物品等の無償提供は受けておらず、研究組織全体に関して起こりうる利益相反はありません。

本研究に関する研究者の利益相反の管理は、参加施設それぞれが自施設の研究者に関しに行っています。当センターにおける利益相反の管理は、国立がん研究センター利益相反委員会が行っていますので、詳細をお知りになりたい場合は、研究代表者までお問い合わせください。

1 5. 本研究に対して分からないことがある場合

本研究に関しまして、質問や疑問がありましたら、いつでも遠慮なく研究事務局までお問い合わせください。また、本研究への参加に同意しない場合でも、質問がありましたらお申し出ください。

1 6. 担当者の連絡先、研究代表者、研究責任者、研究事務局

【研究代表者/研究責任者】 藤森麻衣子
国立がん研究センター 社会と健康研究センター
〒104-0045 東京都中央区築地 5-1-1
TEL : 03-3547-5201 (内線 3320)

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5

6 【共同研究機関の研究責任者】

7 国立がん研究センター中央病院	肝胆膵内科	奥坂拓志
8 国立がん研究センター東病院	肝胆膵内科	池田公史
9 神奈川県立がんセンター	消化器内科	上野誠
10 がん研究会有明病院	消化器内科	尾阪将人
11 東京女子医科大学病院	消化器内科	高山敬子

12
13
14
15
16
17
18 【研究事務局】 佐藤綾子

19 国立がん研究センター 社会と健康研究センター
20 〒104-0045 東京都中央区築地 5-1-1
21 TEL : 03-3547-2511 (PHS6032)
22

23
24 【説明者】

25 説明者名 : ()
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5

6 同意文書
7
8

9 国立がん研究センター中央病院 病院長 殿
10

11 「医師への質問を支援する研究」
12

13 国立研究開発法人日本医療研究開発機構 平成 29 年度革新的がん医療実用化研究事業 領
14 域 5
15

16 研究代表者：藤森麻衣子、課題管理番号：17ck0106237h0001
17
18

- 19
- 20 1. 本研究の目的と意義
 - 21 2. 本研究の対象となる方について
 - 22 3. 本研究の内容と方法
 - 23 4. 研究への参加により予想される利益と不利益、評価調査終了後の対応
 - 24 5. 健康被害が発生した場合の対応・補償について
 - 25 6. 参加いただかない場合でも不利益を受けないこと
 - 26 7. 同意した後にいつでもこれを撤回できること
 - 27 8. 研究にご参加いただいた場合の経済的な負担
 - 28 9. プライバシーの保護と個人の人権の擁護
 - 29 10. 本研究に関する情報公開
 - 30 11. データの二次利用について
 - 31 12. 本研究の倫理審査について
 - 32 13. 参加いただく期間と研究全体の実施予定期間、予定参加人数
 - 33 14. 本研究の資金と利益相反について
 - 34 15. 本研究に対して分からないことがある場合
 - 35 16. 担当者の連絡先、研究代表者、研究事務局
- 36
37
38
39
40
41
42
43
44

45 私は、本臨床研究について以上の項目を説明しました。
46
47

48 説明日： 平成 年 月 日

49 説明者氏名： _____ (自署)
50
51

52 私はこの臨床研究に参加するにあたり、試験の内容について担当者より十分な説明を受け
53 ました。試験の内容を理解しましたので、参加することについて同意します。
54
55

56 同意日： 平成 年 月 日
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5

6 氏名： _____ (自署)
7

8 **Appendices B**
9

10
11 **Informed Consent Form for Patients and Caregivers**
12

13
14 患者さん・同伴者の方用説明文書
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 医師とのコミュニケーションを支援する研究へのご協力の
36
37
38 お願い
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

はじめに

国立がん研究センターでは、患者さんのために最新の医療を提供するとともに、よりよい診断方法や治療方法、そしてよりよいケアを開発するための取り組みをおこなっています。

このたび説明いたしますのは、すい臓がんに対する化学療法を受けている方を対象とし、医療に関わる人達（医師、看護師、心理士、相談員等）に対してよくある質問を箇条書きにした具体的質問集を用いて患者さん、同伴者の方、医師とのコミュニケーションが促進されるか否かを確認するための研究です。

本研究の内容について説明文書を読まれ、今回私たちが計画している研究の主旨をご理解いただき、その上でこの研究にご参加いただけましたら幸いに存じます。

1. 本研究の目的と意義

本研究では患者さん・同伴者の方と担当医師間のコミュニケーションの改善が、患者さんの生活の質に良い影響を及ぼすかどうかを明らかにすることを目的としています。本研究では、患者さんから医師へのよくある質問集を用いて患者さんが担当医師への質問をしやすくするお手伝いを治療早期から導入します。

患者さん・同伴者の方—医師のコミュニケーションは治療を進めていく上でとても重要です。医師は患者さん・同伴者の方に医療に関する説明を十分に行い、理解を確認し、患

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

者さんご自身の自由意思に基づいた治療選択を求める必要があります。また過去の研究で、患者さん・ご家族は医師からの共感的行動を必要としていることが示されています。このような治療についての十分な説明と共感的行動を含む望ましいコミュニケーションが患者さんの健康の保持・増進、ストレスや前向きさにより影響を及ぼすということが明らかにされています。

そこで本研究では、患者さん・同伴者の方に対して具体的な質問集を用いて医師への質問をやすくするプログラムを開発し、患者さん・同伴者の方－医師間の共感的コミュニケーション促進への有効性を検証します。このプログラムが有用であった場合には、治療早期からお一人お一人の自由意思に沿った医療の提供を促す支援方法が実用化され、がん患者さんの生活の質を向上させることができます。一方、有用でなかった際にも、効果がなかった原因等を分析することで、今後有用と考えられる仕組みを作りあげることに役立つものと考えます。

2. 本研究の対象となる方の病状と治療について

すい臓がんと診断され、抗がん剤治療を受けている、満 20 歳以上の、日本語が理解できる患者さんと同伴者の方、担当医が対象となります。

3. 本研究の内容と方法

本研究では、皆様に 3 つのグループ（グループ 1、グループ 2 - 1、グループ 2 - 2）

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5
6

7 のいずれかに入っていただきます。グループ 1、グループ 2 のどちらに入るのかは、調査
8
9 の時期によって、調査者からお願いさせていただきます。

12 グループ 1 では、参加に同意を頂きましたら、診察場面の録音をさせていただき、質問
13
14 票への回答をお願いいたします。

17 グループ 2 では、具体的な質問集を用い医師への質問をしやすくするお手伝い（以下、
18
19 コミュニケーション支援と呼びます）を受けるグループ 2 – 1 と、受けないグループ 2 –
20
21 2 のどちらかに入っていただきます。2 – 1 と 2 – 2 どちらのグループに入るかは、患者
22
23 さんご自身のご希望や担当医の判断で決まるのではなく、「ランダム化」という方法で、コ
24
25 ンピューターを使って、五分五分の確率でどちらかに入ります。コミュニケーション支援
26
27 を受けるグループ 2 – 1 に入った場合には、次回の抗がん剤の治療の待ち時間、あるいは
28
29 治療中（皆様のご都合のよい時間）にコミュニケーション支援を行うトレーニングを受け
30
31 た者（心理士等）からコミュニケーション支援を受けていただきます。コミュニケーショ
32
33 ン支援を受けないグループ 2 – 2 に入った場合には、通常通りの診療になります。どちら
34
35 のグループも、ご参加頂いた時（第 1 週）と第 3 週、3 か月後、6 か月後、1 年後、2 年後、3
36
37 年後に質問票を用いた調査にご協力頂くこととなります。3 か月以降の調査につきましては、
38
39 事前に改めてお電話にてご依頼をさせていただきます。また、第 3 週目の診察の様子を録
40
41 音させていただきます（下記、スケジュールをご参照ください）。
42
43
44
45
46
47
48
49
50
51
52
53
54
55

57 さらに、診察予約状況、現在受けられている治療に関するカルテ記載を担当の医師の許
58
59

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5
6

7 可を得て使用させていただきます。また、皆様の診療内容や医療費に関する情報を把握するた
8
9 めに、診療情報（介護保険、診療報酬明細書の情報を含む）を閲覧させていただきます。

10
11
12 本研究に参加頂くことに同意していただきましたら、皆様には個別の番号をつけさせて
13
14
15 いただきます。すべてのデータは、個別の番号がわからなければ個人が特定できないよう
16
17
18 にしたうえで、データセンター（国立がん研究センター社会と健康研究センター健康支援
19
20
21 研究部）に集めます。

22
23
24 本研究は、平成 30 年 4 月より平成 35 年 3 月までの間に行われます。最終の質問票の調
25
26
27 査を行った時点で、参加終了となります。

28
29
30
31
32 **スケジュール**

33
34
35 <グループ 1 の場合>

同意取得後
医師の診察の録音 質問票を用いた調査

36
37
38
39
40
41
42
43
44
45 <グループ 2 - 1 の場合>

同意取得後	第 2 週	第 3 週	3, 6, 12, 24, 36 か月後
-------	-------	-------	----------------------

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
AND ONCOLOGISTS

第一回目の質問票を用いた調査 10分～30分程度	医師より質問集配布。 具体的な質問集を用いた コミュニケーション支援。 40分～60分程度	医師の診察の録音。 質問票を用いた調査 10分～30分程度	フォローアップのための 質問票を用いた調査 これらの調査は、来院時に 実施します。転院された場 合は郵送にて実施させて いただきます。 10分～30分程度
-----------------------------	--	-------------------------------------	---

<グループ2-2の場合>

同意取得後	第2週	第3週	3, 6, 12, 24, 36か月後
第一回目の質問票を用いた調査 10分～30分程度	通常通りの診療	医師の診察の録音。 質問票を用いた調査 10分～30分程度	フォローアップのための 質問票を用いた調査 これらの調査は、来院時に 実施します。転院された場 合は郵送にて実施させて いただきます。 10分～30分程度

4. 研究への参加により予想される利益と不利益、評価調査終了後の対応

本研究に参加されても、通常診療と比べ、患者さんが診療上、経済上の特別な利益を得られることはありません。

質問票の記入や面談が体調や気持ちの上でご負担となる場合があります。この研究への参加を、もしご負担に感じられるようでしたら、いつでもこの研究へのご協力を中止していただいてもかまいません。なお、調査は個人差もありますが、1回30分程度の時間を要するため、グループ1に参加頂いた方には、調査終了後500円分のクオカードを差し上げま

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

す。また、グループ 2 - 1、グループ 2 - 2 に参加頂いた方には、1 回目の調査時にはト
トバックとボールペン、2 回目以降の調査では 1 回につき 500 円分のクオカードを差し上げ
ます。

5. 健康被害が発生した場合の対応・補償について

本研究は投薬や処置といった治療行為を含まないため、本研究によって有害事象が発生
することは原則ないと考えられますが、万が一質問票を用いた調査や面談により、気分の
落ち込みや不安など、ご不快な状況が発生した場合には、外来・病棟スタッフまたは当院
の精神腫瘍科チームが対応させていただきます。これらの場合、用いられる保険は通常の
あなたが加入されている医療保険となり、この研究からの補償金は発生いたしませんこと、
予めご了承ください。

6. 参加いただかない場合でも不利益を受けないこと

本研究への参加は、皆様の自由意思にもとづくものであり、参加に同意されない場合で
も、患者さんご自身の今後の治療において不利益を受けることは一切ありません。

7. 同意した後にいつでもこれを撤回できること

本研究への同意をいただいた後でも、いつでもこれを撤回することができます。参加へ
の同意を撤回することで不利益を受けることは一切ありません。同意を撤回される場合に

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5
6

7 は、お手数ですが、担当医または研究代表者までお知らせください。同意を撤回する時点
8
9
10 までに集めたデータの研究利用も不可とするかどうかのご判断をいただくため、同意撤回
11
12
13 文書のご提出をお願いいたします。
14
15
16
17
18

19 **8. 研究にご参加いただいた場合の経済的な負担**
20
21

22 本研究にご参加いただくことで皆様の費用負担が通常より増えることはありません。
23
24
25

26 **9. プライバシーの保護と個人の人権の擁護**
27
28

29 本研究で得られた録音した IC レコーダー、診療情報（介護保険、診療報酬明細書の情報
30
31
32 を含む）、解析の過程で生じるテキスト化したデータ及び書類等は、施錠可能なスペースで
33
34
35 保管します。皆様のプライバシーに関する情報は、研究期間終了後 5 年間保存した後に、
36
37
38 紙媒体はシュレッダー、電子媒体はデータの完全消去などにて破棄します。
39
40

41 また、当院の別の部署の担当者が、本研究が正しく行われているかを監査するために皆
42
43
44 様の記録を見ることがありますが、この場合にも皆様のプライバシーは厳重に守られます。
45
46
47
48

49 **10. 本研究に関する情報公開**
50
51

52 本研究に関する情報については、大学病院医療情報ネットワーク臨床試験登録システム
53
54
55 (UMIN-CTR) に登録し、公開いたします。
56
57
58
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

11. データの二次利用について

本研究で得られたデータを二次利用することがあります。この場合は、個人を識別する情報と結びつかないよう匿名化した上、がん患者さんの生活の質の向上に役立てる目的に限り、データを利用いたします。なお、本研究において提供された個人情報の管理責任者は、研究代表者/研究責任者の藤森麻衣子(項目 16 参照)となります。

12. 本研究の倫理審査について

本研究は、国立がん研究センター研究倫理審査委員会の審査を受け、内容や方法が適切であり、皆様の人権が守られていることが確認され、実施について承認を受け、国立がん研究センター理事長の研究許可を得たものです。

13. 参加いただく期間と研究全体の実施予定期間、予定参加人数

この研究は平成 30 年 4 月より平成 35 年 3 月まで行い、その後の結果の分析は平成 36 年 3 月までに行う予定です。研究全体の参加予定人数は約 560 名を予定しております。

14. 本研究の資金と利益相反について

臨床研究における利益相反とは、研究者が企業等から経済的な利益の提供を受け、その利益の存在により臨床研究の結果に影響を及ぼす可能性がある状況のことをいいます。

本研究は、国立研究開発法人日本医療研究開発機構 平成 29 年度革新的がん医療実用化

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5
6

7 研究事業 領域5の研究（研究代表者：藤森麻衣子、課題管理番号：17ck0106237h0001）で
8
9 あり、その他の特定の団体からの資金提供や物品等の無償提供は受けておらず、研究組織
10
11
12 全体に関して起こりうる利益相反はありません。
13
14

15 本研究に関する研究者の利益相反の管理は、参加施設それぞれが自施設の研究者に関し
16
17 て行っています。当センターにおける利益相反の管理は、国立がん研究センター利益相反
18
19 委員会が行っています。詳細をお知りになりたい場合は、担当医までお問い合わせくださ
20
21 い。
22
23
24
25
26
27
28

29 **15. 本研究に対して分からないことがある場合**
30
31

32 本研究に関しまして、質問や疑問がありましたら、いつでも遠慮なく研究事務局までお
33
34 問い合わせください。また、本研究への参加に同意しない場合でも、質問がありましたら
35
36 お申し出ください。
37
38
39
40
41
42

43 **16. 担当者の連絡先、研究代表者、研究責任者、共同研究機関の研究責任者、研究事務局**
44
45

46 【研究代表者/研究責任者】 藤森麻衣子

47
48 国立がん研究センター 社会と健康研究センター

49 〒104-0045 東京都中央区築地 5-1-1

50 TEL : 03-3547-5201 (内線 3320)

51
52
53
54
55 【共同研究機関の研究責任者】
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5

6			
7	国立がん研究センター中央病院	肝胆膵内科	奥坂拓志
8			
9			
10	国立がん研究センター東病院	肝胆膵内科	池田公史
11			
12			
13	神奈川県立がんセンター	消化器内科	上野誠
14			
15			
16	がん研究会有明病院	消化器内科	尾阪将人
17			
18			
19	東京女子医科大学病院	消化器内科	高山敬子
20			
21			
22			

23 【研究事務局】 佐藤綾子

24
25 国立がん研究センター 社会と健康研究センター

26 〒104-0045 東京都中央区築地 5-1-1

27
28 TEL : 03-3547-2511 (PHS6032)

29
30
31
32
33 【説明者】

34
35
36 説明者名 : ()

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
AND ONCOLOGISTS

同意文書

国立がん研究センター中央病院 病院長 殿

「医師とのコミュニケーションを支援する研究」

国立研究開発法人日本医療研究開発機構 平成 29 年度革新的がん医療実用化研究事業 領

域 5

研究代表者：藤森麻衣子、課題管理番号：17ck0106237h0001

1. 本研究の目的と意義
2. 本研究の対象となる方の病状と治療について
3. 本研究の内容と方法
グループ 1： 診察場面の録音・ 質問票を用いた調査・ 診療情報の収集
グループ 2 - 1： 質問票を用いた調査・ 介入： 診察場面の録音・ 診療情報の収集
グループ 2 - 2： 質問票を用いた調査： 診察場面の録音・ 診療情報の収集
4. 研究への参加により予想される利益と不利益、評価調査終了後の対応
5. 健康被害が発生した場合の対応・補償について
6. 参加いただかない場合でも不利益を受けないこと
7. 同意した後にいつでもこれを撤回できること
8. 研究にご参加いただいた場合の経済的な負担

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

			Page
	Reporting Item		Number
Administrative information			
Title	#1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym		1

1	Trial registration	#2a	Trial identifier and registry name. If not yet registered,	7
2			name of intended registry	
3				
4				
5				
6	Trial registration:	#2b	All items from the World Health Organization Trial	7
7				
8	data set		Registration Data Set	
9				
10				
11				
12	Protocol version	#3	Date and version identifier	7
13				
14				
15	Funding	#4	Sources and types of financial, material, and other	31
16			support	
17				
18				
19				
20	Roles and	#5a	Names, affiliations, and roles of protocol contributors	31
21				
22	responsibilities:			
23				
24	contributorship			
25				
26				
27				
28	Roles and	#5b	Name and contact information for the trial sponsor	32
29				
30	responsibilities:			
31				
32	sponsor contact			
33				
34	information			
35				
36				
37				
38	Roles and	#5c	Role of study sponsor and funders, if any, in study	31
39			design; collection, management, analysis, and	
40	responsibilities:		interpretation of data; writing of the report; and the	
41			decision to submit the report for publication, including	
42	sponsor and funder		whether they will have ultimate authority over any of	
43			these activities	
44				
45				
46				
47				
48				
49				
50				
51				
52	Roles and	#5d	Composition, roles, and responsibilities of the	31
53			coordinating centre, steering committee, endpoint	
54	responsibilities:		adjudication committee, data management team, and	
55				
56	committees			
57				
58				
59				
60				

1 other individuals or groups overseeing the trial, if
 2
 3 applicable (see Item 21a for data monitoring committee)
 4
 5

6 Introduction

7			
8			
9	Background and	#6a	Description of research question and justification for
10			
11	rationale		undertaking the trial, including summary of relevant
12			studies (published and unpublished) examining benefits
13			
14			and harms for each intervention
15			
16	Background and	#6b	Explanation for choice of comparators
17			
18	rationale: choice of		
19	comparators		
20			
21			
22	Objectives	#7	Specific objectives or hypotheses
23			
24			
25	Trial design	#8	Description of trial design including type of trial (eg,
26			parallel group, crossover, factorial, single group),
27			allocation ratio, and framework (eg, superiority,
28			equivalence, non-inferiority, exploratory)
29			
30			
31			
32			
33			
34			
35			
36			
37			
38			
39	Methods:		
40			
41	Participants,		
42			
43	interventions, and		
44			
45	outcomes		
46			
47			
48			
49	Study setting	#9	Description of study settings (eg, community clinic,
50			academic hospital) and list of countries where data will be
51			collected. Reference to where list of study sites can be
52			obtained
53			
54			
55			
56			
57			
58			
59			
60			

1	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If	16
2				
3			applicable, eligibility criteria for study centres and	
4			individuals who will perform the interventions (eg,	
5			surgeons, psychotherapists)	
6				
7				
8				
9				
10				
11	Interventions:	#11a	Interventions for each group with sufficient detail to allow	13
12				
13	description		replication, including how and when they will be	
14			administered	
15				
16				
17				
18				
19	Interventions:	#11b	Criteria for discontinuing or modifying allocated	13
20				
21	modifications		interventions for a given trial participant (eg, drug dose	
22			change in response to harms, participant request, or	
23			improving / worsening disease)	
24				
25				
26				
27				
28				
29	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	13
30				
31	adherence		and any procedures for monitoring adherence (eg, drug	
32			tablet return; laboratory tests)	
33				
34				
35				
36	Interventions:	#11d	Relevant concomitant care and interventions that are	20
37				
38	concomitant care		permitted or prohibited during the trial	
39				
40				
41				
42	Outcomes	#12	Primary, secondary, and other outcomes, including the	21
43				
44			specific measurement variable (eg, systolic blood	
45			pressure), analysis metric (eg, change from baseline, final	
46			value, time to event), method of aggregation (eg, median,	
47			proportion), and time point for each outcome. Explanation	
48			of the clinical relevance of chosen efficacy and harm	
49			outcomes is strongly recommended	
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Participant timeline	#13	Time schedule of enrolment, interventions (including any	18
2			run-ins and washouts), assessments, and visits for	
3			participants. A schematic diagram is highly recommended	
4			(see Figure)	
5				
6				
7				
8				
9				
10				
11	Sample size	#14	Estimated number of participants needed to achieve	26
12			study objectives and how it was determined, including	
13			clinical and statistical assumptions supporting any sample	
14			size calculations	
15				
16				
17				
18				
19				
20				
21	Recruitment	#15	Strategies for achieving adequate participant enrolment to	17
22			reach target sample size	
23				
24				
25				
26	Methods:			
27				
28	Assignment of			
29	interventions (for			
30	controlled trials)			
31				
32				
33				
34				
35				
36	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	13
37	generation		computer-generated random numbers), and list of any	
38			factors for stratification. To reduce predictability of a	
39			random sequence, details of any planned restriction (eg,	
40			blocking) should be provided in a separate document that	
41			is unavailable to those who enrol participants or assign	
42			interventions	
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	13
54	concealment		central telephone; sequentially numbered, opaque,	
55				
56				
57				
58	mechanism			
59				
60				

sealed envelopes), describing any steps to conceal the sequence until interventions are assigned

Allocation: [#16c](#) Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions 13

Blinding (masking) [#17a](#) Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how 13

Blinding (masking): [#17b](#) If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial 13

Methods: Data collection, management, and analysis

Data collection plan [#18a](#) Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol 19

1	Data collection plan:	#18b	Plans to promote participant retention and complete	19
2				
3	retention		follow-up, including list of any outcome data to be	
4			collected for participants who discontinue or deviate from	
5			intervention protocols	
6				
7				
8				
9				
10				
11	Data management	#19	Plans for data entry, coding, security, and storage,	19
12			including any related processes to promote data quality	
13			(eg, double data entry; range checks for data values).	
14			Reference to where details of data management	
15			procedures can be found, if not in the protocol	
16				
17				
18	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	27
19			outcomes. Reference to where other details of the	
20			statistical analysis plan can be found, if not in the protocol	
21				
22				
23	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	27
24	analyses		adjusted analyses)	
25				
26				
27				
28	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	27
29	population and		adherence (eg, as randomised analysis), and any	
30	missing data		statistical methods to handle missing data (eg, multiple	
31			imputation)	
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46	Methods: Monitoring			
47				
48				
49	Data monitoring:	#21a	Composition of data monitoring committee (DMC);	19
50	formal committee		summary of its role and reporting structure; statement of	
51			whether it is independent from the sponsor and	
52			competing interests; and reference to where further	
53				
54				
55				
56				
57				
58				
59				
60				

1 details about its charter can be found, if not in the
 2
 3 protocol. Alternatively, an explanation of why a DMC is
 4
 5 not needed
 6
 7

8	Data monitoring:	#21b	Description of any interim analyses and stopping	27
9				
10	interim analysis		guidelines, including who will have access to these	
11				
12			interim results and make the final decision to terminate	
13				
14			the trial	
15				
16				
17				
18	Harms	#22	Plans for collecting, assessing, reporting, and managing	25
19				
20			solicited and spontaneously reported adverse events and	
21				
22			other unintended effects of trial interventions or trial	
23				
24			conduct	
25				
26				
27				
28	Auditing	#23	Frequency and procedures for auditing trial conduct, if	32
29				
30			any, and whether the process will be independent from	
31				
32			investigators and the sponsor	
33				
34				
35	Ethics and			
36				
37	dissemination			
38				
39				
40				
41	Research ethics	#24	Plans for seeking research ethics committee / institutional	13
42				
43	approval		review board (REC / IRB) approval	
44				
45				
46	Protocol	#25	Plans for communicating important protocol modifications	28
47				
48	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
49				
50			relevant parties (eg, investigators, REC / IRBs, trial	
51				
52			participants, trial registries, journals, regulators)	
53				
54				
55				
56				
57				
58				
59				
60				

1	Consent or assent	#26a	Who will obtain informed consent or assent from potential	18
2			trial participants or authorised surrogates, and how (see	
3			Item 32)	
4				
5				
6				
7				
8				
9	Consent or assent:	#26b	Additional consent provisions for collection and use of	42
10			participant data and biological specimens in ancillary	
11	ancillary studies		studies, if applicable	
12				
13				
14				
15				
16	Confidentiality	#27	How personal information about potential and enrolled	28
17			participants will be collected, shared, and maintained in	
18			order to protect confidentiality before, during, and after	
19			the trial	
20				
21				
22				
23				
24				
25				
26	Declaration of	#28	Financial and other competing interests for principal	32
27			investigators for the overall trial and each study site	
28	interests			
29				
30				
31				
32	Data access	#29	Statement of who will have access to the final trial	7
33			dataset, and disclosure of contractual agreements that	
34			limit such access for investigators	
35				
36				
37				
38				
39	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and for	25
40			compensation to those who suffer harm from trial	
41	trial care		participation	
42				
43				
44				
45				
46				
47	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial	28
48			results to participants, healthcare professionals, the	
49	trial results		public, and other relevant groups (eg, via publication,	
50			reporting in results databases, or other data sharing	
51			arrangements), including any publication restrictions	
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Dissemination policy: #31b	Authorship eligibility guidelines and any intended use of	28
2			
3	authorship	professional writers	
4			
5			
6	Dissemination policy: #31c	Plans, if any, for granting public access to the full	7
7			
8	reproducible	protocol, participant-level dataset, and statistical code	
9			
10	research		
11			
12			
13			
14	Appendices		
15			
16			
17	Informed consent	#32 Model consent form and other related documentation	1
18			
19	materials	given to participants and authorised surrogates	
20			
21			
22	Biological specimens	#33 Plans for collection, laboratory evaluation, and storage of	n/a
23			
24		biological specimens for genetic or molecular analysis in	
25			
26		the current trial and for future use in ancillary studies, if	
27			
28		applicable	
29			
30			
31			

32 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-
 33 BY-ND 3.0. This checklist was completed on 20. December 2019 using <https://www.goodreports.org/>,
 34
 35 a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

An integrated communication support program for oncologists, caregivers, and patients with rapidly progressing advanced cancer to promote patient-centered communication: J-SUPPORT 1904 study protocol for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-036745.R1
Article Type:	Protocol
Date Submitted by the Author:	12-Jun-2020
Complete List of Authors:	<p>Fujimori, Maiko; National Cancer Center Japan, Division of Health Care Research, Behavioral Science and Survivorship Research Group, Center for Public Health Sciences, National Cancer Center Japan</p> <p>Sato, Ayako; National Cancer Center Japan, Division of Health Care Research, Behavioral Science and Survivorship Research Group, Center for Public Health Sciences</p> <p>Jinno, Sayaka; National Cancer Center Japan, Division of Health Care Research, Behavioral Science and Survivorship Research Group, Center for Public Health Sciences</p> <p>Okusaka, Takuji; National Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology Division</p> <p>Yamaguchi, Takuhiro; Tohoku University Graduate School of Medicine Department of Medical Biochemistry, Division of Biostatistics</p> <p>Ikeda, Masafumi; National Cancer Center-Hospital East, Department of Hepato-biliary Pancreatic Oncology</p> <p>Ueno, Makoto; Kanagawa Cancer Center, Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division</p> <p>Ozaka, Masato; Public Interest Incorporated Foundation Cancer Institute Hospital of JFCR, Department of Hepatobiliary and Pancreatic Medical Oncology</p> <p>Takayama, Yukiko; Tokyo Women's Medical University Hospital, Department of Medicine, Institute of Gastroenterology</p> <p>Miyaji, Tempei; Tokyo Medical University School of Medicine Graduate School of Medicine, Department of Clinical Trial Data Management</p> <p>Majima, Yoshiyuki; Pancreatic Cancer Action Network</p> <p>Uchitomi, Yosuke; Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital, & Behavioral and Survivorship Research Group, Center for Public Health Sciences</p>
Primary Subject Heading:	Communication
Secondary Subject Heading:	Oncology, Palliative care, Patient-centred medicine
Keywords:	Adult oncology < ONCOLOGY, Adult palliative care < PALLIATIVE CARE, MENTAL HEALTH, SOCIAL MEDICINE

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5
6

7 **TITLE:** An integrated communication support program for oncologists, caregivers, and
8
9 patients with rapidly progressing advanced cancer to promote patient-centered
10
11 communication: J-SUPPORT 1904 study protocol for a randomized controlled trial
12
13
14

15
16 **RUNNING TITLE:** Integrated communication program for advanced cancer patients
17
18 and oncologists
19
20

21 **AUTHORS:**

22
23 **Maiko Fujimori**

24
25 Division of Health Care Research, Behavioral Science and Survivorship Research Group,
26
27 Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
28
29
30

31
32 **Ayako Sato**

33
34 Division of Health Care Research, Behavioral Science and Survivorship Research Group,
35
36 Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
37
38
39

40
41 **Sayaka Jinno**

42
43 Division of Health Care Research, Behavioral Science and Survivorship Research Group,
44
45 Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
46
47
48

49
50 **Takuji Okusaka**

51
52 Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital,
53
54
55
56
57
58 Tokyo, Japan
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 **Takuhiko Yamaguchi**
8

9
10 Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai,
11
12
13 Miyagi, Japan
14

15
16 **Masafumi Ikeda**
17

18
19 Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital,
20
21
22 East, Kashiwa, Chiba, Japan
23

24
25 **Makoto Ueno**
26

27
28 Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology
29
30
31 Division, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
32

33
34 **Masato Ozaka**
35

36
37 Department of Hepatobiliary and Pancreatic Medical Oncology, The Cancer Institute
38
39
40 Hospital of JFCR, Ariake, Tokyo, Japan
41

42
43 **Yukiko Takayama**
44

45
46 Department of Medicine, Institute of Gastroenterology Tokyo Women's Medical
47
48
49 University, Tokyo, Japan
50

51
52 **Tempei Miyaji**
53

54
55 Department of Clinical Trial Data Management, Tokyo University Graduate School of
56
57
58 Medicine, Tokyo, Japan
59

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5
6

7 Division of Health Care Research, Behavioral Science and Survivorship Research Group,
8

9
10 Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
11
12

13 **Yoshiyuki Majima**
14

15
16 NPO Pancreatic Cancer Action Network Japan, Tokyo, Japan
17
18

19 **Yosuke Uchitomi**
20

21
22 Division of Health Care Research, Behavioral Science and Survivorship Research Group,
23
24

25 Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
26
27

28 **CORRESPONDING AUTHOR:** Maiko Fujimori, Center for Public Health Sciences,
29

30 National Cancer Center, Japan
31
32

33
34 Postal address: Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045 JAPAN
35
36

37 E-mail address: mfujimor@ncc.go.jp
38
39

40 Ttelephone number: +81-3-3547-5201 EXT. 3320
41
42
43
44
45

46 Word count: 3716 words, excluding title page, abstract, references, figures, and tables
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

ABSTRACT

Introduction

Communication is an essential aspect of care for patients with progressive serious illnesses. This study aims to evaluate the efficacy of a new, integrated communication support program for oncologists, patients with rapidly progressing advanced cancer and their caregivers.

Methods and Analysis

The proposed integrated communication support program is in the randomized control trial stage. It comprises a cluster of oncologists from comprehensive cancer center hospitals in a metropolitan area in Japan. A total of 20 oncologists, 200 patients with advanced pancreatic cancer, and the patients' caregivers are enrolled in this study as of the writing of this protocol report. Oncologists are randomly assigned to the intervention group (IG) or control group (CG). Patients and caregivers are allocated to the same group as their oncologists. The IG oncologists receive a 2.5-hour individual communication skills training, and patients and caregivers receive a half-hour coaching intervention to facilitate prioritizing and discussing questions and concerns; the CG participants do not receive any training. Follow-up data will be collected quarterly for 6 months for a year

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

and then annually for up to three years. The primary endpoint is the intergroup difference between before- and after-intervention patient-centered communication behaviors during oncology visits.

Ethics and dissemination

This study is conducted in accordance with the ethical guidelines for clinical studies published by Japan's Ministry of Education, Cultural, Sports, Science, and Technology, the Ministry of Health, Labour, and Welfare (MHLW), and the ethical principles established for research on humans stipulated in the Declaration of Helsinki and further amendments thereto. The protocol was approved by the Institutional Review Board of National Cancer Center, Japan on July 4, 2018 (ID: 2017-474).

Trial status

This study is currently enrolling participants; enrollment period ends July 31, 2020; estimated follow-up date is March 31, 2023.

Trial registration number

UMIN Clinical Trial Registry: UMIN000033612; Pre-results.

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5
6
7
8
9

10 (299 words)
11
12
13
14
15

16 **Keywords:** Advance Care Planning, Caregivers, Communication, Decision making,
17
18 Empathy, End-of-life care, Patient-centered care, Patient-physician relationship, Quality
19
20
21
22 of life
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 **ARTICLE SUMMARY**
8
9

10 **Trial registration:** The protocol registered on 2nd August, 2018 at UMIN Clinical Trial
11 Registry. The registration number is UMIN000033612.
12
13
14
15
16
17
18

19 **Data statement:** Study protocol, data definition tables, and dataset will be uploaded to
20 the UMIN- Individual Case Data Repository, <https://www.umin.ac.jp/icdr/index-j.html>.
21
22
23
24
25
26
27

28 **Protocol version:** The protocol version is 1.4 on 20th December, 2019.
29
30
31
32
33

34 **Strengths and limitations of this study:**
35
36

- 37 • A strength of this study is the use of a large group of patients, caregivers, and
38 oncologists in the real-world scenario for which the intervention is being tested.
39
40
- 41 • The use of multicenter participant samples, controls, and patient follow-up allows
42 for reliable study results.
43
44
- 45 • This study includes oncologists, patients, and caregivers for intervention.
46
47
- 48 • The intervention program is complex, consisting of multiple factorial components,
49 which makes it difficult to determine which interventions and components are
50 most efficacious or beneficial; however, participants provide subjective
51
52
53
54
55
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5
6

7 assessments of the intervention components.
8

- 9
- 10 • The study only involves pancreatic cancer, so the generalization potential for other
11
12 cancers is unknown. However, as pancreatic cancer is one of the most rapidly
13
14 progressing cancers, the intervention may also be effective for patients with other
15
16
17
18
19 cancers.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

INTRODUCTION

Pancreatic cancer is the fourth leading cause of death in Japan, with approximately 35,000 new cases diagnosed per year, matching the approximate annual number of deaths from the disease nationally.[1] Over 40% of patients with pancreatic cancer are stage IV at diagnosis, and the 5-year survival rate is 7%.[2] Although the initial treatment goal for pancreatic cancer is to cure, even prolonged survival and maintenance of QOL are difficult to achieve.

Most patients with advanced cancer prefer to discuss their prognosis and treatments with their physicians.[3] However, physicians may feel burdened by open discussions for fear of patients losing hope, or they may face resistance from caregivers;[4] therefore, these discussions rarely occur.[5] Consequently, patients often overestimate the hopefulness of prognoses, underestimate disease severity, and have unrealistic expectations for a cure.[6] Patients who have not discussed prognosis and treatment choices with their oncologists are 3 to 8 times more likely to receive aggressive treatments in their last week of life.[5,7] Although oncologists and patients find that prognostic discussions can be stressful, unnecessary expenses and actual harm to the patient may result from uninformed decisions.[8] Additionally, it has been shown that open discussions do not cause hopelessness or increased fear in patients and that well-

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 informed patients make more appropriate treatment choices.[9,10] Hence, oncologists
8
9
10 need to provide adequate information regarding cancer treatment decisions for patients
11
12
13 and their caregivers approaching the end of life, confirm patients' and caregivers'
14
15
16 understanding, and achieve shared decision making about treatment and care based on
17
18
19 patients' personal values, life goals, and treatment preferences.
20
21

22 In previous study, patients from the diagnosis to the discontinuation of anti-
23
24
25 cancer drug treatment stage (mainly pancreatic cancer patients) showed to desire more
26
27
28 "empathic communication" from oncologists.[11] Empathic communication by
29
30
31 oncologists reduces patients' psychological distress,[12] increases trust in the
32
33
34 oncologist,[12] and enhances information recall.[13] Empathic communication is
35
36
37 essential especially for patients with rapidly progressing serious illnesses. Therefore,
38
39
40 communication skills training (CST) programs have been developed to help physicians
41
42
43 to facilitate communication behaviors that strengthen relationships with patients.[14]
44
45
46 CST involves learner-centered workshop held in small groups and including role-play
47
48
49 with simulated patients (SPs).[15] It is strongly recommended that medical professionals
50
51
52 train themselves in communication skills based on American Society of Clinical
53
54
55 Oncology Consensus Guidelines for patient–clinician communication.[16] Learning tools
56
57
58 (e.g., www.vitaltalk.org) are available to medical practitioners to support this learning.
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

We conducted a prior survey clarifying the four elements of communication skills patients prefer oncologists to have, referred to as SHARE: “setting,” “how to deliver the bad news,” “additional information,” and “reassurance and emotional support.”[17,18] A two-day SHARE-CST program for oncologists was developed based on these preferences.[19] The program is a small-group workshop including the above-mentioned modules; it employs role-play with simulated patients and immediate feedback[15] to allow learners to practice discussing serious news with cancer patients and caregivers, such as transition to palliative care when chemotherapy is failing. The program emphasizes that physicians respect the values of each patient and provide reassurance and emotional support in Asian culture.[20] Our previous randomized controlled trial (RCT) of physicians, including oncologists treating pancreatic cancer, showed that oncologists who participated in SHARE-CST improved their behavior in terms of patient-preferred communication as well as their self-confidence in communication with patients and that their patients experienced a relatively low level of psychological distress and a high level of trust in the oncologist.[12] In Japan, SHARE-CST was implemented as a 10-year project commissioned by the MHLW for physicians nationwide after the enactment of the National Cancer Control Act. Participants reported that their empathic communication attitudes and abilities had improved;[21] however, it

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 was difficult for most oncologists to participate in two-day CST group workshops because
8
9
10 of the busy clinical oncology settings in which they worked.
11
12

13 Patient-centered approaches using question prompt lists (QPLs) have also been
14
15 proposed for the improvement of patient-physician communication. A QPL is an
16
17 inexpensive communication tool employing a structured question list to encourage patient
18
19 question-asking and participation during consultations.[22] The provision of a QPL and
20
21 implementation of communication interventions with QPL before consultation is
22
23 effective in promoting patient question-asking behavior and participation in the
24
25 consultation and in decreasing patients' anxiety.[23] Our previous RCT of patients with
26
27 advanced gastric, colorectal, esophageal, and lung cancer showed that QPL was useful in
28
29 making initial treatment decisions for them but failed to promote patient question-asking
30
31 behavior,[24] in part because Japanese patients tend to wait for physicians to encourage
32
33 them to ask questions.[25] The number of patients asking their physician questions was
34
35 median 1, compared to mean/median 8.5 to 14 in studies in Western countries.[23,24] In
36
37 Japan, it has been reported that cancer patients have preference of not being burden to
38
39 others and of "omakase" (leaving the decision-making to a medical expert), and it is
40
41 difficult to elicit the patient's preference.[26] Thus, in Japan, integrated interventions
42
43 combining CST for oncologists and communication coaching with QPL for patients
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

might increase patient questioning behavior and improve patient-centered communication in consultations.[27,28]

Based on the results of previous trials, this study aims to evaluate the efficacy of a new, integrated communication support program, consisting of a CST for oncologists and communication coaching with QPL for patients with rapidly progressing advanced cancer and their caregivers, promoting oncologists' patient-centered communication behaviors. We hypothesize that, compared to treatment as usual (TAU), the intervention will increase oncologists' patient-centered communication behaviors, increase patients' question-asking behaviors, and improve patient well-being and health services utilization by reducing aggressive interventions and increasing use of palliative care.

METHODS and ANALYSIS

This protocol was written in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) and SPIRIT PRO Extension Guidelines.[29,30]

Study design

This study is a single-blind cluster RCT conducted in four metropolitan cancer-

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5
6

7 treatment hospitals: the National Cancer Center Hospital, the National Cancer Center
8
9 Hospital East, the Cancer Institute Hospital, and the Kanagawa Cancer Center Hospital.
10
11
12 This study protocol has been reviewed and approved by the protocol review committee
13
14 of the Japan Supportive, Palliative, and Psychosocial Oncology Group as J-SUPPORT
15
16 1704 and by the Institutional Review Boards at each participating institution.
17
18
19
20
21

22 An independent data center provides computer-generated random allocation
23
24 sequences. The assignment sequence is centrally managed; assignment results are
25
26 automatically sent to a clinical research coordinator (CRC), electronically. The oncologist
27
28 participants are randomly assigned to an intervention group (IG) or control group (CG)
29
30 after the baseline phase; patient/caregiver participants are assigned to the same group as
31
32 their oncologists. A stratified block-randomization scheme is used to assure balanced
33
34 assignment by site. Within each site, oncologists are randomly assigned approximately
35
36 evenly across IG and CG. Participants in IG provide intervention in addition to TAU, and
37
38 are unblinded.
39
40
41
42
43
44
45
46
47
48
49
50
51

52 **Intervention**

53 54 55 Oncologists

56
57
58 We modified the original SHARE-CST design,[12] adopting a 2.5-hour
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

individual program with a facilitator and a simulated patient (SP), consisting of lecture with a textbook (30 min) and 2 role-plays with immediate feedback (see Table 1). The original SHARE-CST is a small group consisting of 4 oncologists, 2 facilitators and 2 SPs, and included a lecture and 8 role-plays (twice per oncologist) with immediate feedback. The lecture cites evidence of the most important and common patient preferences regarding communication—empathic responses and encouragement to ask questions—and the variability of patients’ preferences in discussing prognoses and being/not being dispassionate; it also demonstrates how to check and elicit patient preferences. Additionally, the lecture explains the QPL and discusses frequently asked questions from patients about information related to treatment and care after standard treatment that relates to patients’ personal values, life goals, and preferences, as well as those of their caregivers. During the role-playing and discussion, participants are required to consider a patient’s emotions and concerns caused by bad news, recognition of their disease, social situations, and information that they would want to know, and to empathize with the patient. Role-play also includes dealing with patients who bring QPLs.

Facilitators provide a lecture, lead the role-play, and discuss patients’ potential emotions and communication-related preferences. Facilitators include psychiatrists, psychologists, and oncologists, all of whom have had 3 years or more of clinical

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

experience in oncology and participated in specialized 30-hour training workshops facilitating communication skills in oncology. The SPs have also participated in train-the-trainer workshops and 15 hours of SP training.

Patient and Caregiver

Communication coaching for patients was developed to facilitate communication with physicians using a 63-question QPL based on in-depth focus-group interviews with 18 participants (5 pancreatic cancer patients, 3 caregivers patients with pancreatic cancer, 4 bereaved people who had lost a family with pancreatic cancer, and 6 pancreatic oncologists), and previous QPL studies.[23,24,31] The QPL is a 10-page A4 sheet containing 63 questions grouped into 8 topics (diagnosis and stage of the disease, current and future treatments, management of current/possible future symptoms, daily life activities, care and prognosis post standard treatment, caregivers' needs, psychological distress and management, and values) and a space for free questions. Patient communication coaching using the QPL is a half-hour program, conducted individually or with a caregiver, consisting of reading the list to select personally relevant questions, prioritizing selected questions, discussing difficulties in asking the questions to their one's oncologist at their next oncology visit, and practicing asking their one's oncologist these

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

questions. The intervention is to be provided to patients individually or with caregivers by clinical psychologists and nurses who have participated in a 10-hour intensive training workshop using an intervention manual. All intervention sessions are noted and summarized. Before patients' visits, the oncologist is told which the questions the patient chose to ask from the QPL and the summary of the intervention. Intervention providers hold weekly conferences to review their coaching sessions.

Control condition

CG oncologists are provided neither training nor educational materials.

Patients/caregivers in the CG are provided TAU.

Participants

Oncologists

Enrolled oncologists must (1) be mainly engaged in anticancer drug treatment of pancreatic cancer patients; (2) have provided written informed consent for trial participation.

Patients

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 Enrolled patients must (1) have a diagnosis of pancreatic cancer
8 (adenocarcinoma); (2) have unresectable pancreatic cancer (UICC stage III or IV) or
9
10 postoperative recurrence; (3) receive a first-line chemotherapy and be scheduled for a
11
12 second course; (4) be aged 20 years or older; (5) have a ECOG performance status score
13
14 of 0 or 1; (6) regularly visit an enrolled oncologist; (7) provide written informed consent
15
16 for trial participation; and (8) be able to read, write, understand, and speak Japanese.
17
18
19
20
21
22
23

24 Patients are excluded if they are (1) judged by their oncologist to have cognitive
25
26 impairment; (2) unable to complete an electronic Patient Reported Outcome (e-PRO)
27
28 Questionnaire; or (3) judged unsuitable for participation by their oncologist.
29
30
31
32
33
34
35
36

37 Caregivers
38
39

40 If an enrolled patient is accompanied by a caregiver, the caregiver is also
41
42 approached. Enrolled caregivers must (1) be aged 20 years or older; (2) regularly
43
44 accompany an enrolled patient as primary caregiver; (3) provide written informed consent
45
46 to trial participation; (4) be able to read, write, understand, and speak Japanese.
47
48
49
50

51 Caregivers are excluded if they are unable to complete an electronic Patient
52
53 Reported Outcome (e-PRO) Questionnaire.
54
55
56
57
58
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

Procedures

This study consists of 3 phases: a baseline phase, an intervention phase, and a follow-up phase (Figure 1). The schedule for outcome measurement is shown in Table 2. After completing the intervention phase, data analysis will ensue. After this study has closed, oncologists in the control group will be provided with the intervention on demand.

Baseline phase

This phase involves oncologist and patient/caregiver recruitment as well as pre-randomization data collection on oncologists' communication behaviors as baseline data for use as a covariate in the RCT analysis. In this phase, 3 to 5 patients and their caregivers (if available) will be recruited for each oncologist. Participants will be asked to allow themselves to be audio-recorded at one oncology visit for primary and secondary communication behavior outcomes and to provide some evaluation on consultation as to study measures for potential use as covariates in the RCT analyses (Table 2).

Intervention phase

This phase involves oncologist randomization, intervention for participants in IG, and follow-up assessment. After oncologists are randomly assigned to the IG or CG, those

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

in the IG receive an individual intervention.

Next, 10 patients and their caregivers (if available) who regularly visit the oncologist are recruited and assigned to the IG or CG. After the IG patients and their caregivers receive an intervention, or 2 weeks to 1 month after baseline in the CG, the conversation between the patient/caregiver and the oncologist at their next consultation is audio-recorded. After the visit, patients/caregivers and the oncologists rate the consultation using a follow-up assessment.

Long-term follow-up phase

Patients and their caregivers will be encouraged to provide long-term follow-up assessments at 3, 6, 12, 24, and 36 months after the first follow-up assessment to evaluate effects on patient's physical and psychological condition and medical utilization at end of life. Caregivers are also asked to provide another assessment at 2 to 6 months post-patient death.

Data management, central monitoring, data monitoring, and auditing

We will collect all data, except for audio-recorded data, through electronic data capture (EDC) and electronic patient reported outcomes (ePRO) systems or paper-based

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

PRO questionnaires (pPRO) if patients are prevented from using the electronic approach.

If participants fail to respond to ePRO or pPRO, a CRC blinded to the assignment will elicit their answers to avoid missing data. Data management and central monitoring will be performed using EDC VIEDOC 4 (PCG Solutions, Uppsala, Sweden) by the J-SUPPORT Data Science Team. Auditing is not planned for this study.

Concomitant treatments

There is no restriction on concomitant treatments.

Stopping rules for participants

If a participant meets any of the following conditions, the research team can discontinue the intervention; however, the participant will not be considered to have dropped out of the trial at that stage and will still receive the assessments: (1) the participant wishes to stop the intervention; (2) the research team judges that the risk of the intervention is greater than the benefit for any reason; (3) the research team judges that it is difficult to continue the intervention because of clinical deterioration; and (4) the research team judges that it is inappropriate to continue the intervention for any reason.

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

Stopping assessment

If a participant withdraws consent for assessment, he or she will not be followed up. Subjects will be excluded from the intention-to-treat (ITT) cohort of the trial only if they are found to meet any exclusion criteria at baseline after participation.

Assessment measures

Table 2 shows the schedule for outcome measurement.

Primary outcome measure

Oncologist's patient-centered communication behaviors

The audio-recorded oncology visits for all participants will be coded for each of the four factors of communication behaviors based on patient preference, referred to as SHARE: setting, delivery of information, additional information, and reassurance and emotional support (see Table 1).[19] The SHARE-RE factor is used as a primary outcome to measure empathic communication between patient/caregiver and oncologist after intervention for both.

Following previous study methods,[19] impressions of conversations from consultations will be assessed using the SHARE-RE factor score, consisting of 8 categories for analysis, in a random order, by two blinded coders who have been trained

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 for 30 hours or more on two occasions with a rating manual.
8
9

10
11
12
13 Secondary outcome measure
14

15
16 *Oncologist's Patient-preferred communication behavior*
17

18
19 Patient-preferred communication will be analyzed using impression ratings from
20
21 two blinded coders, as described above. The analysis will include the audio-recorded
22
23 oncology visits for all participants using the total SHARE score, for all 27
24
25 categories.[18,19] Following previous study methods,[19] the 40 categories of the Roter
26
27 Intention Analysis System (RIAS) will also be used in assessing patient-preferred
28
29 communications.[32]
30
31
32
33
34
35
36
37
38
39

40 *Patient's and caregiver's communication behavior*
41

42
43 Following previous study methods,[19] the 40 categories of the Roter Intention
44
45 Analysis System (RIAS) will also be used in assessing patient's and caregiver's
46
47 communications behavior, for example question-asking.[32]
48
49
50
51
52
53
54

55 *Patient-reported outcome measures*
56

57
58 Several scales will be used to produce a comprehensive profile of each patient
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 participant. These include the Hospital Anxiety and Depression Scale (HADS);[33] the
8
9
10 Physical and Functional Well-being subscales of the Functional Assessment of Cancer
11
12 Therapy (FACT-Physical & Functional);[34] the Short version of the Comprehensive
13
14 Quality of Life Outcome inventory (CoQoLo);[35] the Trust in Oncologists Scale
15
16 (TiOS);[36] the Client Satisfaction Questionnaire (CSQ);[37] the Peace, Equanimity, and
17
18 Acceptance in the Cancer Experience (PEACE) questionnaire;[38] and the Prognosis and
19
20 Treatment Perceptions Questionnaire (PTPQ).[39]
21
22
23
24
25
26
27

28 Patients' relevant medical and sociological background information includes
29
30 stage, diagnosis date, treatment status, treatment history, comorbidities, sex, age, job
31
32 status, household income, household size, social support, marital status, educational
33
34 experience, treatment, and care preference at the end of life. Medical utilization at the end
35
36 of life will be determined by the date of death, any chemotherapy agent given within 14
37
38 days of death, any new chemotherapeutic regimen started within 30 days of death, and
39
40 involvement of hospice and palliative care services; all of this information is obtained
41
42 from medical fee information and the caregivers post-patient death.[27]
43
44
45
46
47
48
49
50
51

52 A patients' assessment of the intervention's usefulness includes "Did you
53
54 understand how to use the QPL and did you actually use it?" "Do you think you will
55
56 continue the intervention?" and "Was the intervention useful to you?" Their assessment
57
58
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

of oncologists includes “Did the oncologist talk about the QPL?” and “How did the oncologist respond to your questions?” Their assessment of QPL includes “Did the QPL help you ask the oncologist questions?” “Is the QPL useful?” “Did you read the QPL before the visit?” and “Do you think you will read the QPL in the future?” as well as whether they asked selected questions to oncologist after the visit, which questions they selected, and “How much you have discussed with your oncologist in the visit?” in the intervention phase.

Caregiver survey measures

Several scales will also be used to gain a comprehensive view of caregivers, including the K6 nonspecific psychological distress scale (K6);[40] the 5 Dimension EuroQol (EQ-5D);[41] and the CSQ.[37] After the patient’s death, the caregiver’s QOL as the bereaved is measured with the Short version of the Good Death Inventory (GDI).[42]

Caregivers’ relevant sociological background information includes sex, age, relationship with the patient, job status, household income, household size, social support, marital status, educational experience, and treatment and care preferences at end of life.

After the first post-intervention visit, caregivers in the IG will evaluate the

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

intervention, the oncologist, and the QPL and report any selected questions used with the oncologist.

Oncologist survey measures

The relevant data concerning the oncologists include their sociological background (sex, age, and clinical experience). The oncologists' evaluation of medical utilization by the patient will be set by their recollection of the dates.

The usefulness of the intervention will also be measured using evaluations provided by the oncologists in the IG.

Harms

No specific and serious adverse events are presumed for participants in this study. However, by participating in the interventions, some participants may potentially experience psychological distress from imagining their situation after standard treatment. The patients/ caregivers and oncologists will also be subjected to time burdens of a half-hour and 2.5 hours for the intervention, and 10–30 minutes for each baseline and follow-up assessment. Therefore, we will give patients/caregivers a reward of 500 Japanese yen for each participant assessment. There are no reward for the intervention and no financial

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

risks associated with study participation.

Compensation

If participants develop unexpected health issues due to study participation during or after completion of this study, treatment will be adequately provided per standard medical care, covered by the National Health Insurance.

Sample size estimation

Our previous study revealed that the effect size of SHARE-RE score was 1.9 at post-intervention.[12] For a sample size based on 80% power to detect a significant difference at a significance level of 0.05 (two-sided), 10 oncologists and 70–100 participants (7–10 per oncologist) would be required for each arm in the follow-up phase, assuming some participant drop out and data loss. Assuming that 80% of patients will be accompanied by caregivers at doctor visits, a total of 112–160 participants would be required. Based on previous studies, a total of 60–150 patients (3 to 5 per oncologist) are then needed in the baseline phase.[27]

Although the total time devoted to CST for the oncologists in this study is reduced from the original SHARE-CST program, the role-plays for individual

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

participants are performed the same time, and communication coaching with QPL for the patients is added. Therefore the effect size from the previous study was adopted for sample size calculation, and 20 oncologists, 3 patients per oncologist, a total of 60 patients in the baseline phase, and 10 patients per oncologist, for a total of 200 patients, are enrolled in the follow-up phase (Figure 1).

Patient and public involvement statement

This study protocol was co-designed by a patient with pancreatic cancer and a family member of a pancreatic cancer patient who participated as researchers. They spoke with other patients to help develop recommendations for when patients' preferences and/or opinions should be considered. They will play a similar role in the implementation of the study. Thus, patients were and will continue to be involved in the study. The results of this study will be available via a study website.

Data analysis

Primary analyses

To examine the intervention effect parameters of all randomly assigned subjects in the primary analysis set according to the ITT principle, we will analyze the primary

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

outcome with SHARE-RE as an indicator of enhanced empathic communication using a generalized linear model. The primary outcome of interest is the difference in SHARE-RE scores between the two groups after intervention. A two-sided p value < 0.05 will be used to indicate statistical significance.

Secondary analyses

We will perform secondary analyses to supplement our primary analysis and obtain a clearer understanding of our clinical questions. The secondary analyses will use models similar to that of the primary analysis and will examine data for the secondary outcome measures. These analyses will be conducted for exploratory purposes.

Interim analyses

No interim analysis is planned.

Publication policy

The protocol and study results will be submitted to peer-reviewed journals. The first author of the main paper will be a member of the steering committee (the authors of the protocol paper). Another person could be the first author if approved by the steering

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

committee. The list of coauthors will be determined before submitting each paper.

Study period

This study period of this trial is April 2017 to March 2023; the registration period is August 2018 to July 2020.

Ethics and dissemination

The present study is subject to ethical guidelines for clinical studies published by Japan's Ministry of Education, Science and Technology and Ministry of Health, Labour, and Welfare and the modified Act on the Protection of Personal Information as well as the ethical principles established for research on humans stipulated in the Declaration of Helsinki and further amendments thereto. If important protocol modifications are needed, the investigators will discuss them and report to the review board for approval. Regarding dissemination, the results obtained will be submitted for publication in peer-reviewed journals. The main and/or relevant findings will be presented at conferences.

DISCUSSION

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

This study is a multi-site randomized controlled trial to evaluate the efficacy of an integrated communication support program for rapidly progressive advanced cancer patients, caregivers, and oncologists to promote patient-centered communication. The intervention program is unique in intervening with both oncologists and patients/caregivers for a brief time at the point of first-line chemotherapy, before they are critically ill.

In clinical oncology, the introduction of personalized precision medicine has allowed great therapeutic progress. Patient-oncologist communication is uncertain and complex, and busy oncologists often find it difficult to take extra time with their patients. As a result, personalized and precise communication between a patient and an oncologist may not be achieved. If empathic communication between patients and oncologists can be improved, including shared decision making based on patient values and preferences about the use of evidence-based medicine, the result can be an effective integration of best practices and patient values, allowing for better use of clinical expertise and available resources.

In this study, it is essential that intervention facilitators and SPs be well trained to maintain the quality of the intervention. In the future, it may be possible to reduce costs by developing internet-based programs. Regarding QPL, clinical benefits may increase

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

when it is possible to link medical records with data from wearable devices. Above all, the use of electronic media is expected to make implementation of the intervention program easier.

Strengths and limitations

This study has two methodological limitations. First, we involve both oncologists and patients/caregivers. The intervention program for both is complex, consisting of multiple factorial components. Thus, if the interventions prove superior to usual care, we will not be able to determine which interventions and components are most efficacious or beneficial in promoting communication. Second, patient intervention will be applied only to patients with pancreatic cancer. The generalization potential of the approach for other cancers is thus unknown. However, because pancreatic cancer is one of most rapidly progressive cancers, the intervention may be effective in other cancers too.

Figure 1 caption

Participant flow diagram

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

Acknowledgements

We thank Ms. T Mashiko and Ms. M Kurosaki for their data management support. We also thank members of PanCan Japan, Ms. S Furutani, Dr M Mori, Dr Y Shirai, Dr S Umezawa, Ms. N Inomata, Mr. M Umehashi, Dr M Okamura, Dr M Odawara, Dr A Hanai, Mr. R Soga, Ms. R Sugihara, Ms. T Akiyama and Ms. M Kanamaru for their support for this study.

Contributors

MF is a principal investigator. MF and YU developed the CST program. MF, AS, SJ, TO, YM and YU developed the QPL. MF, TO, TY, MI, MU, MO, KT, TM, YM and YU participated in the design of this study. All authors prepared the protocol and agree of final protocol and revisions. MF, AS, SJ, MT prepared of investigators brochure (IB) and CRFs. TY played a chief role in the statistical parts. TM played roles in the data management. MF drafted the manuscript. All authors participated in, read and approved the final manuscript.

Funding

This study is supported by a Grant-in-Aid for Japan Agency for Medical

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 Research and Development (JP 17ck0106237h0001) and in part by The National Cancer
8
9
10 Center Research and Development Fund (30-A-11). This funding source had no role in
11
12
13 the design of this study and will not have any role during its execution, analyses,
14
15
16 interpretation of the data, or decision to submit results.
17

18
19 **Sponsor**

20
21
22 None
23
24
25
26
27

28 **Competing interests**

29
30 All authors declare that they have no competing interests regarding this work.
31
32
33
34 TO has received research funding from Ono Pharmaceutical, Kowa, Dainippon
35
36
37 Sumitomo Pharma, Chugai Pharmaceutical, Novartis, Yakult Honsha, AstraZeneca, Eisai,
38
39
40 Lilly, Bristol-Myers Squibb. TY received consulting fees from Ono Pharmaceutical,
41
42
43 Kowa, Japan Tobacco, Chugai Pharmaceutical, Tsumura & CO, CAC Croit, Asahi Intecc,
44
45
46 Asahi Kasei Pharma and Clinical Trial. MI has received honoraria from Novartis Pharma,
47
48
49 Bayer Yakuhin, Bristol-Myers Squibb, Abbott Japan, Eisai, Taiho Pharmaceutical, Eli
50
51
52 Lilly Japan, Daiichi-Sankyo, Yakult, Otsuka Pharmaceutical, Nobelpharma, EA Pharma
53
54
55 and Teijin Pharma, research funding from Bayer Yakuhin, Kyowa Hakko Kirin, Yakult,
56
57
58 Taiho Pharmaceutical, Eli Lilly Japan, Ono Pharmaceutical, Eisai, AstraZeneca, Zeria
59

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5
6

7 Pharmaceutical, Chugai, Bristol Myers Squibb, Merck Serono, Kowa, Nano Carrier,
8
9 ASLAN, Daiichi-Sankyo., Sumitomo Dainippon, Novartis Pharma, Baxalta, Boehringer
10
11
12 Ingelheim and Takara Bio. He is a consulting or advisory role for Nano Carrier, Bayer
13
14
15 Yakuhin, Eisai, Kyowa Hakko Kirin, Novartis Pharma, Shire, MSD, Bristol Myers Squibb,
16
17
18 Eli Lilly Japan, Sumitomo Dainippon, Daiichi-Sankyo, Teijin Pharma, Takara Bio and a
19
20
21 board member of ASLAN, Chugai. MU has received honoraria from Taiho
22
23
24 Pharmaceutical, Yakult Honsha, AstraZeneca, Novartis, Lilly, Teijin Pharma, Shire, Ono
25
26
27 Pharmaceutical, and Merck Serono, and research funding from Taiho Pharmaceutical,
28
29
30 Shire, Daiichi Sankyo, Eisai, AstraZeneca, Ono Pharmaceutical, MSD, Merck Serono,
31
32
33 NanoCarrier, Dainippon Sumitomo Pharma, Incyte, ASLAN Pharmaceuticals, and
34
35
36 Yakult Honsha. MO has received lecture fees from Taiho Pharmaceutical and honoraria
37
38
39 from Taiho Pharmaceutical, Yakult, Bayer, Pfizer and Novartis.
40
41
42
43
44
45

46 **Patient consent for publication**
47

48 Not required.
49
50
51
52
53
54

55 **Ethics approval**
56

57 The protocol was reviewed and approved by the Institutional Review Board of
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 National Cancer Center on 4 July 2018 (ID: 2014-474) as well as by the J-SUPPORT
8
9

10 Scientific Advisory Board.
11
12
13
14
15

16 **Provenance and peer review**
17
18

19 Not commissioned; externally peer reviewed.
20
21
22
23
24

25 **Open access**
26
27

28 This is an open access article distributed in accordance with the Creative
29
30 Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others
31
32 to distribute, remix, adapt, build upon this work non-commercially, and license their
33
34 derivative works on different terms, provided the original work is properly cited,
35
36 appropriate credit is given, any changes made indicated, and the use is non-commercial.
37
38
39
40
41
42

43 See: <http://creativecommons.org/licenses/by-nc/4.0/>.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 **References**
8
9

10 1. Ministry of Health, Labour and Welfare, Japan: White Papers & Reports Annual Health,
11 Labour and Welfare Report 2017.
12

13 2. National Cancer Center, Japan: Cancer Statistics in Japan 2018.
14
15

16 3. Parker SM, Clayton JM, Hancock K, et al. A systematic review of prognostic/end-of-
17 life communication with adults in the advanced stages of a life-limiting illness:
18 patient/caregiver preferences for the content, style, and timing of information. *J Pain*
19 *Symptom Manage* 2007;34(1):81-93.
20
21
22
23
24
25
26
27
28
29

30 4. Otani H, Morita T, Esaki T, et al. Burden on oncologists when communicating the
31 discontinuation of anticancer treatment. *Jpn J Clin Oncol* 2011;41(8):999-1006.
32
33
34
35

36 5. Wright AA, Zhang B, Ray A, et al. Associations between end-of-life discussions,
37 patient mental health, medical care near death, and caregiver bereavement adjustment.
38 *JAMA* 2008;300(14):1665-73.
39
40
41
42
43
44
45

46 6. Weeks JC, Catalano PJ, Cronin A, et al. Patients' expectations about effects of
47 chemotherapy for advanced cancer. *N Engl J Med* 2012;367(17):1616-25.
48
49
50

51 7. Weeks JC, Cook EF, O'Day SJ, et al. Relationship between cancer patients' predictions
52 of prognosis and their treatment preferences. *JAMA* 1998;279(21):1709-14.
53
54
55
56

57 8. Fallowfield LJ, Jenkins VA, Beveridge HA. Truth may hurt but deceit hurts more:
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 communication in palliative care. *Palliat Med* 2002;16(4):297-303.
8

9
10 9. Hagerty RG, Butow PN, Ellis PM, et al. Communicating prognosis in cancer care: a
11
12 systematic review of the literature. *Ann Oncol* 2005;16(7):1005-53.
13
14

15
16 10. Epstein RM, Peters E. Beyond information: exploring patients' preferences. *JAMA*
17
18 2009;302(2):195-7.
19
20

21
22 11. Umezawa S, Fujimori M, Matsushima E, et al. Preferences of advanced cancer
23
24 patients for communication on anticancer treatment cessation and the transition to
25
26 palliative care. *Cancer* 2015;121(23):4240-9.
27
28

29
30 12. Fujimori M, Shirai Y, Asai M, et al. Effect of communication skills training program
31
32 for oncologists based on patient preferences for communication when receiving bad
33
34 news: a randomized controlled trial. *J Clin Oncol* 2014;32(20):2166-72.
35
36

37
38 13. Sep MS, van Osch M, van Vliet LM, et al. The power of clinicians' affective
39
40 communication: how reassurance about non-abandonment can reduce patients'
41
42 physiological arousal and increase information recall in bad news consultations. An
43
44 experimental study using analogue patients. *Pat Educ Couns* 2014;95(1):45-52.
45
46
47
48

49
50 14. Moore PM, Rivera S, Bravo-Soto GA, et al. Communication skills training for
51
52 healthcare professionals working with people who have cancer. *Cochrane Database Syst*
53
54
55
56
57
58 Rev 2018;7:Cd003751.
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 15. Stiefel F, Kiss A, Salmon P, et al. Training in communication of oncology clinicians:
8 a position paper based on the third consensus meeting among European experts in 2018.
9
10 Ann Oncol 2018;29(10):2033-36.
11
12

13
14
15
16 16. Gilligan T, Coyle N, Frankel RM, et al. Patient-Clinician Communication: American
17 Society of Clinical Oncology Consensus Guideline. J Clin Oncol 2017;35(31):3618-32.
18
19

20
21
22 17. Fujimori M, Akechi T, Morita T, et al. Preferences of cancer patients regarding the
23 disclosure of bad news. Psychooncology 2007;16(6):573-81.
24
25

26
27
28 18. Fujimori M, Uchitomi Y. Preferences of cancer patients regarding communication of
29 bad news: a systematic literature review. Jpn J Clin Oncol 2009;39(4):201-16.
30
31

32
33
34 19. Fujimori M, Shirai Y, Asai M, et al. Development and preliminary evaluation of
35 communication skills training program for oncologists based on patient preferences for
36 communicating bad news. Palliat Support Care 2014;12(5):379-86.
37
38

39
40
41
42 20. Tang WR, Chen KY, Hsu SH, et al. Effectiveness of Japanese SHARE model in
43 improving Taiwanese healthcare personnel's preference for cancer truth telling.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

21. Yamada Y, Fujimori M, Shirai Y, et al. Changes in Physicians' Intrapersonal Empathy
after a Communication Skills Training in Japan. Acad Med 2018;93(12):1821-26.

22. Butow PN, Dunn SM, Tattersall MH, et al. Patient participation in the cancer

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 consultation: evaluation of a question prompt sheet. *Ann Oncol* 1994;5(3):199-204.
8
9

10 23. Brandes K, Linn AJ, Butow PN, et al. The characteristics and effectiveness of
11
12 Question Prompt List interventions in oncology: a systematic review of the literature.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

23. Brandes K, Linn AJ, Butow PN, et al. The characteristics and effectiveness of
Question Prompt List interventions in oncology: a systematic review of the literature.
Psychooncology 2015;24(3):245-52.

24. Shirai Y, Fujimori M, Ogawa A, et al. Patients' perception of the usefulness of a
question prompt sheet for advanced cancer patients when deciding the initial treatment: a
randomized, controlled trial. *Psychooncology* 2012;21(7):706-13.

25. Fujimori M, Akechi T, Akizuki N, et al. Good communication with patients receiving
bad news about cancer in Japan. *Psychooncology* 2005;14(12):1043-51.

26. Miyashita M, Sanjo M, Morita T, et al. Good death in cancer care: a nationwide
quantitative study. *Ann Oncol*. 2007 Jun;18(6):1090-7.

27. van Weert JC, Jansen J, Spreeuwenberg PM, et al. Effects of communication skills
training and a Question Prompt Sheet to improve communication with older cancer
patients: a randomized controlled trial. *Crit Rev Oncol Hematol* 2011;80(1):145-59.

28. Epstein RM, Duberstein PR, Fenton JJ, et al. Effect of a Patient-Centered
Communication Intervention on Oncologist-Patient Communication, Quality of Life, and
Health Care Utilization in Advanced Cancer: The VOICE Randomized Clinical Trial.
JAMA Oncol 2017;3(1):92-100.

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 29. Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration:
8
9 guidance for protocols of clinical trials. *BMJ* 2013;346:e7586.
10
11

12 30. Calvert M, Kyte D, Mercieca-Bebber R, et al. Guidelines for Inclusion of Patient-
13
14 Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. *JAMA*.
15
16 2018;319(5):483–494.
17
18

19 31. Brown RF, Butow PN, Dunn SM, et al. Promoting patient participation and shortening
20
21 cancer consultations: a randomised trial. *Br J Cancer* 2001;85(9):1273-9.
22
23
24

25 32. Roter, D.L., Hall, J.A., Kern, D.E., et al. Improving physicians' interviewing skills
26
27 and reducing patients' emotional distress. Randomized clinical trial. *Arch Intern Med*
28
29 1995;155, 1877–1884.
30
31
32

33 33. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr*
34
35 *Scand* 1983;67(6):361-70.
36
37
38

39 34. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy
40
41 scale: development and validation of the general measure. *J Clin Oncol* 1993;11(3):570-
42
43
44 9.
45
46
47

48 35. Miyashita M, Wada M, Morita T, et al. Development and validation of the
49
50 Comprehensive Quality of Life Outcome (CoQoLo) inventory for patients with advanced
51
52 cancer. *BMJ Support Palliat Care*. 2019;9(1):75-83.
53
54
55
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 36. Hillen MA, Postma RM, Verdam MG, et al. Development and validation of an
8 abbreviated version of the Trust in Oncologist Scale-the Trust in Oncologist Scale-short
9 form (TiOS-SF). *Support Care Cancer* 2017;25(3):855-61.
10
11
12

13 37. Zandbelt LC, Smets EM, Oort FJ, et al. Satisfaction with the outpatient encounter: a
14 comparison of patients' and physicians' views. *J Gen Intern Med* 2004;19(11):1088-95.
15
16
17

18 38. Mack JW, Nilsson M, Balboni T, et al. Peace, Equanimity, and Acceptance in the
19 Cancer Experience (PEACE): validation of a scale to assess acceptance and struggle with
20 terminal illness. *Cancer* 2008;112(11):2509-17.
21
22
23

24 39. El-Jawahri A, Traeger L, Park ER, et al. Associations among prognostic
25 understanding, quality of life, and mood in patients with advanced cancer. *Cancer*
26 2014;120(2):278-85.
27
28
29

30 40. Kessler RC, Andrews G, Colpe LJ, et al. Short screening scales to monitor population
31 prevalences and trends in non-specific psychological distress. *Psychol Med*
32 2002;32(6):959-76.
33
34
35

36 41. Brooks R. EuroQol: the current state of play. *Health policy (Amsterdam, Netherlands)*
37 1996;37(1):53-72.
38
39
40

41 42. Miyashita M, Morita T, Sato K, et al. Good death inventory: a measure for evaluating
42 good death from the bereaved family member's perspective. *J Pain Symptom Manage*
43
44
45

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3

4
5
6 2008;35(5):486-98.
7
8
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
 2
 3 AND ONCOLOGISTS
 4
 5
 6
 7
 8
 9

10 Table 1. Components of CST Program Based on SHARE Model
 11

	Description
12 13 14 15 16 Conceptual communication 17 skills model: SHARE 18 19 20 21 22 23 24 25 26 27 S 28 29 30 31 32 33 34 35 36 37 H 38 39 40 41 42 43 44 45 46 A 47 48 49 50 51 52 53 54 RE 55 56 57 58 59 60	Setting up supportive environment for interview, including fundamental communication skills (e.g., greeting patient cordially, looking at patient's eyes and face) Considering how to deliver bad news (e.g., not beginning bad news without preamble, checking to see whether talk is fast paced) Discussing additional information that patient would like to know (e.g., answering patient's questions fully, explaining second opinion) Providing reassurance and addressing patient's emotions with empathic responses (e.g., remaining

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
 2
 3 AND ONCOLOGISTS
 4
 5

	<p>6</p> <p>7 silent out of concern for patient's feelings, accepting</p> <p>8</p> <p>9 patient's expression of emotions)</p> <p>10</p> <p>11</p>
<p>12</p> <p>13 Component</p> <p>14</p> <p>15</p> <p>16</p> <p>17 Lecture</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p> <p>25</p> <p>26</p> <p>27</p> <p>28 Role playing</p> <p>29</p> <p>30</p> <p>31</p> <p>32</p>	<p>12</p> <p>13 Introduction, communication skills model, evidence</p> <p>14</p> <p>15</p> <p>16 on preferences of patients with cancer regarding</p> <p>17</p> <p>18 communication</p> <p>19</p> <p>20 Simulated consultation with simulated patient using</p> <p>21</p> <p>22 communication skills with scenarios, discussing with</p> <p>23</p> <p>24 facilitator, summary</p> <p>25</p> <p>26</p> <p>27</p> <p>28</p> <p>29</p> <p>30</p> <p>31</p> <p>32</p>
<p>33</p> <p>34 Scenarios on</p> <p>35</p> <p>36 communication in advanced</p> <p>37</p> <p>38 care</p> <p>39</p> <p>40</p> <p>41</p> <p>42</p>	<p>33</p> <p>34 Discontinuing chemotherapy</p> <p>35</p> <p>36</p> <p>37</p> <p>38 Dealing with patient asking questions</p> <p>39</p> <p>40</p> <p>41</p> <p>42</p>
<p>43</p> <p>44 Setting</p> <p>45</p> <p>46</p> <p>47</p> <p>48</p> <p>49</p> <p>50</p> <p>51</p>	<p>43</p> <p>44 1 participant</p> <p>45</p> <p>46</p> <p>47 1 facilitator</p> <p>48</p> <p>49</p> <p>50 1 simulated patient</p> <p>51</p>
<p>52</p> <p>53 Schedule</p> <p>54</p> <p>55</p> <p>56</p> <p>57</p> <p>58</p> <p>59</p> <p>60</p>	<p>52</p> <p>53 Orientation and lecture (30 minutes)</p> <p>54</p> <p>55</p> <p>56</p> <p>57</p> <p>58</p> <p>59</p> <p>60</p>

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

	Role playing with immediate feedback (60 minutes X 2)
--	---

Abbreviation: CST, communication skills training.

Table 2. Schedule for outcome measurement

	Outcome	Measurement	Baseline Phase		Intervention Phase		Follow-up Phase	
			Day 28 of 1st line chemotherapy	Day 42 of 1st line chemotherapy	Day 28 of 1st line chemotherapy	Day 42 of 1st line chemotherapy	3, 6, 12, 24, 36 months after	After post-mortem of the patient
Patient in baseline phase	Patient's communication behavior	RIAS		○				
	Patient's medical and sociological background	Cancer stage, diagnosis date, treatment status, treatment history, comorbidities, sex, age, work status, household income, household size, social support, marital status, educational	○					

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

		<p>experience, treatment, and care preference at the end of life</p> <p>"How did the oncologist respond to your questions?" "Did you ask selected questions during consultation?"</p> <p>"How much have you discussed with your oncologist in the visit?"</p>							
<p>Patient in intervention and follow-up phase</p>	<p>Patient's communication behavior</p> <p>Patient's psychological distress</p> <p>Patient's physical and functional QOL</p> <p>Patient's comprehensive QOL</p> <p>Patient's trust in oncologist</p> <p>Patient's satisfaction with oncologist</p>	<p>RIAS</p> <p>HADS</p> <p>FACT-Physical & Functional</p> <p>Short version of CoQOLo</p> <p>TiOS</p> <p>CSQ</p>				<p>○</p> <p>○</p> <p>○</p> <p>○</p> <p>○</p> <p>○</p>			

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
AND ONCOLOGISTS

	Patient's acceptance in cancer experience	PEACE			<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	
	Patient's prognosis and treatment perception	PTPQ			<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	
	Patient's evaluation of consultation	"How did the oncologist respond to your questions?" "Did you ask selected questions during consultation?" "How much have you discussed with your oncologist in the visit?" "Did you understand how to use the QPL and did you actually use it?"				<input type="radio"/>		
	Patient's evaluation of intervention and QPL in intervention group	"Do you think you will continue the intervention?" "Was the intervention useful to you?" "Did the oncologist talk about the QPL?"				<input type="radio"/>		

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
AND ONCOLOGISTS

		<p>“Did the QPL helped you ask the oncologist questions?” “Is the QPL useful?”</p> <p>“Did you read the QPL before the visit?” “Do you think you will read the QPL in the future?”</p> <p>Cancer stage, diagnosis date, treatment status, treatment history, comorbidities, sex, age, job status, household income, household size, social support, marital status, educational experience, treatment, and care preference at the end of life</p>						
	<p>Patient's medical and sociological background</p>							
	<p>Patient's medical utilization at the end of life</p>	<p>The date of death, any chemotherapy agent given within 14 days</p>						

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

		of death, any new chemotherapeutic regimen started within 30 days of death, and involvement of hospice and palliative care services						
Caregiver in baseline phase	Caregiver's communication behavior	RIAS		○				
	Caregiver's characteristics	Sex, age, relationship with the patient, job status, household income, household size, social support, marital status, educational experience, and treatment and care preferences at the end of life	○					
	Caregiver's evaluation of consultation	"How did the oncologist respond to your questions?" "Did you ask selected questions during consultation?" "How much		○				

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
AND ONCOLOGISTS

	<p>Caregiver's evaluation of consultation</p>	<p>"How did the oncologist respond to your questions?" "Did you ask selected questions during consultation?" "How much have you discussed with your oncologist in the visit?"</p>				<p>o</p>	
	<p>Caregiver's evaluation of intervention and QPL in intervention group</p>	<p>"Did you understand how to use the QPL and did you actually use it?" "Do you think you will continue the intervention?" "Was the intervention useful to you?" "Did the oncologist talk about the QPL?" "Did the QPL help you ask the oncologist questions?" "Is the QPL useful?" "Did you read the QPL before the visit?" "Do</p>				<p>o</p>	

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

		you think you will read the QPL in the future?"						
	Short version of Good Death Inventory	Short version of Good Death Inventory						○
Oncologist	Oncologist's Patient-centered communication behaviors	SHARE-RE		○		○		
	Oncologist's Patient-preferred communication behavior	SHARE-total		○		○		
	Oncologist's Patient-preferred communication behavior	RIAS		○		○		
	Oncologist's sociological background	Sex, age, clinical experience	○					
	Oncologist's evaluation of medical utilization by patient	The date of management		○		○		
	Oncologist's evaluation of intervention	The usefulness of the intervention				○		

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

Abbreviation: RIAS, Roter intention analysis system

HADS, Hospital Anxiety and Depression Scale

FACT-Physical & Functional, Physical well-being and Functional well-being subscales of the Functional Assessment of Cancer Therapy

CoQOLo, Comprehensive Quality of Life Outcome inventory

TiOS, Trust in Oncologists Scale

CSQ, Client Satisfaction Questionnaire

PEACE, Peace, Equanimity, and Acceptance in the Cancer Experience questionnaire

PTPQ, Prognosis and Treatment Perceptions Questionnaire


K6, K6 nonspecific psychological distress scale

EQ-5D, 5 Dimension EuroQol

GDI, Good Death Inventory

IG, Intervention Group

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

			Page
	Reporting Item		Number
Administrative information			
Title	#1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym		1

1	Trial registration	#2a	Trial identifier and registry name. If not yet registered,	7
2			name of intended registry	
3				
4				
5				
6	Trial registration:	#2b	All items from the World Health Organization Trial	7
7	data set		Registration Data Set	
8				
9				
10				
11				
12	Protocol version	#3	Date and version identifier	7
13				
14				
15	Funding	#4	Sources and types of financial, material, and other	31
16			support	
17				
18				
19				
20	Roles and	#5a	Names, affiliations, and roles of protocol contributors	31
21	responsibilities:			
22				
23	contributorship			
24				
25				
26				
27				
28	Roles and	#5b	Name and contact information for the trial sponsor	32
29	responsibilities:			
30				
31	sponsor contact			
32	information			
33				
34				
35				
36				
37				
38	Roles and	#5c	Role of study sponsor and funders, if any, in study	31
39	responsibilities:		design; collection, management, analysis, and	
40			interpretation of data; writing of the report; and the	
41	sponsor and funder		decision to submit the report for publication, including	
42			whether they will have ultimate authority over any of	
43			these activities	
44				
45				
46				
47				
48				
49				
50				
51				
52	Roles and	#5d	Composition, roles, and responsibilities of the	31
53	responsibilities:		coordinating centre, steering committee, endpoint	
54			adjudication committee, data management team, and	
55	committees			
56				
57				
58				
59				
60				

1 other individuals or groups overseeing the trial, if
 2
 3 applicable (see Item 21a for data monitoring committee)
 4
 5

6 Introduction

7			
8			
9	Background and	#6a	Description of research question and justification for
10			
11	rationale		undertaking the trial, including summary of relevant
12			studies (published and unpublished) examining benefits
13			
14			and harms for each intervention
15			
16			
17			
18			
19	Background and	#6b	Explanation for choice of comparators
20			
21	rationale: choice of		
22			
23	comparators		
24			
25			
26	Objectives	#7	Specific objectives or hypotheses
27			
28			
29	Trial design	#8	Description of trial design including type of trial (eg,
30			parallel group, crossover, factorial, single group),
31			allocation ratio, and framework (eg, superiority,
32			equivalence, non-inferiority, exploratory)
33			
34			
35			
36			
37			
38			
39	Methods:		
40			
41	Participants,		
42			
43	interventions, and		
44			
45	outcomes		
46			
47			
48			
49	Study setting	#9	Description of study settings (eg, community clinic,
50			academic hospital) and list of countries where data will be
51			collected. Reference to where list of study sites can be
52			obtained
53			
54			
55			
56			
57			
58			
59			
60			

1	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If	16
2				
3			applicable, eligibility criteria for study centres and	
4			individuals who will perform the interventions (eg,	
5			surgeons, psychotherapists)	
6				
7				
8				
9				
10				
11	Interventions:	#11a	Interventions for each group with sufficient detail to allow	13
12				
13	description		replication, including how and when they will be	
14			administered	
15				
16				
17				
18				
19	Interventions:	#11b	Criteria for discontinuing or modifying allocated	13
20				
21	modifications		interventions for a given trial participant (eg, drug dose	
22			change in response to harms, participant request, or	
23			improving / worsening disease)	
24				
25				
26				
27				
28				
29	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	13
30				
31	adherence		and any procedures for monitoring adherence (eg, drug	
32			tablet return; laboratory tests)	
33				
34				
35				
36	Interventions:	#11d	Relevant concomitant care and interventions that are	20
37				
38	concomitant care		permitted or prohibited during the trial	
39				
40				
41				
42	Outcomes	#12	Primary, secondary, and other outcomes, including the	21
43				
44			specific measurement variable (eg, systolic blood	
45			pressure), analysis metric (eg, change from baseline, final	
46			value, time to event), method of aggregation (eg, median,	
47			proportion), and time point for each outcome. Explanation	
48			of the clinical relevance of chosen efficacy and harm	
49			outcomes is strongly recommended	
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Participant timeline	#13	Time schedule of enrolment, interventions (including any	18
2			run-ins and washouts), assessments, and visits for	
3			participants. A schematic diagram is highly recommended	
4			(see Figure)	
5				
6				
7				
8				
9				
10				
11	Sample size	#14	Estimated number of participants needed to achieve	26
12			study objectives and how it was determined, including	
13			clinical and statistical assumptions supporting any sample	
14			size calculations	
15				
16				
17				
18				
19				
20				
21	Recruitment	#15	Strategies for achieving adequate participant enrolment to	17
22			reach target sample size	
23				
24				
25				
26	Methods:			
27				
28	Assignment of			
29	interventions (for			
30	controlled trials)			
31				
32				
33				
34				
35				
36	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	13
37	generation		computer-generated random numbers), and list of any	
38			factors for stratification. To reduce predictability of a	
39			random sequence, details of any planned restriction (eg,	
40			blocking) should be provided in a separate document that	
41			is unavailable to those who enrol participants or assign	
42			interventions	
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	13
54	concealment		central telephone; sequentially numbered, opaque,	
55				
56				
57				
58	mechanism			
59				
60				

sealed envelopes), describing any steps to conceal the sequence until interventions are assigned

Allocation: [#16c](#) Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions 13

Blinding (masking) [#17a](#) Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how 13

Blinding (masking): [#17b](#) If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial 13

Methods: Data collection, management, and analysis

Data collection plan [#18a](#) Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol 19

1	Data collection plan:	#18b	Plans to promote participant retention and complete	19
2				
3	retention		follow-up, including list of any outcome data to be	
4			collected for participants who discontinue or deviate from	
5			intervention protocols	
6				
7				
8				
9				
10				
11	Data management	#19	Plans for data entry, coding, security, and storage,	19
12			including any related processes to promote data quality	
13			(eg, double data entry; range checks for data values).	
14			Reference to where details of data management	
15			procedures can be found, if not in the protocol	
16				
17				
18				
19				
20				
21				
22				
23	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	27
24			outcomes. Reference to where other details of the	
25			statistical analysis plan can be found, if not in the protocol	
26				
27				
28				
29				
30				
31	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	27
32	analyses		adjusted analyses)	
33				
34				
35				
36	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	27
37	population and		adherence (eg, as randomised analysis), and any	
38	missing data		statistical methods to handle missing data (eg, multiple	
39			imputation)	
40				
41				
42				
43				
44				
45				
46	Methods: Monitoring			
47				
48				
49	Data monitoring:	#21a	Composition of data monitoring committee (DMC);	19
50	formal committee		summary of its role and reporting structure; statement of	
51			whether it is independent from the sponsor and	
52			competing interests; and reference to where further	
53				
54				
55				
56				
57				
58				
59				
60				

1 details about its charter can be found, if not in the
 2
 3 protocol. Alternatively, an explanation of why a DMC is
 4
 5 not needed
 6
 7

8	Data monitoring:	#21b	Description of any interim analyses and stopping	27
9				
10	interim analysis		guidelines, including who will have access to these	
11				
12			interim results and make the final decision to terminate	
13				
14			the trial	
15				
16				
17				
18	Harms	#22	Plans for collecting, assessing, reporting, and managing	25
19				
20			solicited and spontaneously reported adverse events and	
21				
22			other unintended effects of trial interventions or trial	
23				
24			conduct	
25				
26				
27				
28	Auditing	#23	Frequency and procedures for auditing trial conduct, if	32
29				
30			any, and whether the process will be independent from	
31				
32			investigators and the sponsor	
33				
34				
35	Ethics and			
36				
37	dissemination			
38				
39				
40				
41	Research ethics	#24	Plans for seeking research ethics committee / institutional	13
42				
43	approval		review board (REC / IRB) approval	
44				
45				
46	Protocol	#25	Plans for communicating important protocol modifications	28
47				
48	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
49				
50			relevant parties (eg, investigators, REC / IRBs, trial	
51				
52			participants, trial registries, journals, regulators)	
53				
54				
55				
56				
57				
58				
59				
60				

1	Consent or assent	#26a	Who will obtain informed consent or assent from potential	18
2			trial participants or authorised surrogates, and how (see	
3			Item 32)	
4				
5				
6				
7				
8				
9	Consent or assent:	#26b	Additional consent provisions for collection and use of	42
10	ancillary studies		participant data and biological specimens in ancillary	
11			studies, if applicable	
12				
13				
14				
15				
16	Confidentiality	#27	How personal information about potential and enrolled	28
17			participants will be collected, shared, and maintained in	
18			order to protect confidentiality before, during, and after	
19			the trial	
20				
21				
22				
23				
24				
25				
26	Declaration of	#28	Financial and other competing interests for principal	32
27	interests		investigators for the overall trial and each study site	
28				
29				
30				
31				
32	Data access	#29	Statement of who will have access to the final trial	7
33			dataset, and disclosure of contractual agreements that	
34			limit such access for investigators	
35				
36				
37				
38				
39	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and for	25
40	trial care		compensation to those who suffer harm from trial	
41			participation	
42				
43				
44				
45				
46				
47	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial	28
48	trial results		results to participants, healthcare professionals, the	
49			public, and other relevant groups (eg, via publication,	
50			reporting in results databases, or other data sharing	
51			arrangements), including any publication restrictions	
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Dissemination policy: #31b	Authorship eligibility guidelines and any intended use of	28
2			
3	authorship	professional writers	
4			
5			
6	Dissemination policy: #31c	Plans, if any, for granting public access to the full	7
7			
8	reproducible	protocol, participant-level dataset, and statistical code	
9			
10	research		
11			
12			
13			
14	Appendices		
15			
16			
17	Informed consent	#32 Model consent form and other related documentation	1
18			
19	materials	given to participants and authorised surrogates	
20			
21			
22			
23	Biological specimens	#33 Plans for collection, laboratory evaluation, and storage of	n/a
24			
25		biological specimens for genetic or molecular analysis in	
26			
27		the current trial and for future use in ancillary studies, if	
28			
29		applicable	
30			
31			

32 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-
 33 BY-ND 3.0. This checklist was completed on 20. December 2019 using <https://www.goodreports.org/>,
 34
 35 a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

An integrated communication support program for oncologists, caregivers, and patients with rapidly progressing advanced cancer to promote patient-centered communication: J-SUPPORT 1904 study protocol for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-036745.R2
Article Type:	Protocol
Date Submitted by the Author:	23-Jul-2020
Complete List of Authors:	<p>Fujimori, Maiko; National Cancer Center Japan, Division of Health Care Research, Behavioral Science and Survivorship Research Group, Center for Public Health Sciences, National Cancer Center Japan</p> <p>Sato, Ayako; National Cancer Center Japan, Division of Health Care Research, Behavioral Science and Survivorship Research Group, Center for Public Health Sciences</p> <p>Jinno, Sayaka; National Cancer Center Japan, Division of Health Care Research, Behavioral Science and Survivorship Research Group, Center for Public Health Sciences</p> <p>Okusaka, Takuji; National Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology Division</p> <p>Yamaguchi, Takuhiro; Tohoku University Graduate School of Medicine Department of Medical Biochemistry, Division of Biostatistics</p> <p>Ikeda, Masafumi; National Cancer Center-Hospital East, Department of Hepato-biliary Pancreatic Oncology</p> <p>Ueno, Makoto; Kanagawa Cancer Center, Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division</p> <p>Ozaka, Masato; Public Interest Incorporated Foundation Cancer Institute Hospital of JFCR, Department of Hepatobiliary and Pancreatic Medical Oncology</p> <p>Takayama, Yukiko; Tokyo Women's Medical University Hospital, Department of Medicine, Institute of Gastroenterology</p> <p>Miyaji, Tempei; Tokyo Medical University School of Medicine Graduate School of Medicine, Department of Clinical Trial Data Management</p> <p>Majima, Yoshiyuki; Pancreatic Cancer Action Network</p> <p>Uchitomi, Yosuke; Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital, & Behavioral and Survivorship Research Group, Center for Public Health Sciences</p>
Primary Subject Heading:	Communication
Secondary Subject Heading:	Oncology, Palliative care, Patient-centred medicine
Keywords:	Adult oncology < ONCOLOGY, Adult palliative care < PALLIATIVE CARE, MENTAL HEALTH, SOCIAL MEDICINE

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5
6

7 **TITLE:** An integrated communication support program for oncologists, caregivers, and
8
9 patients with rapidly progressing advanced cancer to promote patient-centered
10
11 communication: J-SUPPORT 1904 study protocol for a randomized controlled trial
12
13
14

15
16 **RUNNING TITLE:** Integrated communication program for advanced cancer patients
17
18 and oncologists
19
20

21 **AUTHORS:**

22
23 **Maiko Fujimori**

24
25 Division of Health Care Research, Behavioral Science and Survivorship Research Group,
26
27 Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
28
29
30

31
32 **Ayako Sato**

33
34 Division of Health Care Research, Behavioral Science and Survivorship Research Group,
35
36 Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
37
38
39

40
41 **Sayaka Jinno**

42
43 Division of Health Care Research, Behavioral Science and Survivorship Research Group,
44
45 Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
46
47
48

49
50 **Takuji Okusaka**

51
52 Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital,
53
54
55
56
57
58 Tokyo, Japan
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 **Takuhiko Yamaguchi**
8

9
10 Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai,
11
12
13 Miyagi, Japan
14

15
16 **Masafumi Ikeda**
17

18
19 Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital,
20
21
22 East, Kashiwa, Chiba, Japan
23

24
25 **Makoto Ueno**
26

27
28 Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology
29
30
31 Division, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
32

33
34 **Masato Ozaka**
35

36
37 Department of Hepatobiliary and Pancreatic Medical Oncology, The Cancer Institute
38
39
40 Hospital of JFCR, Ariake, Tokyo, Japan
41

42
43 **Yukiko Takayama**
44

45
46 Department of Medicine, Institute of Gastroenterology Tokyo Women's Medical
47
48
49 University, Tokyo, Japan
50

51
52 **Tempei Miyaji**
53

54
55 Department of Clinical Trial Data Management, Tokyo University Graduate School of
56
57
58 Medicine, Tokyo, Japan
59

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 Division of Health Care Research, Behavioral Science and Survivorship Research Group,
8

9
10 Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
11
12

13 **Yoshiyuki Majima**
14

15
16 NPO Pancreatic Cancer Action Network Japan, Tokyo, Japan
17
18

19 **Yosuke Uchitomi**
20

21
22 Division of Health Care Research, Behavioral Science and Survivorship Research Group,
23
24

25 Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
26
27

28 **CORRESPONDING AUTHOR:** Maiko Fujimori, Center for Public Health Sciences,
29

30 National Cancer Center, Japan
31
32

33
34 Postal address: Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045 JAPAN
35
36

37 E-mail address: mfujimor@ncc.go.jp
38
39

40 Ttelephone number: +81-3-3547-5201 EXT. 3320
41
42
43
44
45

46 Word count: 3716 words, excluding title page, abstract, references, figures, and tables
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

ABSTRACT

Introduction

Communication is an essential aspect of care for patients with progressive serious illnesses. This study aims to evaluate the efficacy of a new, integrated communication support program for oncologists, patients with rapidly progressing advanced cancer and their caregivers.

Methods and Analysis

The proposed integrated communication support program is in the randomized control trial stage. It comprises a cluster of oncologists from comprehensive cancer center hospitals in a metropolitan area in Japan. A total of 20 oncologists, 200 patients with advanced pancreatic cancer, and the patients' caregivers are enrolled in this study as of the writing of this protocol report. Oncologists are randomly assigned to the intervention group (IG) or control group (CG). Patients and caregivers are allocated to the same group as their oncologists. The IG oncologists receive a 2.5-hour individual communication skills training, and patients and caregivers receive a half-hour coaching intervention to facilitate prioritizing and discussing questions and concerns; the CG participants do not receive any training. Follow-up data will be collected quarterly for 6 months for a year

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

and then annually for up to three years. The primary endpoint is the intergroup difference between before- and after-intervention patient-centered communication behaviors during oncology visits.

Ethics and dissemination

This study is conducted in accordance with the ethical guidelines for clinical studies published by Japan's Ministry of Education, Cultural, Sports, Science, and Technology, the Ministry of Health, Labour, and Welfare (MHLW), and the ethical principles established for research on humans stipulated in the Declaration of Helsinki and further amendments thereto. The protocol was approved by the Institutional Review Board of National Cancer Center, Japan on July 4, 2018 (ID: 2017-474).

Trial status

This study is currently enrolling participants; enrollment period ends July 31, 2020; estimated follow-up date is March 31, 2023.

Trial registration number

UMIN Clinical Trial Registry: UMIN000033612; Pre-results.

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5
6
7
8
9

10 (299 words)
11
12
13
14
15

16 **Keywords:** Advance Care Planning, Caregivers, Communication, Decision making,
17
18 Empathy, End-of-life care, Patient-centered care, Patient-physician relationship, Quality
19
20
21
22 of life
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 **ARTICLE SUMMARY**
8
9

10 **Trial registration:** The protocol registered on 2nd August, 2018 at UMIN Clinical Trial
11 Registry. The registration number is UMIN000033612.
12
13
14
15
16
17
18

19 **Data statement:** Study protocol, data definition tables, and dataset will be uploaded to
20 the UMIN- Individual Case Data Repository, <https://www.umin.ac.jp/icdr/index-j.html>.
21
22
23
24
25
26
27

28 **Protocol version:** The protocol version is 1.4 on 20th December, 2019.
29
30
31
32
33

34 **Strengths and limitations of this study:**
35
36

- 37 • A strength of this study is the use of a large group of patients, caregivers, and
38 oncologists in the real-world scenario for which the intervention is being tested.
39
40
- 41 • The use of multicenter participant samples, controls, and patient follow-up allows
42 for reliable study results.
43
44
- 45 • This study includes oncologists, patients, and caregivers for intervention.
46
47
- 48 • The intervention program is complex, consisting of multiple factorial components,
49 which makes it difficult to determine which interventions and components are
50 most efficacious or beneficial; however, participants provide subjective
51
52
53
54
55
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 assessments of the intervention components.
8
9

- 10 • The study only involves pancreatic cancer, so the generalization potential for other
11 cancers is unknown. However, as pancreatic cancer is one of the most rapidly
12 progressing cancers, if the intervention is effective for patients with pancreatic
13 cancer who have severe physical and psychological conditions, it may be applied
14 to patients with other cancers as well.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

INTRODUCTION

Pancreatic cancer is the fourth leading cause of death in Japan, with approximately 35,000 new cases diagnosed per year, matching the approximate annual number of deaths from the disease nationally.[1] Over 40% of patients with pancreatic cancer are stage IV at diagnosis, and the 3-year survival rate for stage III and IV is 11.9% and 2.5%, respectively.[2] Although the initial treatment goal for pancreatic cancer is to cure, even prolonged survival and maintenance of QOL are difficult to achieve.

Most patients with advanced cancer prefer to discuss their prognosis and treatments with their physicians.[3] However, physicians may feel burdened by open discussions for fear of patients losing hope, or they may face resistance from caregivers;[4] therefore, these discussions rarely occur.[5] Consequently, patients often overestimate the hopefulness of prognoses, underestimate disease severity, and have unrealistic expectations for a cure.[6] Patients who have not discussed prognosis and treatment choices with their oncologists are 3 to 8 times more likely to receive aggressive treatments in their last week of life.[5,7] Although oncologists and patients find that prognostic discussions can be stressful, unnecessary expenses and actual harm to the patient may result from uninformed decisions.[8] Additionally, it has been shown that open discussions do not cause hopelessness or increased fear in patients and that well-

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 informed patients make more appropriate treatment choices.[9,10] Hence, oncologists
8
9
10 need to provide adequate information regarding cancer treatment decisions for patients
11
12
13 and their caregivers approaching the end of life, confirm patients' and caregivers'
14
15
16 understanding, and achieve shared decision making about treatment and care based on
17
18
19 patients' personal values, life goals, and treatment preferences.
20
21

22 In previous study, patients from the diagnosis to the discontinuation of anti-
23
24
25 cancer drug treatment stage (mainly pancreatic cancer patients) showed to desire more
26
27
28 "empathic communication" from oncologists.[11] Empathic communication by
29
30
31 oncologists reduces patients' psychological distress,[12] increases trust in the
32
33
34 oncologist,[12] and enhances information recall.[13] Empathic communication is
35
36
37 essential especially for patients with rapidly progressing serious illnesses. Therefore,
38
39
40 communication skills training (CST) programs have been developed to help physicians
41
42
43 to facilitate communication behaviors that strengthen relationships with patients.[14]
44
45
46 CST involves learner-centered workshop held in small groups and including role-play
47
48
49 with simulated patients (SPs).[15] It is strongly recommended that medical professionals
50
51
52 train themselves in communication skills based on American Society of Clinical
53
54
55 Oncology Consensus Guidelines for patient–clinician communication.[16] Learning tools
56
57
58 (e.g., www.vitaltalk.org) are available to medical practitioners to support this learning.
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

We conducted a prior survey clarifying the four elements of communication skills patients prefer oncologists to have, referred to as SHARE: “setting,” “how to deliver the bad news,” “additional information,” and “reassurance and emotional support.”[17,18] A two-day SHARE-CST program for oncologists was developed based on these preferences.[19] The program is a small-group workshop including the above-mentioned modules; it employs role-play with simulated patients and immediate feedback[15] to allow learners to practice discussing serious news with cancer patients and caregivers, such as transition to palliative care when chemotherapy is failing. The program emphasizes that physicians respect the values of each patient and provide reassurance and emotional support and has been implemented in several Asian countries.[20] Our previous randomized controlled trial (RCT) of physicians, including oncologists treating pancreatic cancer, showed that oncologists who participated in SHARE-CST improved their behavior in terms of patient-preferred communication as well as their self-confidence in communication with patients and that their patients experienced a relatively low level of psychological distress and a high level of trust in the oncologist.[12] In Japan, SHARE-CST was implemented as a 10-year project commissioned by the MHLW for physicians nationwide after the enactment of the National Cancer Control Act. Participants reported that their empathic communication

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 attitudes and abilities had improved;[21] however, it was difficult for most oncologists to
8
9 participate in two-day CST group workshops because of the busy clinical oncology
10
11 settings in which they worked.
12
13
14
15

16 Patient-centered approaches using question prompt lists (QPLs) have also been
17
18 proposed for the improvement of patient-physician communication. A QPL is an
19
20 inexpensive communication tool employing a structured question list to encourage patient
21
22 question-asking and participation during consultations.[22] The provision of a QPL and
23
24 implementation of communication interventions with QPL before consultation is
25
26 effective in promoting patient question-asking behavior and participation in the
27
28 consultation and in decreasing patients' anxiety.[23] Our previous RCT of patients with
29
30 advanced gastric, colorectal, esophageal, and lung cancer showed that QPL was useful in
31
32 making initial treatment decisions for them but failed to promote patient question-asking
33
34 behavior,[24] in part because Japanese patients tend to wait for physicians to encourage
35
36 them to ask questions.[25] The number of patients asking their physician questions was
37
38 median 1, compared to mean/median 8.5 to 14 in studies in Western countries.[23,24] In
39
40 Japan, it has been reported that cancer patients have preference of not being burden to
41
42 others and of “omakase” (leaving the decision-making to a medical expert), and it is
43
44 difficult to elicit the patient's preference.[26] Thus, in Japan, integrated interventions
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

combining CST for oncologists and communication coaching with QPL for patients might increase patient questioning behavior and improve patient-centered communication in consultations.[27,28]

Based on the results of previous trials, this study aims to evaluate the efficacy of a new, integrated communication support program, consisting of a CST for oncologists and communication coaching with QPL for patients with rapidly progressing advanced cancer and their caregivers, promoting oncologists' patient-centered communication behaviors. We hypothesize that, compared to treatment as usual (TAU), the intervention will increase oncologists' patient-centered communication behaviors, increase patients' question-asking behaviors, and improve patient well-being and health services utilization by reducing aggressive interventions and increasing use of palliative care.

METHODS and ANALYSIS

This protocol was written in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) and SPIRIT PRO Extension Guidelines.[29,30]

Study design

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

This study is a single-blind cluster RCT conducted in four metropolitan cancer-treatment hospitals: the National Cancer Center Hospital, the National Cancer Center Hospital East, the Cancer Institute Hospital, and the Kanagawa Cancer Center Hospital. This study protocol has been reviewed and approved by the protocol review committee of the Japan Supportive, Palliative, and Psychosocial Oncology Group as J-SUPPORT 1704 and by the Institutional Review Boards at each participating institution.

An independent data center provides computer-generated random allocation sequences. The assignment sequence is centrally managed; assignment results are automatically sent to a clinical research coordinator (CRC), electronically. The oncologist participants are randomly assigned to an intervention group (IG) or control group (CG) after the baseline phase; patient/caregiver participants are assigned to the same group as their oncologists. A stratified block-randomization scheme is used to assure balanced assignment by site. Within each site, oncologists are randomly assigned approximately evenly across IG and CG. Participants in IG provide intervention in addition to TAU, and are unblinded.

Intervention

Oncologists

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

We modified the original SHARE-CST design,[12] adopting a 2.5-hour individual program with a facilitator and a simulated patient (SP), consisting of lecture with a textbook (30 min) and 2 role-plays with immediate feedback (see Table 1). The original SHARE-CST is a small group consisting of 4 oncologists, 2 facilitators and 2 SPs, and included a lecture and 8 role-plays (twice per oncologist) with immediate feedback. The lecture cites evidence of the most important and common patient preferences regarding communication—empathic responses and encouragement to ask questions—and the variability of patients’ preferences in discussing prognoses and being/not being dispassionate; it also demonstrates how to check and elicit patient preferences. Additionally, the lecture explains the QPL and discusses frequently asked questions from patients about information related to treatment and care after standard treatment that relates to patients’ personal values, life goals, and preferences, as well as those of their caregivers. During the role-playing and discussion, participants are required to consider a patient’s emotions and concerns caused by bad news, recognition of their disease, social situations, and information that they would want to know, and to empathize with the patient. Role-play also includes dealing with patients who bring QPLs.

Facilitators provide a lecture, lead the role-play, and discuss patients’ potential emotions and communication-related preferences. Facilitators include psychiatrists,

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

psychologists, and oncologists, all of whom have had 3 years or more of clinical experience in oncology and participated in specialized 30-hour training workshops facilitating communication skills in oncology. The SPs have also participated in train-the-trainer workshops and 15 hours of SP training.

Patient and Caregiver

Communication coaching for patients was developed to facilitate communication with physicians using a 63-question QPL based on in-depth focus-group interviews with 18 participants (5 pancreatic cancer patients, 3 caregivers patients with pancreatic cancer, 4 bereaved people who had lost a family with pancreatic cancer, and 6 pancreatic oncologists), and previous QPL studies.[23,24,31] The QPL is a 10-page A4 sheet containing 63 questions grouped into 8 topics (diagnosis and stage of the disease, current and future treatments, management of current/possible future symptoms, daily life activities, care and prognosis post standard treatment, caregivers' needs, psychological distress and management, and values) and a space for free questions. Patient communication coaching using the QPL is a half-hour program, conducted individually or with a caregiver, consisting of reading the list to select personally relevant questions, prioritizing selected questions, discussing difficulties in asking the questions to their one's

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

oncologist at their next oncology visit, and practicing asking their one's oncologist these questions. The intervention is to be provided to patients individually or with caregivers by clinical psychologists and nurses who have participated in a 10-hour intensive training workshop using an intervention manual. The intervention providers note and summarize the content of all intervention sessions, that is, the information that the patient want to know and their preferences of treatment and care. Before patients' visits, the oncologist is told which the questions the patient chose to ask from the QPL and the summary of the intervention. Intervention providers hold weekly conferences to review their coaching sessions.

Control condition

CG oncologists are provided neither training nor educational materials.

Patients/caregivers in the CG are provided TAU.

Participants

Oncologists

Enrolled oncologists must (1) be mainly engaged in anticancer drug treatment of pancreatic cancer patients; (2) have provided written informed consent for trial

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 participation.
8
9

10
11
12
13 Patients in baseline phase and intervention and long-term follow-up phase
14

15
16 Enrolled patients must (1) have a diagnosis of pancreatic cancer
17
18 (adenocarcinoma); (2) have unresectable pancreatic cancer (UICC stage III or IV) or
19
20 postoperative recurrence; (3) receive a first-line chemotherapy and be scheduled for a
21
22 second course; (4) be aged 20 years or older; (5) have a ECOG performance status score
23
24 of 0 or 1; (6) regularly visit an enrolled oncologist; (7) provide written informed consent
25
26 for trial participation; and (8) be able to read, write, understand, and speak Japanese.
27
28
29
30
31
32

33
34 Patients are excluded if they are (1) judged by their oncologist to have cognitive
35
36 impairment; (2) unable to complete an electronic Patient Reported Outcome (e-PRO)
37
38 Questionnaire; or (3) judged unsuitable for participation by their oncologist.
39
40
41
42
43
44
45

46 Caregivers in baseline phase and intervention and long-term follow-up phase
47

48
49 If an enrolled patient is accompanied by a caregiver, the caregiver is also
50
51 approached. Enrolled caregivers must (1) be aged 20 years or older; (2) regularly
52
53 accompany an enrolled patient as primary caregiver; (3) provide written informed consent
54
55 to trial participation; (4) be able to read, write, understand, and speak Japanese.
56
57
58
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

Caregivers are excluded if they are unable to complete an electronic Patient Reported Outcome (e-PRO) Questionnaire.

Procedures

This study consists of 3 phases: a baseline phase, an intervention phase, and a follow-up phase (Figure 1). The schedule for outcome measurement is shown in Table 2. After completing the intervention phase, data analysis will ensue. After this study has closed, oncologists in the control group will be provided with the intervention on demand.

Baseline phase

This phase involves oncologist and patient/caregiver recruitment as well as pre-randomization data collection on oncologists' communication behaviors as baseline data for use as a covariate in the RCT analysis. In this phase, 3 to 5 patients and their caregivers (if available) will be recruited for each oncologist. Participants will be asked to allow themselves to be audio-recorded at one oncology visit and to provide the evaluation of consultation for primary and secondary outcomes as covariates in the analyses (Table 2).

Intervention phase

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

This phase involves oncologist randomization, intervention for participants in IG, and follow-up assessment. After oncologists are randomly assigned to the IG or CG, those in the IG receive an individual intervention.

Next, 10 patients and their caregivers (if available) who regularly visit the oncologist are recruited and assigned to the IG or CG. After the IG patients and their caregivers receive an intervention, or 2 weeks to 1 month after baseline in the CG, the conversation between the patient/caregiver and the oncologist at their next consultation is audio-recorded. After the consultation, patients/caregivers and the oncologists rate the consultation using a follow-up assessment.

Long-term follow-up phase

Patients and their caregivers will be encouraged to provide long-term follow-up assessments at 3, 6, 12, 24, and 36 months after the first follow-up assessment to evaluate effects on patient's physical and psychological condition and medical utilization at end of life. Caregivers are also asked to provide another assessment at 2 to 6 months post-patient death.

Data management, central monitoring, data monitoring, and auditing

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

We will collect all data, except for audio-recorded data, through electronic data capture (EDC) and electronic patient reported outcomes (ePRO) systems or paper-based PRO questionnaires (pPRO) if patients are prevented from using the electronic approach. If participants fail to respond to ePRO or pPRO, a CRC blinded to the assignment will elicit their answers to avoid missing data. Data management and central monitoring will be performed using EDC VIEDOC 4 (PCG Solutions, Uppsala, Sweden) by the J-SUPPORT Data Science Team. Auditing is not planned for this study.

Concomitant treatments

There is no restriction on concomitant treatments.

Stopping rules for participants

If a participant meets any of the following conditions, the research team can discontinue the intervention; however, the participant will not be considered to have dropped out of the trial at that stage and will still receive the assessments: (1) the participant wishes to stop the intervention; (2) the research team judges that the risk of the intervention is greater than the benefit for any reason; (3) the research team judges that it is difficult to continue the intervention because of clinical deterioration; and (4) the

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

research team judges that it is inappropriate to continue the intervention for any reason.

Stopping assessment

If a participant withdraws consent for assessment, he or she will not be followed up. Subjects will be excluded from the intention-to-treat (ITT) cohort of the trial only if they are found to meet any exclusion criteria at baseline after participation.

Assessment measures

Table 2 shows the schedule for outcome measurement.

Primary outcome measure

Oncologist's patient-centered communication behaviors

The audio-recorded oncology visits for all participants will be coded for each of the four factors of communication behaviors based on patient preference, referred to as SHARE: setting, delivery of information, additional information, and reassurance and emotional support (see Table 1).[19] The SHARE-RE factor is used as a primary outcome to measure empathic communication between patient/caregiver and oncologist after intervention for both.

Following previous study methods,[19] impressions of conversations between

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 patient/caregiver and oncologist from consultations will be assessed using the SHARE-
8
9
10 RE factor score, consisting of 8 categories for analysis, in a random order, by two blinded
11
12
13 coders who have been trained for 30 hours or more on two occasions with a rating manual.
14
15
16

17
18
19 Secondary outcome measure

20
21
22 *Oncologist's Patient-preferred communication behavior*
23
24

25 Patient-preferred communication will be analyzed using impression ratings from
26
27
28 two blinded coders, as described above. The analysis will include the audio-recorded
29
30
31 oncology visits for all participants using the total SHARE score, for all 27
32
33
34 categories.[18,19] Following previous study methods,[19] the 40 categories of the Roter
35
36
37 Intention Analysis System (RIAS) will also be used in assessing patient-preferred
38
39
40 communications.[32]
41
42
43
44
45

46 *Patient's and caregiver's communication behavior*
47
48

49 Following previous study methods,[19] the 40 categories of the Roter Intention
50
51
52 Analysis System (RIAS) will also be used in assessing patient's and caregiver's
53
54
55 communications behavior, for example question-asking.[32]
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 *Patient-reported outcome measures*
8
9

10 Several scales will be used to produce a comprehensive profile of each patient
11 participant. These include the Hospital Anxiety and Depression Scale (HADS);[33] the
12 Physical and Functional Well-being subscales of the Functional Assessment of Cancer
13 Therapy (FACT-Physical & Functional);[34] the Short version of the Comprehensive
14 Quality of Life Outcome inventory (CoQoLo);[35] the Trust in Oncologists Scale
15 (TiOS);[36] the Client Satisfaction Questionnaire (CSQ);[37] the Peace, Equanimity, and
16 Acceptance in the Cancer Experience (PEACE) questionnaire;[38] and the Prognosis and
17 Treatment Perceptions Questionnaire (PTPQ).[39]
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 Patients' relevant medical and sociological background information includes
35 stage, diagnosis date, treatment status, treatment history, comorbidities, sex, age, job
36 status, household income, household size, social support, marital status, educational
37 experience, treatment, and care preference at the end of life. Medical utilization at the end
38 of life will be determined by the date of death, any chemotherapy agent given within 14
39 days of death, any new chemotherapeutic regimen started within 30 days of death, and
40 involvement of hospice and palliative care services; all of this information is obtained
41 from medical fee information and the caregivers post-patient death.[27]
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

58 A patients' assessment of the intervention's usefulness includes "Did you
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

understand how to use the QPL and did you actually use it?" "Do you think you will continue the intervention?" and "Was the intervention useful to you?" Their assessment of oncologists includes "Did the oncologist talk about the QPL?" and "How did the oncologist respond to your questions?" Their assessment of QPL includes "Did the QPL help you ask the oncologist questions?" "Is the QPL useful?" "Did you read the QPL before the visit?" and "Do you think you will read the QPL in the future?" as well as whether they asked selected questions to oncologist after the consultation, which questions they selected, and "How much you have discussed with the oncologist in the visit?" in the intervention phase.

Caregiver survey measures

Several scales will also be used to gain a comprehensive view of caregivers, including the K6 nonspecific psychological distress scale (K6);[40] the 5 Dimension EuroQol (EQ-5D);[41] and the CSQ.[37] After the patient's death, the caregiver's QOL as the bereaved is measured with the Short version of the Good Death Inventory (GDI).[42]

Caregivers' relevant sociological background information includes sex, age, relationship with the patient, job status, household income, household size, social support,

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

marital status, educational experience, and treatment and care preferences at end of life.

After the first post-intervention visit, caregivers in the IG will evaluate the intervention, the oncologist, and the QPL and report any selected questions used with the oncologist.

Oncologist survey measures

The relevant data concerning the oncologists include their sociological background (sex, age, and clinical experience). The oncologists' evaluation of medical utilization by the patient will be set by their recollection of the dates.

The usefulness of intervention will also be measured using evaluations provided by the oncologists in the IG.

Harms

No specific and serious adverse events are presumed for participants in this study.

However, by participating in the interventions, some participants may potentially experience psychological distress from imagining their situation after standard treatment.

The patients/ caregivers and oncologists will also be subjected to time burdens of a half-hour and 2.5 hours for the intervention, and 10–30 minutes for each baseline and follow-

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

up assessment. Therefore, we will give patients/caregivers a reward of 500 Japanese yen for each participant assessment. There are no reward for the intervention and no financial risks associated with study participation.

Compensation

If participants develop unexpected health issues due to study participation during or after completion of this study, treatment will be adequately provided per standard medical care, covered by the National Health Insurance.

Sample size estimation

Our previous study revealed that the effect size of SHARE-RE score was 1.9 at post-intervention.[12] For a sample size based on 80% power to detect a significant difference at a significance level of 0.05 (two-sided), 10 oncologists and 70–100 participants (7–10 per oncologist) would be required for each arm in the follow-up phase, assuming some participant drop out and data loss. Assuming that 80% of patients will be accompanied by caregivers at doctor visits, a total of 112–160 participants would be required. Based on previous studies, a total of 60–150 patients (3 to 5 per oncologist) are then needed in the baseline phase.[27]

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

Although the total time devoted to CST for the oncologists in this study is reduced from the original SHARE-CST program, the role-plays for individual participants are performed the same time, and communication coaching with QPL for the patients is added. Therefore the effect size from the previous study was adopted for sample size calculation, and 20 oncologists, 3 patients per oncologist, a total of 60 patients in the baseline phase, and 10 patients per oncologist, for a total of 200 patients, are enrolled in the follow-up phase (Figure 1).

Patient and public involvement statement

This study protocol was co-designed by a patient with pancreatic cancer and a family member of a pancreatic cancer patient who participated as researchers. They spoke with other patients to help develop recommendations for when patients' preferences and/or opinions should be considered. They will play a similar role in the implementation of the study. Thus, patients were and will continue to be involved in the study. The results of this study will be available via a study website.

Data analysis

Primary analyses

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

To examine the intervention effect parameters of all randomly assigned subjects in the primary analysis set according to the ITT principle, we will analyze the primary outcome with SHARE-RE as an indicator of enhanced empathic communication using a generalized linear model. The primary outcome of interest is the difference in SHARE-RE scores between the two groups after intervention. A two-sided p value < 0.05 will be used to indicate statistical significance.

Secondary analyses

We will perform secondary analyses to supplement our primary analysis and obtain a clearer understanding of our clinical questions. The secondary analyses will use models similar to that of the primary analysis and will examine data for the secondary outcome measures. These analyses will be conducted for exploratory purposes.

Interim analyses

No interim analysis is planned.

Publication policy

The protocol and study results will be submitted to peer-reviewed journals. The

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

first author of the main paper will be a member of the steering committee (the authors of the protocol paper). Another person could be the first author if approved by the steering committee. The list of coauthors will be determined before submitting each paper.

Study period

This study period of this trial is April 2017 to March 2023; the registration period is August 2018 to July 2020.

Ethics and dissemination

The present study is subject to ethical guidelines for clinical studies published by Japan's Ministry of Education, Science and Technology and Ministry of Health, Labour, and Welfare and the modified Act on the Protection of Personal Information as well as the ethical principles established for research on humans stipulated in the Declaration of Helsinki and further amendments thereto. If important protocol modifications are needed, the investigators will discuss them and report to the review board for approval. Regarding dissemination, the results obtained will be submitted for publication in peer-reviewed journals. The main and/or relevant findings will be presented at conferences.

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5
6
7
8
9

10 **DISCUSSION**
11

12
13 This study is a multi-site randomized controlled trial to evaluate the efficacy of
14
15 an integrated communication support program for rapidly progressive advanced cancer
16
17 patients, caregivers, and oncologists to promote patient-centered communication. The
18
19 intervention program is unique in intervening with both oncologists and
20
21 patients/caregivers for a brief time at the point of first-line chemotherapy, before they are
22
23 critically ill.
24
25
26
27
28
29

30
31 In clinical oncology, the introduction of personalized precision medicine has
32
33 allowed great therapeutic progress. Patient-oncologist communication is uncertain and
34
35 complex, and busy oncologists often find it difficult to take extra time with their patients.
36
37 As a result, personalized and precise communication between a patient and an oncologist
38
39 may not be achieved. If empathic communication between patients and oncologists can
40
41 be improved, including shared decision making based on patient values and preferences
42
43 about the use of evidence-based medicine, the result can be an effective integration of
44
45 best practices and patient values, allowing for better use of clinical expertise and available
46
47 resources.
48
49
50
51
52
53
54
55

56
57 In this study, it is essential that intervention facilitators and SPs be well trained
58
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

to maintain the quality of the intervention. In the future, it may be possible to reduce costs by developing internet-based programs. Regarding QPL, clinical benefits may increase when it is possible to link medical records with data from wearable devices. Above all, the use of electronic media is expected to make implementation of the intervention program easier.

Strengths and limitations

This study has two methodological limitations. First, the intervention program for both oncologists and patients/caregivers is complex, consisting of multiple factorial components. Thus, if the interventions prove superior to usual care, we will not be able to determine which interventions and components are most efficacious or beneficial in promoting communication. Second, patient intervention will be applied only to patients with pancreatic cancer. The generalization potential of the approach for other cancers is thus unknown. However, as pancreatic cancer is one of the most rapidly progressing cancers, if the intervention is effective for patients with pancreatic cancer who have severe physical and psychological conditions, it may be applied to patients with other cancers as well.

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 **Figure 1 caption**
8

9
10 Participant flow diagram
11

12
13 Abbreviation: CST, communication skills training
14
15
16
17
18

19 **Acknowledgements**
20

21
22 We thank Ms. T Mashiko and Ms. M Kurosaki for their data management
23 support. We also thank members of PanCan Japan, Ms. S Furutani, Dr M Mori, Dr Y
24 Shirai, Dr S Umezawa, Ms. N Inomata, Mr. M Umehashi, Dr M Okamura, Dr M Odawara,
25 Dr A Hanai, Mr. R Soga, Ms. R Sugihara, Ms. T Akiyama and Ms. M Kanamaru for their
26 support for this study.
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Contributors**
41

42 MF is a principal investigator. MF and YU developed the CST program. MF,
43 AS, SJ, TO, YM and YU developed the QPL. MF, TO, TY, MI, MU, MO, KT, TM, YM
44 and YU participated in the design of this study. All authors prepared the protocol and
45 agree of final protocol and revisions. MF, AS, SJ, MT prepared of investigators brochure
46 (IB) and CRFs. TY played a chief role in the statistical parts. TM played roles in the data
47 management. MF drafted the manuscript. All authors participated in, read and approved
48
49
50
51
52
53
54
55
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 the final manuscript.
8
9
10
11
12

13 **Funding**
14

15
16 This study is supported by a Grant-in-Aid for Japan Agency for Medical
17 Research and Development (JP 17ck0106237h0001) and in part by The National Cancer
18 Center Research and Development Fund (30-A-11). This funding source had no role in
19 the design of this study and will not have any role during its execution, analyses,
20 interpretation of the data, or decision to submit results.
21
22
23
24
25
26
27
28
29

30
31 **Sponsor**
32

33 None
34
35
36
37
38
39

40 **Competing interests**
41

42 All authors declare that they have no competing interests regarding this work.
43
44 TO has received research funding from Ono Pharmaceutical, Kowa, Dainippon
45 Sumitomo Pharma, Chugai Pharmaceutical, Novartis, Yakult Honsha, AstraZeneca, Eisai,
46 Lilly, Bristol-Myers Squibb. TY received consulting fees from Ono Pharmaceutical,
47 Kowa, Japan Tobacco, Chugai Pharmaceutical, Tsumura & CO, CAC Croit, Asahi Intecc,
48 Asahi Kasei Pharma and Clinical Trial. MI has received honoraria from Novartis Pharma,
49
50
51
52
53
54
55
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5
6

7 Bayer Yakuhin, Bristol-Myers Squibb, Abbott Japan, Eisai, Taiho Pharmaceutical, Eli
8
9 Lilly Japan, Daiichi-Sankyo, Yakult, Otsuka Pharmaceutical, Nobelpharma, EA Pharma
10
11 and Teijin Pharma, research funding from Bayer Yakuhin, Kyowa Hakko Kirin, Yakult,
12
13 Taiho Pharmaceutical, Eli Lilly Japan, Ono Pharmaceutical, Eisai, AstraZeneca, Zeria
14
15 Pharmaceutical, Chugai, Bristol Myers Squibb, Merck Serono, Kowa, Nano Carrier,
16
17 ASLAN, Daiichi-Sankyo., Sumitomo Dainippon, Novartis Pharma, Baxalta, Boehringer
18
19 Ingelheim and Takara Bio. He is a consulting or advisory role for Nano Carrier, Bayer
20
21 Yakuhin, Eisai, Kyowa Hakko Kirin, Novartis Pharma, Shire, MSD, Bristol Myers Squibb,
22
23 Eli Lilly Japan, Sumitomo Dainippon, Daiichi-Sankyo, Teijin Pharma, Takara Bio and a
24
25 board member of ASLAN, Chugai. MU has received honoraria from Taiho
26
27 Pharmaceutical, Yakult Honsha, AstraZeneca, Novartis, Lilly, Teijin Pharma, Shire, Ono
28
29 Pharmaceutical, and Merck Serono, and research funding from Taiho Pharmaceutical,
30
31 Shire, Daiichi Sankyo, Eisai, AstraZeneca, Ono Pharmaceutical, MSD, Merck Serono,
32
33 NanoCarrier, Dainippon Sumitomo Pharma, Incyte, ASLAN Pharmaceuticals, and
34
35 Yakult Honsha. MO has received lecture fees from Taiho Pharmaceutical and honoraria
36
37 from Taiho Pharmaceutical, Yakult, Bayer, Pfizer and Novartis.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

58 **Patient consent for publication**
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 Not required.
8
9

10
11
12
13 **Ethics approval**
14

15
16 The protocol was reviewed and approved by the Institutional Review Board of
17
18 National Cancer Center on 4 July 2018 (ID: 2014-474) as well as by the J-SUPPORT
19
20 Scientific Advisory Board.
21
22
23
24
25
26
27

28 **Provenance and peer review**
29

30 Not commissioned; externally peer reviewed.
31
32
33
34
35
36

37 **Open access**
38

39
40 This is an open access article distributed in accordance with the Creative
41
42 Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others
43
44 to distribute, remix, adapt, build upon this work non-commercially, and license their
45
46 derivative works on different terms, provided the original work is properly cited,
47
48 appropriate credit is given, any changes made indicated, and the use is non-commercial.
49
50
51

52 See: <http://creativecommons.org/licenses/by-nc/4.0/>.
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
AND ONCOLOGISTS

For peer review only

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 **References**
8
9

- 10 1. Ministry of Health, Labour and Welfare, Japan: White Papers & Reports Annual Health,
11 Labour and Welfare Report 2017.
12
13 2. National Cancer Center, Japan: Cancer Statistics in Japan 2019.
14
15 3. Parker SM, Clayton JM, Hancock K, et al. A systematic review of prognostic/end-of-
16 life communication with adults in the advanced stages of a life-limiting illness:
17 patient/caregiver preferences for the content, style, and timing of information. *J Pain*
18 *Symptom Manage* 2007;34(1):81-93.
19
20 4. Otani H, Morita T, Esaki T, et al. Burden on oncologists when communicating the
21 discontinuation of anticancer treatment. *Jpn J Clin Oncol* 2011;41(8):999-1006.
22
23 5. Wright AA, Zhang B, Ray A, et al. Associations between end-of-life discussions,
24 patient mental health, medical care near death, and caregiver bereavement adjustment.
25 *JAMA* 2008;300(14):1665-73.
26
27 6. Weeks JC, Catalano PJ, Cronin A, et al. Patients' expectations about effects of
28 chemotherapy for advanced cancer. *N Engl J Med* 2012;367(17):1616-25.
29
30 7. Weeks JC, Cook EF, O'Day SJ, et al. Relationship between cancer patients' predictions
31 of prognosis and their treatment preferences. *JAMA* 1998;279(21):1709-14.
32
33 8. Fallowfield LJ, Jenkins VA, Beveridge HA. Truth may hurt but deceit hurts more:
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 communication in palliative care. *Palliat Med* 2002;16(4):297-303.

8
9
10 9. Hagerty RG, Butow PN, Ellis PM, et al. Communicating prognosis in cancer care: a
11
12 systematic review of the literature. *Ann Oncol* 2005;16(7):1005-53.

13
14
15 10. Epstein RM, Peters E. Beyond information: exploring patients' preferences. *JAMA*
16
17 2009;302(2):195-7.

18
19
20
21 11. Umezawa S, Fujimori M, Matsushima E, et al. Preferences of advanced cancer
22
23 patients for communication on anticancer treatment cessation and the transition to
24
25 palliative care. *Cancer* 2015;121(23):4240-9.

26
27
28 12. Fujimori M, Shirai Y, Asai M, et al. Effect of communication skills training program
29
30 for oncologists based on patient preferences for communication when receiving bad
31
32 news: a randomized controlled trial. *J Clin Oncol* 2014;32(20):2166-72.

33
34
35 13. Sep MS, van Osch M, van Vliet LM, et al. The power of clinicians' affective
36
37 communication: how reassurance about non-abandonment can reduce patients'
38
39 physiological arousal and increase information recall in bad news consultations. An
40
41 experimental study using analogue patients. *Pat Educ Couns* 2014;95(1):45-52.

42
43
44 14. Moore PM, Rivera S, Bravo-Soto GA, et al. Communication skills training for
45
46 healthcare professionals working with people who have cancer. *Cochrane Database Syst*
47
48
49 Rev 2018;7:Cd003751.

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 15. Stiefel F, Kiss A, Salmon P, et al. Training in communication of oncology clinicians:
8 a position paper based on the third consensus meeting among European experts in 2018.
9
10 Ann Oncol 2018;29(10):2033-36.
11
12

13
14
15
16 16. Gilligan T, Coyle N, Frankel RM, et al. Patient-Clinician Communication: American
17 Society of Clinical Oncology Consensus Guideline. J Clin Oncol 2017;35(31):3618-32.
18
19

20
21
22 17. Fujimori M, Akechi T, Morita T, et al. Preferences of cancer patients regarding the
23 disclosure of bad news. Psychooncology 2007;16(6):573-81.
24
25

26
27
28 18. Fujimori M, Uchitomi Y. Preferences of cancer patients regarding communication of
29 bad news: a systematic literature review. Jpn J Clin Oncol 2009;39(4):201-16.
30
31

32
33
34 19. Fujimori M, Shirai Y, Asai M, et al. Development and preliminary evaluation of
35 communication skills training program for oncologists based on patient preferences for
36 communicating bad news. Palliat Support Care 2014;12(5):379-86.
37
38

39
40
41
42 20. Tang WR, Chen KY, Hsu SH, et al. Effectiveness of Japanese SHARE model in
43 improving Taiwanese healthcare personnel's preference for cancer truth telling.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

21. Yamada Y, Fujimori M, Shirai Y, et al. Changes in Physicians' Intrapersonal Empathy
after a Communication Skills Training in Japan. Acad Med 2018;93(12):1821-26.

22. Butow PN, Dunn SM, Tattersall MH, et al. Patient participation in the cancer

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 consultation: evaluation of a question prompt sheet. *Ann Oncol* 1994;5(3):199-204.
8

9
10 23. Brandes K, Linn AJ, Butow PN, et al. The characteristics and effectiveness of
11
12 Question Prompt List interventions in oncology: a systematic review of the literature.
13
14
15
16 *Psychooncology* 2015;24(3):245-52.
17

18
19 24. Shirai Y, Fujimori M, Ogawa A, et al. Patients' perception of the usefulness of a
20
21 question prompt sheet for advanced cancer patients when deciding the initial treatment: a
22
23 randomized, controlled trial. *Psychooncology* 2012;21(7):706-13.
24
25

26
27
28 25. Fujimori M, Akechi T, Akizuki N, et al. Good communication with patients receiving
29
30 bad news about cancer in Japan. *Psychooncology* 2005;14(12):1043-51.
31
32

33
34 26. Miyashita M, Sanjo M, Morita T, et al. Good death in cancer care: a nationwide
35
36 quantitative study. *Ann Oncol*. 2007 Jun;18(6):1090-7.
37
38

39
40 27. van Weert JC, Jansen J, Spreeuwenberg PM, et al. Effects of communication skills
41
42 training and a Question Prompt Sheet to improve communication with older cancer
43
44 patients: a randomized controlled trial. *Crit Rev Oncol Hematol* 2011;80(1):145-59.
45
46
47

48
49 28. Epstein RM, Duberstein PR, Fenton JJ, et al. Effect of a Patient-Centered
50
51 Communication Intervention on Oncologist-Patient Communication, Quality of Life, and
52
53 Health Care Utilization in Advanced Cancer: The VOICE Randomized Clinical Trial.
54
55
56
57 *JAMA Oncol* 2017;3(1):92-100.
58

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 29. Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration:
8
9 guidance for protocols of clinical trials. *BMJ* 2013;346:e7586.
10
11

12 30. Calvert M, Kyte D, Mercieca-Bebber R, et al. Guidelines for Inclusion of Patient-
13
14 Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. *JAMA*.
15
16 2018;319(5):483–494.
17
18

19 31. Brown RF, Butow PN, Dunn SM, et al. Promoting patient participation and shortening
20
21 cancer consultations: a randomised trial. *Br J Cancer* 2001;85(9):1273-9.
22
23
24

25 32. Roter, D.L., Hall, J.A., Kern, D.E., et al. Improving physicians' interviewing skills
26
27 and reducing patients' emotional distress. Randomized clinical trial. *Arch Intern Med*
28
29 1995;155, 1877–1884.
30
31
32

33 33. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr*
34
35 *Scand* 1983;67(6):361-70.
36
37
38

39 34. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy
40
41 scale: development and validation of the general measure. *J Clin Oncol* 1993;11(3):570-
42
43
44 9.
45
46
47

48 35. Miyashita M, Wada M, Morita T, et al. Development and validation of the
49
50 Comprehensive Quality of Life Outcome (CoQoLo) inventory for patients with advanced
51
52 cancer. *BMJ Support Palliat Care*. 2019;9(1):75-83.
53
54
55
56
57
58
59
60

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2 AND ONCOLOGISTS
3
4
5
6

7 36. Hillen MA, Postma RM, Verdam MG, et al. Development and validation of an
8 abbreviated version of the Trust in Oncologist Scale-the Trust in Oncologist Scale-short
9 form (TiOS-SF). *Support Care Cancer* 2017;25(3):855-61.
10
11
12

13
14
15 37. Zandbelt LC, Smets EM, Oort FJ, et al. Satisfaction with the outpatient encounter: a
16 comparison of patients' and physicians' views. *J Gen Intern Med* 2004;19(11):1088-95.
17
18
19

20
21
22 38. Mack JW, Nilsson M, Balboni T, et al. Peace, Equanimity, and Acceptance in the
23 Cancer Experience (PEACE): validation of a scale to assess acceptance and struggle with
24 terminal illness. *Cancer* 2008;112(11):2509-17.
25
26
27

28
29
30 39. El-Jawahri A, Traeger L, Park ER, et al. Associations among prognostic
31 understanding, quality of life, and mood in patients with advanced cancer. *Cancer*
32
33
34
35
36
37 2014;120(2):278-85.
38
39

40 40. Kessler RC, Andrews G, Colpe LJ, et al. Short screening scales to monitor population
41 prevalences and trends in non-specific psychological distress. *Psychol Med*
42
43
44
45
46 2002;32(6):959-76.
47
48

49 41. Brooks R. EuroQol: the current state of play. *Health policy (Amsterdam, Netherlands)*
50
51
52 1996;37(1):53-72.
53
54

55 42. Miyashita M, Morita T, Sato K, et al. Good death inventory: a measure for evaluating
56
57
58
59
60 good death from the bereaved family member's perspective. *J Pain Symptom Manage*

1 INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS
2
3 AND ONCOLOGISTS
4
5

6
7 2008;35(5):486-98.
8
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

Table 1. Components of CST Program Based on SHARE Model

	Description
Conceptual communication skills model: SHARE	
S	Setting up supportive environment for interview, including fundamental communication skills (e.g., greeting patient cordially, looking at patient's eyes and face)
H	Considering how to deliver bad news (e.g., not beginning bad news without preamble, checking to see whether talk is fast paced)
A	Discussing additional information that patient would like to know (e.g., answering patient's questions fully, explaining second opinion)
RE	Providing reassurance and addressing patient's emotions with empathic responses (e.g., remaining silent out of concern for patient's feelings, accepting patient's expression of emotions)
Component	
Lecture	Introduction, communication skills model, evidence on preferences of patients with cancer regarding communication
Role playing	Simulated consultation with simulated patient using communication skills with scenarios, discussing with facilitator, summary
Scenarios on communication in advanced care	Discontinuing chemotherapy Dealing with patient asking questions
Setting	1 participant 1 facilitator 1 simulated patient
Schedule	Orientation and lecture (30 minutes) Role playing with immediate feedback (60 minutes X 2)

Abbreviation: CST, communication skills training.

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

Table 2. Schedule for outcome measurement

	Outcome	Measurement	Baseline Phase		Intervention Phase		Follow-up Phase	
			Day 28 of 1st line chemotherapy	Day 42 of 1st line chemotherapy	Day 28 of 1st line chemotherapy	Day 42 of 1st line chemotherapy	3, 6, 12, 24, 36 months after	After post-mortem of the patient
Patient in baseline phase	Patient's communication behavior	RIAS		○				
	Patient's medical and sociological background	Cancer stage, diagnosis date, treatment status, treatment history, comorbidities, sex, age, work status, household income, household size, social support, marital status, educational experience, treatment, and care preference at the end of life	○					
	Patient's evaluation of consultation	"How did the oncologist respond to your questions?" "Did you ask selected questions during consultation?" "How much have you discussed with the oncologist in the visit?"		○				
Patient in intervention and follow-up phase	Patient's communication behavior	RIAS				○		
	Patient's psychological distress	HADS			○	○	○	
	Patient's physical and functional QOL	FACT-Physical & Functional			○	○	○	
	Patient's comprehensive QOL	Short version of CoQOLo			○	○	○	
	Patient's trust in oncologist	TIOS			○	○	○	
	Patient's satisfaction with oncologist	CSQ			○	○	○	
	Patient's acceptance in cancer experience	PEACE			○	○	○	
	Patient's prognosis and treatment perception	PTPQ			○	○	○	
	Patient's evaluation of consultation	"How did the oncologist respond to your questions?" "Did you ask selected questions during consultation?" "How much have you discussed with the oncologist in the visit?"				○		
	Patient's evaluation of intervention in the IG	"Did you understand how to use the QPL and did you actually use it?" "Do you think you will continue the intervention?" "Was the intervention useful to you?" "Did the oncologist talk about the QPL?" "Did the QPL helped you ask the oncologist questions?" "Is the QPL useful?" "Did you read the QPL before the visit?" "Do you think you will read the QPL in the future?"				○		
Patient's medical and sociological background	Cancer stage, diagnosis date, treatment status, treatment history, comorbidities, sex, age, job status, household income, household size, social support, marital status, educational experience, treatment, and care preference at the end of life			○				
Patient's medical utilization at the end of life	The date of death, any chemotherapy agent given within 14 days of death, any new chemotherapeutic regimen started within 30 days of death, and involvement of hospice and palliative care services						○	
Caregiver in baseline phase	Caregiver's communication behavior	RIAS		○				
	Caregiver's characteristics	Sex, age, relationship with the patient, job status, household income, household size, social support, marital status, educational experience, and preferences on treatment and care for the patient at the end of life	○					
	Caregiver's evaluation of consultation	"How did the oncologist respond to your questions?" "Did you ask selected questions during consultation?" "How much have you discussed with your oncologist in the visit?"		○				
Caregiver in intervention and follow-up phase	Caregiver's communication behavior	RIAS				○		
	Caregiver's psychological distress	K6			○	○	○	○
	Caregiver's QOL	EQ-5D			○	○	○	○
	Caregiver's satisfaction with oncologist	CSQ			○	○	○	
	Caregiver's sociological background	Sex, age, relationship with the patient, job status, household income, household size, social support, marital status, educational experience, and preferences on treatment and care for the patient at the end of life						
	Caregiver's prognosis and treatment perception	PTPQ			○	○	○	

INTEGRATED COMMUNICATION PROGRAM FOR ADVANCED CANCER PATIENTS AND ONCOLOGISTS

	Caregiver's evaluation of consultation	"How did the oncologist respond to your questions?" "Did you ask selected questions during consultation?" "How much have you discussed with the oncologist in the visit?"					<input type="radio"/>		
	Caregiver's evaluation of intervention in the IG	"Did you understand how to use the QPL and did you actually use it?" "Do you think you will continue the intervention?" "Was the intervention useful to you?" "Did the oncologist talk about the QPL?" "Did the QPL help you ask the oncologist questions?" "Is the QPL useful?" "Did you read the QPL before the visit?" "Do you think you will read the QPL in the future?"					<input type="radio"/>		
	Patient's comprehensive end-of-life QOL	Short version of GDI							<input type="radio"/>
Oncologist	Oncologist's Patient-centered communication behaviors	SHARE-RE		<input type="radio"/>			<input type="radio"/>		
	Oncologist's Patient-preferred communication behavior	SHARE-total		<input type="radio"/>			<input type="radio"/>		
	Oncologist's Patient-preferred communication behavior	RIAS		<input type="radio"/>			<input type="radio"/>		
	Oncologist's sociological background	Sex, age, clinical experience	<input type="radio"/>						
	Oncologist's evaluation of medical utilization by patient	The date of management		<input type="radio"/>			<input type="radio"/>		
	Oncologist's evaluation of intervention	The usefulness of intervention					<input type="radio"/>		

Abbreviation: RIAS, Roter intention analysis system

HADS, Hospital Anxiety and Depression Scale

QOL, quality of life

FACT-Physical & Functional, Physical well-being and Functional well-being subscales of the Functional Assessment of Cancer Therapy

CoQOLo, Comprehensive Quality of Life Outcome inventory

TiOS, Trust in Oncologists Scale

CSQ, Client Satisfaction Questionnaire

PEACE, Peace, Equanimity, and Acceptance in the Cancer Experience questionnaire


PTPQ, Prognosis and Treatment Perceptions Questionnaire

K6, K6 nonspecific psychological distress scale

EQ-5D, 5 Dimension EuroQol

GDI, Good Death Inventory

IG, intervention group



Abbreviation: CST, communication skills training

Figure 1. Participant flow diagram

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

			Page
	Reporting Item		Number
Administrative information			
Title	#1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym		1

1	Trial registration	#2a	Trial identifier and registry name. If not yet registered,	7
2			name of intended registry	
3				
4				
5				
6	Trial registration:	#2b	All items from the World Health Organization Trial	7
7	data set		Registration Data Set	
8				
9				
10				
11				
12	Protocol version	#3	Date and version identifier	7
13				
14				
15	Funding	#4	Sources and types of financial, material, and other	31
16			support	
17				
18				
19				
20	Roles and	#5a	Names, affiliations, and roles of protocol contributors	31
21	responsibilities:			
22				
23	contributorship			
24				
25				
26				
27				
28	Roles and	#5b	Name and contact information for the trial sponsor	32
29	responsibilities:			
30				
31	sponsor contact			
32				
33	information			
34				
35				
36				
37				
38	Roles and	#5c	Role of study sponsor and funders, if any, in study	31
39	responsibilities:		design; collection, management, analysis, and	
40			interpretation of data; writing of the report; and the	
41	sponsor and funder		decision to submit the report for publication, including	
42			whether they will have ultimate authority over any of	
43			these activities	
44				
45				
46				
47				
48				
49				
50				
51				
52	Roles and	#5d	Composition, roles, and responsibilities of the	31
53	responsibilities:		coordinating centre, steering committee, endpoint	
54			adjudication committee, data management team, and	
55	committees			
56				
57				
58				
59				
60				

other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)

Introduction

1			
2			
3			
4			
5			
6	Introduction		
7			
8			
9	Background and	#6a	Description of research question and justification for
10			
11	rationale		undertaking the trial, including summary of relevant
12			studies (published and unpublished) examining benefits
13			
14			
15			
16			and harms for each intervention
17			
18			
19	Background and	#6b	Explanation for choice of comparators
20			
21	rationale: choice of		
22			
23	comparators		
24			
25			
26	Objectives	#7	Specific objectives or hypotheses
27			
28			
29	Trial design	#8	Description of trial design including type of trial (eg,
30			parallel group, crossover, factorial, single group),
31			
32			allocation ratio, and framework (eg, superiority,
33			equivalence, non-inferiority, exploratory)
34			
35			
36			
37			
38			
39	Methods:		
40			
41	Participants,		
42			
43	interventions, and		
44			
45	outcomes		
46			
47			
48			
49	Study setting	#9	Description of study settings (eg, community clinic,
50			academic hospital) and list of countries where data will be
51			collected. Reference to where list of study sites can be
52			obtained
53			
54			
55			
56			
57			
58			
59			
60			

1	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If	16
2				
3			applicable, eligibility criteria for study centres and	
4			individuals who will perform the interventions (eg,	
5			surgeons, psychotherapists)	
6				
7				
8				
9				
10				
11	Interventions:	#11a	Interventions for each group with sufficient detail to allow	13
12				
13	description		replication, including how and when they will be	
14			administered	
15				
16				
17				
18				
19	Interventions:	#11b	Criteria for discontinuing or modifying allocated	13
20				
21	modifications		interventions for a given trial participant (eg, drug dose	
22			change in response to harms, participant request, or	
23			improving / worsening disease)	
24				
25				
26				
27				
28				
29	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	13
30				
31	adherence		and any procedures for monitoring adherence (eg, drug	
32			tablet return; laboratory tests)	
33				
34				
35				
36	Interventions:	#11d	Relevant concomitant care and interventions that are	20
37				
38	concomitant care		permitted or prohibited during the trial	
39				
40				
41				
42	Outcomes	#12	Primary, secondary, and other outcomes, including the	21
43				
44			specific measurement variable (eg, systolic blood	
45			pressure), analysis metric (eg, change from baseline, final	
46			value, time to event), method of aggregation (eg, median,	
47			proportion), and time point for each outcome. Explanation	
48			of the clinical relevance of chosen efficacy and harm	
49			outcomes is strongly recommended	
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Participant timeline	#13	Time schedule of enrolment, interventions (including any	18
2			run-ins and washouts), assessments, and visits for	
3			participants. A schematic diagram is highly recommended	
4			(see Figure)	
5				
6				
7				
8				
9				
10				
11	Sample size	#14	Estimated number of participants needed to achieve	26
12			study objectives and how it was determined, including	
13			clinical and statistical assumptions supporting any sample	
14			size calculations	
15				
16				
17				
18				
19				
20				
21	Recruitment	#15	Strategies for achieving adequate participant enrolment to	17
22			reach target sample size	
23				
24				
25				
26	Methods:			
27				
28	Assignment of			
29	interventions (for			
30	controlled trials)			
31				
32				
33				
34				
35				
36	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	13
37	generation		computer-generated random numbers), and list of any	
38			factors for stratification. To reduce predictability of a	
39			random sequence, details of any planned restriction (eg,	
40			blocking) should be provided in a separate document that	
41			is unavailable to those who enrol participants or assign	
42			interventions	
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	13
54	concealment		central telephone; sequentially numbered, opaque,	
55				
56				
57				
58	mechanism			
59				
60				

sealed envelopes), describing any steps to conceal the sequence until interventions are assigned

Allocation: [#16c](#) Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions 13

Blinding (masking) [#17a](#) Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how 13

Blinding (masking): [#17b](#) If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial 13

emergency unblinding

Methods: Data collection, management, and analysis

Data collection plan [#18a](#) Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol 19

1	Data collection plan:	#18b	Plans to promote participant retention and complete	19
2				
3	retention		follow-up, including list of any outcome data to be	
4			collected for participants who discontinue or deviate from	
5			intervention protocols	
6				
7				
8				
9				
10				
11	Data management	#19	Plans for data entry, coding, security, and storage,	19
12			including any related processes to promote data quality	
13			(eg, double data entry; range checks for data values).	
14			Reference to where details of data management	
15			procedures can be found, if not in the protocol	
16				
17				
18	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	27
19			outcomes. Reference to where other details of the	
20			statistical analysis plan can be found, if not in the protocol	
21				
22				
23	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	27
24	analyses		adjusted analyses)	
25				
26				
27				
28	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	27
29	population and		adherence (eg, as randomised analysis), and any	
30	missing data		statistical methods to handle missing data (eg, multiple	
31			imputation)	
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46	Methods: Monitoring			
47				
48				
49	Data monitoring:	#21a	Composition of data monitoring committee (DMC);	19
50	formal committee		summary of its role and reporting structure; statement of	
51			whether it is independent from the sponsor and	
52			competing interests; and reference to where further	
53				
54				
55				
56				
57				
58				
59				
60				

1 details about its charter can be found, if not in the
 2 protocol. Alternatively, an explanation of why a DMC is
 3 not needed
 4
 5
 6
 7

8	Data monitoring:	#21b	Description of any interim analyses and stopping	27
9	interim analysis		guidelines, including who will have access to these	
10			interim results and make the final decision to terminate	
11			the trial	
12				
13				
14				
15				
16				
17				
18	Harms	#22	Plans for collecting, assessing, reporting, and managing	25
19			solicited and spontaneously reported adverse events and	
20			other unintended effects of trial interventions or trial	
21			conduct	
22				
23				
24				
25				
26				
27				
28	Auditing	#23	Frequency and procedures for auditing trial conduct, if	32
29			any, and whether the process will be independent from	
30			investigators and the sponsor	
31				
32				
33				
34				
35	Ethics and			
36	dissemination			
37				
38				
39				
40				
41	Research ethics	#24	Plans for seeking research ethics committee / institutional	13
42	approval		review board (REC / IRB) approval	
43				
44				
45				
46	Protocol	#25	Plans for communicating important protocol modifications	28
47	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
48			relevant parties (eg, investigators, REC / IRBs, trial	
49			participants, trial registries, journals, regulators)	
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Consent or assent	#26a	Who will obtain informed consent or assent from potential	18
2			trial participants or authorised surrogates, and how (see	
3			Item 32)	
4				
5				
6				
7				
8				
9	Consent or assent:	#26b	Additional consent provisions for collection and use of	42
10	ancillary studies		participant data and biological specimens in ancillary	
11			studies, if applicable	
12				
13				
14				
15				
16	Confidentiality	#27	How personal information about potential and enrolled	28
17			participants will be collected, shared, and maintained in	
18			order to protect confidentiality before, during, and after	
19			the trial	
20				
21				
22				
23				
24				
25				
26	Declaration of	#28	Financial and other competing interests for principal	32
27	interests		investigators for the overall trial and each study site	
28				
29				
30				
31				
32	Data access	#29	Statement of who will have access to the final trial	7
33			dataset, and disclosure of contractual agreements that	
34			limit such access for investigators	
35				
36				
37				
38				
39	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and for	25
40	trial care		compensation to those who suffer harm from trial	
41			participation	
42				
43				
44				
45				
46				
47	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial	28
48	trial results		results to participants, healthcare professionals, the	
49			public, and other relevant groups (eg, via publication,	
50			reporting in results databases, or other data sharing	
51			arrangements), including any publication restrictions	
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Dissemination policy: #31b	Authorship eligibility guidelines and any intended use of	28
2			
3	authorship	professional writers	
4			
5			
6	Dissemination policy: #31c	Plans, if any, for granting public access to the full	7
7			
8	reproducible	protocol, participant-level dataset, and statistical code	
9			
10	research		
11			
12			
13			
14	Appendices		
15			
16			
17	Informed consent	#32 Model consent form and other related documentation	1
18			
19	materials	given to participants and authorised surrogates	
20			
21			
22			
23	Biological specimens	#33 Plans for collection, laboratory evaluation, and storage of	n/a
24			
25		biological specimens for genetic or molecular analysis in	
26			
27		the current trial and for future use in ancillary studies, if	
28			
29		applicable	
30			
31			

32 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-
 33 BY-ND 3.0. This checklist was completed on 20. December 2019 using <https://www.goodreports.org/>,
 34
 35 a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60